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Abstract: Die beste therapeutische Option für Patienten mit Organversagen ist häufig eine Transplan-
tation. Um die immunologische Abstossung eines Organs aus einem genetisch nicht-identischen Spender
zu verhindern, müssen transplantierte Patienten lebenslang eine immunsuppressive Therapie einnehmen.
Derzeit verfügbare immunsuppressive Medikamente sind sehr wirksam gegen die akute Abstossung aber
weniger effizient in der Prävention der chronischen Abstossung, und verursachen zum Teil schwerwiegende
Nebenwirkungen. Neue Strategien zur Abstossungsprävention sind die Voraussetzung für eine verbesserte
Lebenserwartung und Lebensqualität nach Organtransplantation. Die beste Lösung wäre die Induktion
von immunologischer Toleranz, ein Zustand, in welchem das Immunsystem das Transplantat ohne Im-
munsuppression akzeptiert, aber auf pathogene Keime reagiert; verschiedene ungelöste Probleme verhin-
dern aber eine breite klinische Anwendung von diesem Prinzip. Die Apoptose, eine Form von vorpro-
grammiertem Zelltod mit einer entscheidenden Funktion für die Gewebe-Homöostase in multizellulären
Organismen, reguliert das Immunsystem und spielt eine kritische Rolle in der Erhaltung der Selbst-
Toleranz. In dieser Studie untersuche ich die potentielle Rolle einer pharmakologischen Modulation der
Apoptose als eine neue Strategie zur Abstossungsprävention und Toleranz-Induktion. Kapitel 1 ist eine
Einführung zur Transplantationsimmunologie und zu den klinischen und experimentellen Optionen für die
Abstossungsprävention. Kapitel 2 erklärt die Prinzipien der Apoptose, deren Rolle in der Regulation des
Immunsystems und die Optionen für eine pharmakologische Modulation der Apoptose. Im Kapitel 3 wer-
den die Resultate der Experimente über die immunsuppressive Wirkung der pro-apoptotischen Substanz
ABT-737 in vitro und in einem Haut-Transplantationsmodell in der Maus vorgestellt. Die Wirkung von
ABT-737 in vivo war begrenzt, aber verstärkt in Kombination mit dem Calcineurin Hemmer Cyclosporin
A. Im Kapitel 4 werden der Synergismus mit Cyclosporin A und die immunomodulatorische Wirkung von
ABT-737 weiter untersucht. Diese mechanistischen Studien waren die Basis für die Entwicklung eines
neuen Protokolls zur Toleranzinduktion, wie beschrieben im Kapitel 5. Die Wirkung von ABT-737 auf
Gedächtnis-Lymphozyten, ein wichtiges Hindernis für Toleranz in der Klinik wird im Kapitel 6 unter-
sucht. Kapitel 7 fasst die immunmodulatorische Wirkung von ABT-737 und anderen pro-apoptotischen
Substanzen zusammen. Im Kapitel 8 diskutiere ich die mögliche Applikation von diesem neuen Prinzip
im Bereich der Transplantation. Transplantation is often the best therapeutic option for patients with
end-stage organ failure. However, organ transplantation from a genetically not identical individual in-
evitably leads to immunological graft rejection, which must be prevented by lifelong immunosuppressive
therapy. Currently available immunosuppressive drugs effectively prevent acute allograft rejection, but
are less effective in the long-term and induce major side effects. Therefore, new strategies are required to
improve survival and quality of life after transplantation. Induction of donor-specific tolerance, a state in
which the immune system accepts the transplanted organ without immunosuppression and normally re-
acts to pathogens, would represent the ideal solution to this problem. However, several obstacles preclude
the establishment of tolerance induction protocols clinical practice. Apoptosis, a form of programmed
cell death with a fundamental role in the maintenance of tissue homeostasis in multicellular organisms,
is critically involved in the regulation of the immune system and in the maintenance of self- tolerance. In
this project, I investigated the potential role of a pharmacological modulation of the apoptosis pathway
as a new strategy to prevent rejection and to induce tolerance after solid organ transplantation. Chapter
1 provides an introduction to transplantation immunology and to clinical and experimental approaches to
prevent allograft rejection. Chapter 2 deals with apoptosis, its role as a regulator of the immune system
and the available options to pharmacologically modulate it. Chapter 3 describes the immunosuppressive
effect of the pro-apoptotic drug ABT-737 in vitro and in a skin transplantation model. The immunosup-
pressive effect of ABT-737 as a single agent was limited, but markedly increased in combination with the
calcineurin inhibitor cyclosporine A. Chapter 4 analyzes more in details the synergistic effect of these two
drugs and characterizes the immunomodulatory properties of ABT-737. The information obtained from
these mechanistic studies was the basis for the development of a new therapeutic approach to induce
immunological tolerance targeting the apoptosis pathway, as described in chapter 5. Finally, the effect
of ABT-737 on memory lymphocytes, a major barrier to tolerance induction in humans, is described in
chapter 6. In chapter 7 I give an overview about the immuno-modulatory properties of ABT-737 and
other pro-apoptotic drugs. Chapter 8 discusses the potential role of these agents in transplantation.
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Zusammenfassung
Die beste therapeutische Option für Patienten mit Organversagen ist häufig eine Transplanta-
tion. Um die  immunologische Abstossung eines Organs aus einem genetisch nicht-identischen 
Spender zu verhindern, müssen transplantierte Patienten lebenslang eine immunsuppressive 
Therapie einnehmen. Derzeit verfügbare  immunsuppressive Medikamente sind sehr wirksam 
gegen die  akute Abstossung aber weniger effizient in der Prävention der chronischen Ab-
stossung, und verursachen zum Teil schwerwiegende Nebenwirkungen. Neue  Strategien zur 
Abstossungsprävention sind die Voraussetzung für eine verbesserte Lebenserwartung und Le-
bensqualität nach Organtransplantation. Die beste Lösung wäre die Induktion von immunolo-
gischer Toleranz, ein Zustand, in welchem das Immunsystem das Transplantat ohne Immun-
suppression akzeptiert, aber auf pathogene Keime reagiert; verschiedene ungelöste Probleme 
verhindern aber eine breite  klinische Anwendung von diesem Prinzip. Die Apoptose, eine 
Form von vorprogrammiertem Zelltod mit einer entscheidenden Funktion für die Gewebe-
Homöostase in multizellulären Organismen, reguliert das Immunsystem und spielt eine  kriti-
sche Rolle in der Erhaltung der Selbst-Toleranz. In dieser Studie  untersuche ich die potentielle 
Rolle  einer pharmakologischen Modulation der Apoptose als eine neue  Strategie zur Ab-
stossungsprävention und Toleranz-Induktion.
Kapitel 1 ist eine Einführung zur Transplantationsimmunologie und zu den klinischen und 
experimentellen Optionen für die Abstossungsprävention. Kapitel 2 erklärt die  Prinzipien der 
Apoptose, deren Rolle in der Regulation des Immunsystems und die Optionen für eine phar-
makologische Modulation der Apoptose. Im Kapitel 3 werden die Resultate der Experimente 
über die  immunsuppressive Wirkung der pro-apoptotischen Substanz ABT-737 in vitro und in 
einem Haut-Transplantationsmodell in der Maus vorgestellt. Die Wirkung von ABT-737 in vivo 
war begrenzt, aber verstärkt in Kombination mit dem Calcineurin Hemmer Cyclosporin A. Im 
Kapitel 4 werden der Synergismus mit Cyclosporin A und die  immunomodulatorische Wir-
kung von ABT-737 weiter untersucht. Diese  mechanistischen Studien waren die Basis für die 
Entwicklung eines neuen Protokolls zur Toleranzinduktion, wie beschrieben im Kapitel 5. Die 
Wirkung von ABT-737 auf Gedächtnis-Lymphozyten, ein wichtiges Hindernis für Toleranz in 
der Klinik wird im Kapitel 6 untersucht. Kapitel 7 fasst die immunmodulatorische Wirkung 
von ABT-737 und anderen pro-apoptotischen Substanzen zusammen. Im Kapitel 8 diskutiere 
ich die mögliche Applikation von diesem neuen Prinzip im Bereich der Transplantation. 
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Summary
Transplantation is often the best therapeutic option for patients with end-stage organ failure. 
However, organ transplantation from a genetically not identical individual inevitably leads to 
immunological graft rejection, which must be prevented by lifelong immunosuppressive ther-
apy. Currently available  immunosuppressive drugs effectively prevent acute  allograft rejection, 
but are  less effective  in the long-term and induce major side  effects. Therefore, new strategies 
are required to improve survival and quality of life after transplantation. Induction of donor-
specific tolerance, a state in which the immune system accepts the transplanted organ with-
out immunosuppression and normally reacts to pathogens, would represent the ideal solution 
to this problem. However, several obstacles preclude the  establishment of tolerance induction 
protocols clinical practice. Apoptosis, a form of programmed cell death with a  fundamental 
role in the maintenance of tissue homeostasis in multicellular organisms, is critically involved 
in the regulation of the  immune system and in the  maintenance of self-tolerance. In this pro-
ject, I investigated the potential role  of a pharmacological modulation of the  apoptosis path-
way as a  new strategy to prevent rejection and to induce tolerance after solid organ trans-
plantation.
Chapter 1 provides an introduction to transplantation immunology and to clinical and ex-
perimental approaches to prevent allograft rejection. Chapter 2 deals with apoptosis, its role 
as a regulator of the immune system and the available options to pharmacologically modulate 
it. Chapter 3 describes the immunosuppressive effect of the pro-apoptotic drug ABT-737 in 
vitro and in a  skin transplantation model. The immunosuppressive  effect of ABT-737 as a sin-
gle agent was limited, but markedly increased in combination with the calcineurin inhibitor 
cyclosporine A. Chapter 4 analyzes more in details the synergistic effect of these two drugs 
and characterizes the immunomodulatory properties of ABT-737. The information obtained 
from these mechanistic studies was the basis for the development of a  new therapeutic ap-
proach to induce immunological tolerance targeting the apoptosis pathway, as described in 
chapter 5. Finally, the effect of ABT-737 on memory lymphocytes, a  major barrier to toler-
ance induction in humans, is described in chapter 6. In chapter 7 I give an overview about 
the immuno-modulatory properties of ABT-737 and other pro-apoptotic drugs. Chapter 8 
discusses the potential role of these agents in transplantation.
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Riassunto
Il trapianto è  spesso la miglior opzione terapeutica per pazienti con un’insufficienza organica, 
ma obbliga il paziente ad assumere  per tutta  la vita una terapia immunosoppressiva al fine di 
prevenire il rigetto, un’inevitabile risposta  del sistema immunitario dopo trapianto di un orga-
no da un donatore geneticamente non identico. I medicamenti attualmente disponibili sono 
adatti alla  prevenzione del rigetto acuto, ma meno efficaci sul lungo periodo e  sono associati 
ad effetti collaterali anche gravi. Per questa ragione occorre sviluppare nuove strategie per 
migliorare la  speranza e  la qualità  di vita in pazienti trapiantati. La migliore soluzione in tal 
senso è l’induzione di tolleranza immunologica  verso il donatore, uno stato in cui il sistema 
immunitario accetta l’organo trapiantato senza immunosoppressione e reagisce in modo 
normale contro agenti patogeni. Tuttavia diversi ostacoli precludono l’applicazione di proto-
colli mirati all’induzione di tolleranza in ambito clinico. L’apoptosi, una forma di morte  pro-
grammata di fondamentale importanza  nel mantenimento dell’omeostasi tissutale in organi-
smi multicellulari, gioca un ruolo determinante nella regolazione del sistema immunitario e nel 
mantenimento della  auto-tolleranza. In questo progetto valuto l’opportunità  di sfruttare una 
modulazione farmacologica dei meccanismi che regolano l’apoptosi quale nuovo approccio 
per prevenire il rigetto e per indurre tolleranza immunologica.
Il capitolo 1 introduce i principi immunologici responsabili per il rigetto e le strategie cliniche 
e sperimentali per prevenirlo. L’apoptosi, il suo ruolo quale regolatore del sistema immunitario 
e le opzioni farmacologiche per modularne i meccanismi sono esposti nel capitolo 2. Nel ca-
pitolo 3 sono descritti i risultati dello studio sulle proprietà immunosuppressive della sostanza 
pro-apoptotica ABT-737 in vitro e in un modello di trapianto di pelle nel topo, che  mette in 
evidenza come l’effetto di tale  medicamento sia fortemente potenziato se  combinato con la 
ciclosporina. Questo sinergismo è ulteriormente analizzato nel capitolo 4. La caratterizzazio-
ne delle proprietà  immuno-modulatrici di ABT-737 rappresentano lo spunto per lo sviluppo di 
un nuovo protocollo per l’induzione di tolleranza immunologica basato sulla modulazione del-
la  apoptosi, come discusso nel capitolo 5. Nel capitolo 6 si prende in considerazione ABT-
737 per l’inibizione di linfociti memoria, un ostacolo fondamentale per l’applicazione della  
tolleranza in ambito clinico. Nel capitolo 7 riassumo le proprietà  immuno-modulatrici di ABT-
737 e altre  sostanze  pro-apoptotiche e nel capitolo 8 ne discuto le possibili applicazioni nel-
l’ambito della prevenzione del rigetto.
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Human leukocyte antigen
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Inhibitor of apoptosis
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Interleukin
Lymphocyte function-associated antigen
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Major histocompatibility complex
Mixed lymphocyte reaction
Mycophenolate mofetil
Mammalian target of rapamycin
Nuclear factor of activated T cells
Nuclear factor-κB
Propidium iodide
Programmed death 1
T cell receptor
Transforming growth factor
Tumor necrosis factor
TNF-related apoptosis-inducing ligand
Regulatory T cell
X-linked inhibitor of apoptosis
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Section I: General introduction
Chapter 1: Transplantation immunology
The immune self
The immune system protects the body from 
pathogenic microorganisms and tumors. The 
first critical task to achieve this aim is the 
recognition of harmful agents. The im-
mune system detects invading microorgan-
isms by two complementary and sequential 
strategies (Murphy, Travers et al. 2008). 
First, the innate  immune system reacts to 
danger signals and recognizes pathogens 
relying on a limited repertoire of molecular 
structures that are typically expressed by mi-
croorganisms, so cal led pathogen-
associated molecular patterns (PAMPs). 
This initial discrimination between self and 
non-self is of ancient origin and allows a 
rapid identification of infectious agents. 
However, throughout evolution pathogens 
developed a variety of solutions to overcome 
this sophisticated but rather static barrier. 
Therefore, vertebrates developed a  more 
sophisticated immunological recognition sys-
tem: antigen receptors (B and T cell recep-
tors) are generated by random rearrange-
ment of gene segments resulting in a recep-
tor repertoire that enables the adaptive im-
mune system to virtually recognize any anti-
gen that can be encountered in nature (To-
negawa 1976). This dynamic and plastic sys-
tem inevitably leads to the generation of 
lymphocytes with affinity to self-antigens, 
which have to be suppressed to avoid the 
catastrophic situation of the  immune system 
reacting against the host body (the  “horror 
autotoxicus” described by Paul Ehrlich). 
Thus, discrimination of self and non-self is a 
fundamental function of the adaptive im-
mune system.
Ray Owen’s seminal study of dizygotic cattle 
twins (Owen 1945) and Peter Medawar’s 
experiments in mice and chickens (Billing-
ham, Brent et al. 1953) showed that expo-
sure to foreign tissue during embryonic de-
velopment results in specific immunological 
non-reactivity (tolerance) to donor antigens, 
indicating that discrimination of self and 
non-self by the adaptive immune system is 
an acquired state. The explanation of this 
central principle  of adaptive immunity was 
proposed by Frank M. Burnet and is known 
as the clonal selection theory (Tab. 1) 
(Burnet 1959): self-reactive lymphocytes are 
deleted before they can mature by an active 
process, which eventually defines the anti-
gen receptor repertoire. Importantly, accord-
ing to this concept, tolerance can be de-
fined as a “specific depression of the im-
mune response induced by a previous expo-
sure to the antigen”(Tauber 1994). Thus, 
the immune self is not genetically deter-
mined and can be considered as a  dynami-
cally evolving entity, influenced by the  inter-
action of the immune system with the envi-
ronment. Although additional factors are 
involved in the maintenance  of self-
tolerance (e.g. regulatory T cells (Tregs)), the 
general concept of the clonal selection the-
ory has been proved right. The concept of a 
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1. Each lymphocyte bears a single type of 
receptor with a unique specificity
2. Receptor occupation leads to cell activa-
tion
3. The differentiated effector cells derived 
from activated lymphocyte will bear re-
ceptors of identical specificity as the pa-
rental cell
4. Lymphocytes bearing receptors specific 
for ubiquitous self molecules are deleted 
at an early stage and are therefore ab-
sent from the repertoire of mature lym-
phocytes
Tab. 1. Postulates of the clonal selection 
theory
dynamic immunological selfhood opens the 
opportunity to modulate the immune self to 
treat autoimmunity and to prevent allograft 
rejection.
Mechanisms of allograft rejection
Transplantation of living cells, tissues or or-
gans is often the  only or the  best treatment 
for patients with organ failure. Nowadays 
kidney, liver, heart, lung, pancreas, Langer-
hans islets, skin, hematopoietic stem cells, 
small intestine and composite grafts are  suc-
cessfully transplanted in the clinic (Morris 
2004; Sayegh and Carpenter 2004). Trans-
plantation of human kidney is the most 
frequent procedure in this field (181 kidneys 
transplanted in Switzerland in 2010 among 
a total of 389 organs) (Swisstransplant 
2010) and, although alternative  modalities 
of treatment are available, represents the 
most effective therapy for advanced renal 
failure in terms of survival and quality of life 
(Simmons and Abress 1990; Port, Wolfe  et 
al. 1993). However, transplantation from a 
genetically dissimilar individual (allogeneic 
transplant) can be considered as a iatro-
genic violation of the immune self that in-
duces an immune response in the host and 
inevitably leads to graft rejection (Nankivell 
and Alexander 2010).
Rejection of allografts is the  result of a 
complex immune response involving the 
transplanted tissue and the host innate and 
the adaptive immune system (Fig. 1) (Morris 
and Knechtle 2008). The trauma caused by 
the surgical procedure and by the hemody-
namic and neuroendocrine  response  to 
brainstem death in deceased donors leads to 
an inflammatory response in the trans-
planted tissue and activate the innate im-
mune system (Meltzer, Veillette et al. 
2012). This early antigen-independent re-
sponse is not sufficient to induce rejection, 
as demonstrated by the acceptance  of syn-
geneic grafts, but plays an important role in 
the stimulation of the subsequent antigen-
specific immune reaction (Kim, Bedi et al. 
2008). Activation of the endothelium and 
induction of cytokines, such as IL-6 and IL-1, 
promotes the graft infiltration of inflamma-
tory cells and the  migration of tissue-
resident, bone-marrow-derived dendritic 
cells (or passenger leukocytes) from the 
transplanted organ to the host lymphoid tis-
sue, where donor antigens are recognized 
by the adaptive immune system (Larsen, 
Morris et al. 1990; Celli, Albert et al. 2011).
The major histocompatibility complex 
(MHC; human leukocyte antigen – HLA – in 
humans) encodes for the  most important 
tissue antigens in transplantation and plays 
a crucial role in determining survival of 
transplanted organs (Opelz and Wujciak 
1994). In humans it is encoded on chromo-
some 6 and can be divided in three classes 
(Beck, Geraghty et al. 1999): MHC class I 
proteins are  expressed on all nucleated cells 
and are responsible  for the presentation of 
peptides primarily from the intracellular en-
vironment to CD8 T cells; MHC class II pro-
teins are  constitutively expressed on profes-
sional antigen presenting cells (such as den-
dritic cells, macrophages and B lympho-
cytes), but can be induced in many other cell 
types (such as renal tubular epithelial cells 
(Waeckerle-Men, Starke et al. 2007)) and 
are responsible  for the presentation of pep-
tides from the extracellular environment to 
CD4 T cells; the MHC class III region en-
codes for other proteins with disparate func-
tions in the immune system and is less rele-
vant in this particular context. At least six 
HLA loci are  recognized in humans: the 
three class I genes (HLA-A, HLA-B, HLA-C) 
and the three main class II genes (HLA-DP, 
HLA-DQ, HLA-DR) are transmitted as a  sin-
gle mendelian trait in a maternal and a pa-
ternal haplotype and are  codominantly ex-
pressed, so that siblings will have  a 25% 
chance to be HLA-identical, 50% haplo-
identical and 25% full-mismatched. Impor-
tantly, MHC molecules are characterized by 
an extensive  polymorphism (Gaur and 
Nepom 1996), so that MHC-identical unre-
lated individuals are very rare.
An additional barrier to transplantation is 
represented by minor histocompatibility 
antigens: polymorphic peptides presented 
by MHC molecules that assume a particular 
role in MHC-matched transplant combina-
tions (Peugh, Superina et al. 1986). The best 
characterized example  is the male-specific 
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HY antigen: females lack the  Y chromosome 
and recognize peptides encoded by Y chro-
mosome as foreign. Several other minor his-
tocompatibility antigens have been de-
scribed and directly reflect the intraspecies 
genetic variation, which assumes a renewed 
relevance after sequencing of the human 
genome. However, not all polymorphic pep-
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Fig. 1. The immune response after solid organ transplantation (Morris and 
Knechtle 2008)
tides display the  same immunogenicity and 
only a limited number of them have been 
shown to play a relevant role as minor histo-
compatibility antigens (Roopenian, Choi et 
al. 2002). Thus, identity of histocompatibility 
antigens is in fact only possible in monozy-
gotic twins, the only combination, in which 
organ transplantation will not result in graft 
rejection.
T lymphocytes are key players in most 
forms of acute rejection (Rosenberg and 
Singer 1992). As introduced above, the T 
cell repertoire  is the result of positive and 
negative selection in the thymus: only T cells 
that express a  T cell receptor (TCR) that 
binds to self-peptide/self-MHC complexes 
but do not react too strongly with self-
antigens survive and migrate to peripheral 
lymphoid organs as mature naïve T cells. The 
aim of this process is the generation of a 
broad T cell repertoire  to recognize all pos-
sible  invading organisms with a minimal risk 
for autoimmunity. Thus, T cells bearing a 
TCR that recognize donor antigens (not ex-
pressed by the recipients) are not deleted 
from the repertoire and react to alloantigens 
in three different ways (Fig. 2) (Gould and 
Auchincloss 1999). Direct allopresenta-
tion occurs when a recipient T cell recog-
nizes a donor-peptide/donor-MHC complex 
presented by donor passenger leukocytes 
migrating from the graft into the  regional 
lymphoid organs in the initial phase after 
transplantation. Because T cells are positively 
selected to bind MHC molecules, the allo-
geneic peptide/MHC complex provides a 
strong stimulus to the  immune system and a 
high percentage of T cells (1-10%) is typi-
cally activated after exposure to alloantigens 
(Reiser, Darnault et al. 2000; Nesic, Maric et 
al. 2002). For an indirect allopresentation 
donor-derived antigens are  processed by an-
tigen presenting cells of recipient origin and 
presented in the  context of a  donor-peptide/
recipient-MHC complex. Because of their 
polymorphism, peptides from MHC mole-
cules are critical in this setting, but minor 
histocompatibility antigens are presented in 
the same way. Cross-presentation (presenta-
tion of extracellular proteins on MHC class I) 
represents an alternative form of indirect 
allopresentation (Carbone, Kurts et al. 
1998). Moreover, it has been shown that 
recipient dendritic cells can acquire intact 
donor-MHC molecules. This process, called 
semidirect allopresentation, may explain 
how T cells that have been primed by 
recipient-derived dendritic cells can target 
the graft itself (expressing only donor-
derived MHC), but the relevance of this 
mechanism remains to be assessed (Russo, 
Zhou et al. 2000).
Binding of the TCR is necessary but not suf-
ficient for a full activation of a naïve T cell. 
Cell-adhesion molecules (such as CD2, LFA-
1 and ICAM-3) are additionally required to 
stabilize  the  interaction between T cells and 
antigen presenting cells (APCs) in the su-
10
Fig. 2. Direct (A), indirect (B) and semidirect 
(C) allo-recognition (Morris and Knechtle 
2008)
pramolecular organization of receptors and 
ligands called immunological synapse 
(Bromley, Burack et al. 2001). Moreover, ac-
cording to the three-signal model, TCR trig-
gering (signal 1) results in activation and dif-
ferentiation of a naïve T cell only in combi-
nation with co-stimulation (signal 2) and a 
differentiation stimulus mostly provided by 
cytokines (signal 3) (Kapsenberg 2003; Hal-
loran 2004). The most important costimula-
tion is provided by the interaction of CD28 
with B7 molecules and of CD154 (CD40L) 
with CD40, but these processes are  known 
to be partially redundant. Moreover, addi-
tional co-stimulatory (such as CD27, TIM or 
4-1BB) and co-inhibitory molecules (such as 
CTLA-4 or PD-1) influence  signal 2 in a 
complex dynamic interaction (Clarkson and 
Sayegh 2005), which has assumed a thera-
peutical relevance in the field of transplanta-
tion in the last years (s. next section). In the 
presence of an adequate costimulation, T 
cells proliferate, differentiate into effector T 
cells and migrate into the graft.
The destruction of the graft is orchestrated 
by the differentiation of CD4 T cells in Th1, 
Th2, Th17 and Treg cells and is accom-
plished by a direct injury of transplanted tis-
sue and by a further activation of endothe-
lial and inflammatory cells. Cytotoxic CD8 T 
cells induce cell death in target cells by re-
leasing perforin and granzymes and by a 
Fas-dependent activation of the  extrinsic 
apoptosis pathway. CD4 T cells directly 
damage the graft by secreting tumor necro-
sis factor (TNF) α and β. Antibodies target-
ing donor MHC molecules, natural killer 
cells, macrophages, eosinophils and other 
cytokines are additionally involved in the 
complex process of allograft rejection 
(Nankivell and Alexander 2010).
The mechanisms described here typically oc-
cur in the context of an acute allograft rejec-
tion. Other mechanisms are involved in hy-
peracute  and chronic rejection. Hyperacute 
rejection is mediated by preformed or natu-
ral antibodies targeting ABO blood group 
antigens, or MHC class I or class II molecules 
in sensitized recipients. Rejection occurs 
within minutes after revascularization 
through activation of the complement sys-
tem. This problem can be avoided by ABO-
matching and is largely a  thing of the past 
since the introduction of pretransplant 
cross-match screening (Kissmeyer-Nielsen, 
Olsen et al. 1966). Chronic allograft rejec-
tion leads to a progressive deterioration of 
the graft function over years and has as-
sumed a critical relevance since the  success 
of modern immunosuppression to control 
acute rejection (s. next section). In the case 
of kidney transplantation, chronic allograft 
nephropathy is characterized by a  concentric 
arteriosclerosis of graft blood vessels, with 
interstitial fibrosis and tubular atrophy. Im-
munological mechanisms, chronic inflamma-
tion, ischemia-reperfusion injury, endothelial 
dysfunction and pharmacological factors are 
likely to be involved in the pathogensis of 
this incompletely understood process (Bedi, 
Riella  et al. 2010; Nankivell and Kuypers 
2011).
Strategies to prevent allograft rejection
Preventing allograft rejection is the critical 
issue in transplantation medicine. The suc-
cess of transplantation in the last decades is 
in large part attributable  to the introduction 
of effective  immunosuppressive drugs, 
mostly targeting the complex process of T 
cell activation and proliferation (Halloran 
2004; Taylor, Watson et al. 2005). The most 
important classes of immunosuppressive 
drugs in clinical transplantation and their 
mechanisms of action are summarized in 
this section (Tab. 2, Fig. 3).
Glucocorticoids are an old class of drugs 
with multiple anti-inflammatory and immu-
nomodulatory effects and are still routinely 
used in most immunosuppressive regimens 
and as a first-line treatment of acute rejec-
tion episodes. Steroids bind to the glucocor-
ticoid receptor in the cytoplasm inducing its 
translocation into the nucleus. The interac-
tion of the steroid-receptor complex with 
transcription factors such as activator pro-
tein 1 (AP1) and nuclear factor-κB (NF-κB) 
influences the transcription of a  bunch of 
genes critically involved in allograft rejection 
(such as IL-1, IL-2, IL-6, IFN-γ and TNF-α). At 
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h ighe r doses add i t i ona l r ecep to r -
independent effects have been described 
(Adcock and Ito 2000).
Anti-proliferative drugs are the  second im-
portant historical class of immunosuppres-
sants (Elion 1993). Only with the  combina-
tion of steroids and the anti-metabolite 
azathioprine in the early 1960s effective 
immunosuppression became a reality and 
the first allogeneic transplantations were 
successfully performed (Calne 1960; Murray, 
Merrill et al. 1963). Azathioprine is metabo-
lized to 6-mercaptopurine and incorporated 
into DNA and RNA blocking replication and 
transcription. Moreover, it inhibits the de 
novo purine synthesis pathway with a partial 
selectivity for lymphocytes. As a  result, lym-
phocyte  proliferation and IL-2 production 
are markedly inhibited by azathioprine, but 
bone marrow depression inevitably occurs. 
Recent studies revealed that azathioprine 
additionally interferes with costimulation 
signaling, converting CD28 costimulation 
into an apoptotic stimulus (Tiede, Fritz et al. 
2003). Anti-proliferative agents are  still part 
of most immunosuppressive regimens but 
inhibitors of nucleotide synthesis are used 
instead of anti-metabolites in most centers, 
because of better efficacy and reduced tox-
icity. Mycophenolate mofetil (MMF) is the 
most important member of this class; it se-
lectively suppresses purine synthesis in lym-
phocytes by inhibition of the  enzyme inosine 
monophosphate dehydrogenase (Sollinger 
1995).
Calcineurin inhibitors (CNIs) revolutionized 
transplantation in the 1980s and have rep-
resented the cornerstone of immunosup-
pression for more than two decades (Borel, 
Feurer et al. 1977). CNIs suppress T cell acti-
vation by inhibition of the TCR – calcineurin 
– nuclear factor of activated T cells (NFAT) 
pathway (signal 1) in the early phase after 
exposure to the  alloantigen (Clipstone and 
Crabtree 1992). CNIs exert their immuno-
suppressive effect only after binding to im-
munophilins (more precisely, cyclosporine 
A (CsA) binds to cyclophilin A and tacro-
limus (FK506) to FKBP-12); both complexes 
inhibit the phosphatase activity of calci-
neurin, preventing the de-phorphorylation 
and the  nuclear translocation of NFAT. 
Blocking signal 1 dramatically reduces IL-2 
production and IL-2 receptor (CD25) expres-
sion resulting in an abortive  T cell activation. 
Several additional effects of CNIs have been 
described: CsA enhances the expression of 
transforming growth factor β (TGF-β), influ-
ences the regulation of apoptosis in lym-
phocytes (s. chapter 2) and the activation of 
dendritic cells (Chen, Guo et al. 2004). 
Moreover, CsA reduces the  expression of 
MHC class II in renal epithelial cells and 
therefore the antigenicity of transplanted 
kidneys (Milton, Spencer et al. 1986). Unfor-
tunately, immunophilins and calcineurin 
have been found to play a role  in a  variety 
of cell types other than lymphocytes, result-
ing in major side effects (Kiani, Rao et al. 
2000). Therefore, more selective NFAT-
inhibitors have recently been developed to 
block signal 1 without calcineurin inhibition 
(Aramburu, Yaffe et al. 1999).
12
1. Glucocorticoids
2. Calcineurin inhibitors
- Cyclosporine A
- Tacrolimus
3. mTOR inhibitors
- Sirolimus
- Everolimus
4. Anti-proliferative drugs
- Mycophenolate
- Azathioprine
5. Depleting antibodies
- Polyclonal horse or rabbit antithymo-
cyte globulin (ATG)
- Anti-CD3: Muromonab-CD3 (OKT-3)
- Anti-CD52: Alemtuzumab 
(Campath-1H)
- Anti-CD20: Rituximab
6. Non-depleting antibodies and fusion 
proteins
- Anti-CD25: Basiliximab, Daclizumab
- Anti-B7: Belatacept
7. Intravenous immune globulin
Tab. 2. Classification of immunosuppressive 
therapies used in organ transplantation
Similar to FK506, mTOR inhibitors also 
bind to the immunophilin FKBP-12, but ex-
ert their immunosuppressive effect by inhib-
iting the mammalian target of rapamycin 
(mTOR), a  key component of the cell cycle 
regulatory signaling (Heitman, Movva  et al. 
1991). In lymphocytes, the stimulus for pro-
liferation is provided by triggering cell sur-
face receptors (particularly by binding of IL-2 
to IL-2R), which leads to activation of janus 
kinase 3 and mTOR complex 1 (signal 3). 
The FKBP-12-sirolimus complex blocks this 
process, preventing proliferation of activated 
T cells. Sirolimus and everolimus are 
mostly used in CNI-free immunosuppression 
regimens in combination with MMF and 
may have a clinically relevant anti-neoplastic 
effect (Webster, Lee et al. 2006).
The small molecule  immunosuppressive 
drugs briefly described here are often com-
bined with protein drugs (biologics). Anti-
body preparations, usually classified as de-
pleting or nondepleting, exert their immu-
nomodulatory effect in different ways. The 
m o s t i m p o r t a n t m e c h a n i s m s a r e 
complement-dependent lysis of targeted 
cells, mimicking of the physiological ligand 
resulting in triggering or blockade of signal 
transduction, induction of surface molecule 
internalization and stimulation of phagocytic 
cells (Morris and Knechtle 2008). Techniques 
to generate antibodies with a  single, geneti-
cally defined monoclonal specificity opened 
the opportunity to target surface molecules 
involved in adaptive immune responses and 
therefore to establish selective therapeutic 
options. This led to an explosion in the de-
velopment of biologics in the field of trans-
plantation and autoimmunity in the last 
years. Polyclonal (anti-thymocyte globulin – 
ATG) and monoclonal (muronomab-CD3, 
alemtuzumab, rituximab) lymphocyte  de-
pleting antibodies are generally indicated 
for induction therapy and for the treatment 
of refractory rejection. Nondepleting mono-
clonal antibodies and fusion proteins have 
been designed to bind to essential factors in 
the activation of alloreactive T cells. Block-
ade of signal 2 is a promising approach in 
this setting and the B7-directed fusion pro-
tein belatacept has recently been shown to 
provide a good immunosuppression after 
kidney transplantation without the nephro-
toxic side effects of CNIs (Vincenti, Larsen et 
al. 2005). Inhibition of CD40-CD154 signal-
ing by targeting CD154 showed great prom-
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Fig. 3. T cell activation and site of action of immunosuppressive drugs
ise in rodent models (Larsen, Elwood et al. 
1996), but first clinical trials failed because 
of unexpected thromboembolic side effects 
(Kawai, Andrews et al. 2000). Signal 3 can 
be inhibited by anti-CD25 antibodies (dacli-
zumab and basiliximab). These antibodies 
bind to the IL-2R and hinder the activation 
of the  receptor by IL-2, and may have addi-
tional beneficial effects on Tregs (Vincenti, 
Kirkman et al. 1998).
Thus, a diversified armamentarium of drugs 
is currently available to prevent and to treat 
acute allograft rejection. The  progressive de-
velopment of novel immunosuppressive 
strategies was accompanied by miraculous 
outcome improvement (Morris 2004). After 
the initial discouraging experiences, the in-
troduction of azathioprine in combination 
with steroids allowed to achieve a 1-year 
graft survival of 50% in the late 1970s. But 
it was the  discovery of CNIs that radically 
changed the efficacy of immunosuppres-
sion, leading to a  continuous improvement 
in 1-year graft survival (Fig. 4). Current stan-
dard immunosuppressive regimes, including 
CNI, MMF and steroids, in combination with 
an induction therapy with depleting or anti-
CD25 antibodies for patients with a high 
risk for rejection, result in 95% 1-year graft 
survival in most centres (Hariharan, John-
son et al. 2000; Ekberg, Tedesco-Silva et al. 
2007). Thus, nowadays acute allograft rejec-
tion after solid organ transplantation is a 
preventable and curable disease, but major 
problems remain to be solved.
Currently available  immunosuppressive 
drugs unselectively inhibit the immune sys-
tem and induce a generalized immuno-
suppression. Therefore, the ameliorated 
efficacy in allograft rejection was inevitably 
related to a risk for infections and tumors 
(Fishman and Rubin 1998; Kasiske, Snyder 
et al. 2004). The identification of immuno-
logical markers to estimate the degree  of 
immunosuppression required by each single 
patient would allow to better balance the 
trade-off between prevention of allograft 
rejection and over-immunosuppression 
(Cippa and Fehr 2011). Moreover, the long-
term exposure to these drugs results in ma-
jor side effects not directly related to their 
immunosuppressive  activity. Importantly, 
several immunosuppressive drugs have a 
negative impact on cardiovascular risk fac-
tors: dyslipidemia is a common side effect of 
CNIs, mTOR inhibitors and steroids, hyper-
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Fig. 4. One-year graft survival and graft half-life in a cohort of first 
deceased kidney transplant recipients (Kasper and Harrison 2005)
tension and diabetes are often registered in 
patients treated with CNIs and steroids 
(Feehally, Floege et al. 2007). These factors 
do not directly influence 1-year graft survival 
but have a deleterious long-term impact on 
patient survival and quality of life. Moreover, 
the well-known nephrotoxic properties of 
CNIs lead to a progressive deterioration of 
renal function after transplantation (Cippa 
and Fehr 2010). Thus, about 50% of the 
renal graft loss beyond the first year after 
transplantation is due to the  death of the 
patient with a functioning graft, mostly be-
cause of cardiovascular events (Pascual, The-
ruvath et al. 2002). Moreover, despite their 
potency against acute rejection, currently 
available immunosuppressive drugs are 
much less effective in preventing chronic 
allograft rejection (Nankivell and Kuypers 
2011). As a result, the long-term outcome 
after transplantation could not significantly 
be improved in the last decades (Fig. 4) and 
innovative strategies are required to ap-
proach this challenging issue.
Two principles have to be pursued for the 
establishment of new strategies for allograft 
rejection control: tissue-selectivity and 
allo-selectivity. First, to avoid off-target 
side effects, immunomodulatory drugs or 
procedures should selectively target the tis-
sues involved in allograft rejection. Consid-
ering the critical role  of the adaptive im-
mune system in this setting, the lymphatic 
cells are the most obvious target, but the 
transplanted organ may represent an addi-
tional element of interest as trigger and as 
final target of the immune response (Cypel, 
Yeung et al. 2011). Second, to avoid gener-
alized immunosuppression, only allo-reactive 
lymphocytes should be suppressed in their 
activity. This task is particularly challenging: 
antigen-selectivity is determined by the  anti-
gen receptor (B and T cell receptor), but be-
cause of the high variability of this single 
selectivity marker, this does not represent a 
reasonable pharmacological target. Thus, 
allo-selectivity can probably only be achieved 
by exposing the recipient to donor antigens 
and modulating the properties of the re-
sponding lymphocytes. Exposure to donor 
antigens by the administration of a donor 
specific transfusion (DST) before trans-
plantation has been shown to generate 
Tregs and may improve outcome of kidney 
transplants, but has been abandoned in 
most centers because the procedure in-
duced sensitization to the donor in a sub-
group of patients (Bushell, Karim et al. 
2003; Marti, Henschkowski et al. 2006). 
However, this approach may assume a new 
relevance in combination with novel immu-
nomodulatory agents. The molecular under-
standing of the T cell activation process is 
critical in this setting and the rational devel-
opment of drugs binding to receptors selec-
tively involved in T cell activation (such as 
costimulation molecules and CD25) is an 
important step in this direction. However, 
allo-selectivity will be  inevitably lost if the 
immunomodulatory drug is administered 
long-term after transplantation, because the 
immune response  against newly encoun-
tered environmental antigens would also be 
affected. Thus, the most promising ap-
proach to induce true allo-selectivity is rep-
resented by a  short conditioning protocol 
including exposure to donor antigens that 
leads to a sustained donor-specific hypore-
sponsiveness or tolerance.
Transplantation tolerance
Induction of donor-specific tolerance, a  state 
in which the immune system does not react 
against the  transplanted tissue but normally 
responds to foreign antigens, conceptually 
corresponds to a re-programming of the 
adaptive immune system with a partial re-
definition of the immune self (Waldmann, 
Adams et al. 2008). The first step towards 
the realization of this aim was taken in the 
1950s by Peter Medawar, who demon-
strated that tolerance is acquired during 
embryonic development in mice (Billingham, 
Brent et al. 1953). The early attempts to 
translate these results into clinical practice 
were mostly abandoned after the introduc-
tion of effective  immunosuppressive drugs 
(Schwartz and Dameshek 1959; Murray, 
Merrill et al. 1960; Starzl and Zinkernagel 
2001). However, the more recent recogni-
tion of the substantial limitations of immu-
nosuppression in the long-term encouraged 
15
the transplant community to reconsider al-
lograft tolerance as a realistic aim in clinical 
transplantation (Fehr and Sykes 2004; 
Waldmann 2010; Dolgin 2012).
To find a way to establish tolerance in 
transplantation it is necessary to understand 
the mechanisms physiologically determining 
tolerance to self-antigens. This is the re-
sult of the concerted action of processes 
that operate at different sites and stages of 
development (Goodnow, Sprent et al. 2005; 
Murphy, Travers et al. 2008) (Tab. 3). As dis-
cussed before, central clonal selection is 
the first and most important checkpoint to 
eliminate  newly formed auto-reactive lym-
phocytes, but central tolerization is not per-
fect and additional peripheral mechanisms 
are required to prevent autoimmunity.
Critical in this setting is the  role  of antigen 
presenting cells (APCs). “Danger signals” 
delivered by pathogens, by the innate and 
the adaptive immune system and by the tis-
sue influence the activation (or “licensing”) 
of APCs by regulating the  expression of co-
stimulatory and co-inhibitory factors. The 
“licensed” APC expresses high levels of 
MHC and costimulatory molecules such as 
CD40, CD80 and CD86 and fully activates T 
cells reacting against the presented anti-
gens. In contrast, in the absence of ade-
quate costimulation, reactive  T cells become 
anergic and undergo apoptosis. Thus, T 
cells that escape central selection are inacti-
vated or deleted from the repertoire  when 
antigen recognition occurs in a  “danger-
free” environment.
Immunological regulation, resulting from a 
complex interaction between immune cells, 
is an additional critical mechanism for the 
maintenance of self-tolerance. It has been 
r e c o g n i z e d t h a t a p o p u l a t i o n o f 
CD4+CD25+FoxP3+ T cells, called regula-
tory T cells (Tregs), plays a  critical role in this 
setting. This is well demonstrated by the in-
duction of catastrophic systemic autoimmu-
nity after selective ablation of FoxP3 express-
ing cells or their functional inhibition using 
an anti-GITR antibody (Sakaguchi, Sakaguchi 
et al. 1995; Shimizu, Yamazaki et al. 2002; 
Kim, Rasmussen et al. 2007). The majority of 
Tregs develops in the thymus (natural Tregs), 
but naïve CD4 T cells can also convert to 
Tregs (induced Tregs) when stimulated un-
der the effect of TGF-β and IL-10 (Chen, Jin 
et al. 2003). Moreover, differentiation to 
Tregs can be obtained experimentally by ac-
tivation of naïve CD4 T cells under the effect 
of rapamycin (Battaglia, Stabilini et al. 
2005), anti-CD154 (Taylor, Friedman et al. 
2002) or phosphodiesterase inhibitors (Feng, 
Nadig et al. 2011). Tregs exert their immu-
nosuppressive effect influencing other lym-
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Mechanism Site of action
Central clonal deletion Apoptosis Thymus, bone marrow
Peripheral anergy Cellular inactivation by weak 
signaling without costimula-
tion
Secondary lymphoid organs
Peripheral clonal deletion Apoptosis Secondary lymphoid organs 
and sites of inflammation
Regulatory cells Suppression by cytokines, 
intercellular signals
Secondary lymphoid organs 
and sites of inflammation
Antigen segregation Physical barrier to antigen 
access to lymphoid system
Peripheral organs
Tab. 3. Mechanisms controlling self-tolerance (Murphy, Travers et al. 2008, modified)
phocytes and APCs via  direct cell-cell con-
tact, secretion of interleukins or by cytotox-
icity (Wood, Bushell et al. 2011). Moreover, 
Tregs promote the  generation of additional 
Tregs, thereby sustaining peripheral toler-
ance over time in a process called infec-
tious tolerance (Qin, Cobbold et al. 1993). 
In the last years, there was an increasing in-
terest on the  role of peripheral tissues in 
the regulation of the adaptive  immune sys-
tem (Matzinger and Kamala 2011). Since 
decades it has been known that tissue grafts 
transplanted in so-called immune privi-
leged sites (such as the anterior eye  cham-
ber or the testes) are not rejected by the 
immune system (Medawar 1948). Physical 
barriers that protect the tissue from an in-
teraction with the immune system have 
been described in these particular parts of 
the body, but additional regulatory mecha-
nisms are likely to be involved. Similar 
mechanisms probably explain the lack of re-
jection of the mammalian fetus by the ma-
ternal immune system, the only example of 
allogeneic tolerance physiologically occur-
ring in nature (Mold, Michaelsson et al. 
2008).
The processes involved in the maintenance 
of self-tolerance briefly discussed here can 
be exploited to establish experimental 
strategies to induce donor-specific tolerance 
aiming at acceptance of solid organ trans-
plants.
Central tolerance can be achieved through 
the induction of mixed chimerism and is 
discussed in details in the next paragraph.
Peripheral anergy and clonal deletion are 
obtained by costimulation blockade. A 
combined costimulation blockade using the 
anti-CD154 (anti-CD40L) antibody MR1 and 
CTLA4Ig was sufficient to induce long-term 
acceptance of cardiac or islet allografts in 
mice (Larsen, Elwood et al. 1996), but not in 
more stringent models of skin grafting or in 
large animals (Markees, Phillips et al. 1997; 
Kirk, Burkly et al. 1999). Moreover, a  gener-
alized allo-antigen exposure (as obtained 
with DST) under the cover of MR1 resulted 
in a substantial prolongation of MHC-
mismatched skin graft survival and to per-
manent allograft acceptance in thymecto-
mized mice, indicating that this procedure 
was sufficient to tolerize the peripheral im-
mune system in naïve mice, but that newly 
arising T cells were not inhibited using this 
approach (Markees, Phillips et al. 1998).
Regulatory mechanisms are key elements in 
the modulation of the adaptive immune sys-
tem, and Tregs may find a  clinical applica-
tion to induce tolerance in the near future 
(Leslie  2011). Two general strategies are 
pursued: the application of Tregs as a com-
ponent of a cellular therapy or the  develop-
ment of drugs selectively modulating Tregs 
in vivo (Li and Turka 2010). Transfer of ex 
v i v o g e n e r a t e d o r e x p a n d e d 
CD4+CD25+FoxP3+ Tregs can prevent 
acute and chronic allograft rejection and de-
velopment of transplant arteriosclerosis in 
mouse and humanized mouse models (Feng, 
Wood et al. 2008; Nadig, Wieckiewicz et al. 
2010; Warnecke, Feng et al. 2010). How-
ever, Tregs are less effective in the inhibition 
of memory cells and T-effector cells acti-
vated under inflammatory conditions. 
Moreover, their unfavorable ex vivo expan-
sion properties and technical limitations re-
lated to the high numbers of Tregs required 
for immune regulation remain to be solved 
for a clinical application of this approach. 
The selective  stimulation of Tregs in vivo 
may represent a  technically less challenging 
strategy. Antigen recognition under 
costimulation blockade or rapamycin gener-
ates allo-reactive Tregs that can induce  tol-
erance in minor histocompatibility mis-
matched models (Graca, Honey et al. 2000; 
Lee, Rusche et al. 2001). Apart from 
CD4+CD25+FoxP3+ Tregs, non-lymphoid 
regulatory cells, such as regulatory den-
dritic cells (Steinman, Hawiger et al. 2003), 
mesenchymal stem cells (English and Mahon 
2011) and regulatory macrophages are con-
sidered potential targets for the induction of 
tolerance (Dugast and Vanhove 2009).
Antigen segregation has also been inves-
tigated as a possible strategy to prevent allo-
graft rejection. The  most important applica-
tion of this approach is the encapsulation of 
pancreas islets (Vaithilingam and Tuch 
2011).
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Mixed chimerism
It has been known for many years that 
transplantation of hematopoietic stem cells 
(HSCs) during development results in donor-
specific tolerance  (Billingham, Brent et al. 
1953). This process is mediated by donor-
derived APCs that migrate into the thymus 
and contribute to negative selection leading 
to a selective  deletion of donor-reactive 
newly arising T cells. Obtaining the same 
result in a recipient with a mature immune 
system is much more difficult, because sup-
pression of peripheral and intra-thymic al-
loreactivity is necessary. The most simple but 
invasive approach to achieve this aim in 
mice is a complete deletion of the preexist-
ing immune system by lethal irradiation, fol-
lowed by reconstitution with donor bone 
marrow (BM) to induce “full chimerism”. 
This procedure is not clinically applicable be-
cause of the toxicity of the  induction regi-
men and because of the high risk for graft 
versus host disease (GvHD) (Sykes 2001; 
Pilat and Wekerle 2010). However, it has 
been recognized that reconstitution with a 
mixture  of donor and recipient BM to induce 
a state called mixed chimerism, in which 
recipient and donor HSCs co-exist, similarly 
leads to donor-specific tolerance (Ildstad and 
Sachs 1984). In this situation, recipient- and 
donor-derived APCs migrate into the thymus 
and induce central deletion of both recipi-
ent- and donor-reactive T cells (Fig. 5). Cen-
tral tolerance in mixed chimeras is systemic 
and robust, as shown by acceptance of fully 
MHC-mismatched skin and vascularized al-
lografts in rodents and large animals (Sachs, 
Sykes et al. 2011). Importantly, the induc-
tion of mixed chimerism is much less prob-
lematic than a full donor chimerism. First, 
because BM-derived cells are more efficient 
than thymic stromal cells for negative selec-
tion, the presence of recipient-derived APCs 
in the thymus is associated with a reduced 
risk for GvHD. Second, because deletion of 
recipient BM is not required, mixed chimer-
ism can be achieved using less toxic non-
myeloablative conditioning protocols (Sykes 
2001).
The prerequisites to achieve mixed chimer-
ism are a  tolerization of the preexisting im-
mune system and the engraftment of donor 
HSCs. A general re-setting of the peripheral 
adaptive immune system in naïve  mice  can 
be achieved by depleting doses of anti-CD4 
and anti-CD8 monoclonal antibodies, but 
the efficacy of this approach is limited in 
humans (Sykes, Szot et al. 1997). A more 
attractive strategy is represented by a selec-
tive inactivation or deletion of allo-reactive T 
cells using the tolerance induction strategies 
introduced before. This leads to a combined 
approach: a tolerance inducting therapy (ef-
fective in the short-term but not sufficient to 
maintain long-term tolerance by itself) al-
lows engraftment of HSCs and the progres-
sive  establishment of central deletion main-
tains permanent tolerance.
18
Fig. 5. Mechanism of tolerance in mixed chimeras
The most investigated approach is the  com-
bination of HSC transplantation with 
costimulation blockade. In fact, a single 
injection of anti-CD154 (MR1) in combina-
tion with low-dose total body irradiation 
(TBI, 3 Gy) or donor specific transfusion 
(DST) was sufficient to induce mixed chimer-
ism using standard doses of BM cells (20-
50x106 cells/mouse) (Wekerle, Sayegh et al. 
1998; Seung, Mordes et al. 2003). Double 
costimulation blockade with MR1 and 
CTLA4Ig induced mixed chimerism even 
without any cytoreductive treatment after 
injection of mega-doses of BM cells 
(200x106 cells/mouse) (Wekerle, Kurtz et al. 
2000). The mechanism of initial tolerance 
in animals receiving BM cells under the  ef-
fect of costimulation blockers is complex 
and not completely understood (Wekerle, 
Kurtz et al. 2002). After a phase  of T cell 
anergy (Kurtz, Shaffer et al. 2004), the most 
important mechanism is peripheral clonal 
deletion of donor-reactive T cells (Wekerle, 
Sayegh et al. 1998).  MR1-induced T cell de-
letion is the result of an incomplete APC li-
censing determined by the inhibition of the 
CD40-signaling and not a direct effect of 
CD154 binding on activated T cells (Kurtz, 
Ito et al. 2001). Incompletely activated APCs 
induce apoptosis in donor-reactive  T cells 
primarily through activation of the intrinsic 
apoptosis pathway (s. chapter 2), but several 
studies indicated that an initial additional 
reduction in the number of donor-reactive T 
cells is required to establish tolerance across 
MHC barriers (Li, Li et al. 1999; Wells, Li et 
al. 1999; Li, Strom et al. 2001; Wekerle, 
Kurtz et al. 2001). Interestingly, although 
T regs a re  gene ra l l y imp l i ca ted in 
costimulation-based protocols, in mixed 
chimerism models no evidence for classical 
regulatory T cells was detected (Kurtz, Shaf-
fer et al. 2004; Kurtz, Wekerle et al. 2004). 
However, deletion of CD4 T cells (but not of 
CD25 cells) in the initial phase precluded 
mixed chimerism induction, demonstrating 
that the initial presence of CD4+CD25- cells 
is required for the tolerization of CD8 T cells 
(Fehr, Takeuchi et al. 2005; Fehr, Haspot et 
al. 2008). Although Tregs are probably not 
pivotal for mixed chimerism induction using 
non-ablative irradiation and MR1, it has re-
cently been demonstrated that injection of 
ex vivo generated Tregs promotes mixed 
chimerism induction allowing tolerance in-
duction without cytoreductive conditioning 
(Pilat, Baranyi et al. 2010). Further studies 
using this approach in non-human primates 
are ongoing.
In the first studies using the  mixed chimer-
ism approach, irradiation was systematically 
included in the  conditioning protocol not 
only to suppress peripheral allo-reactive 
lymphocytes, but also to promote HSC en-
graftment with the assumption that a par-
tial depletion of recipient hematopoietic 
stem cells was required to “create space” in 
the BM (Tomita, Sachs et al. 1994). The de-
velopment of i rradiat ion-free, non-
myelosuppressive protocols demonstrated 
that this theory was wrong (Sykes, Szot et 
al. 1997; Wekerle, Kurtz et al. 2000). The 
mechanisms involved in BM engraftment 
after intra-venous injection of HSCs have 
only been partially elucidated. It is known 
that HSCs physiologically migrate from the 
BM to the blood (mobilization) and from the 
blood to the BM (homing) in normal ani-
mals. HSCs injected into the blood partici-
pate  to this dynamic process and compete 
with circulating host HSCs for the available 
stem cell niches in the BM (Kondo, Wagers 
et al. 2003). Irradiation or cytotoxic agents 
may promote the mobilization of HSCs and 
facilitate the engraftment of donor derived 
HSCs, but this is apparently not necessary if 
mega-doses of BM are used (Wekerle, Kurtz 
et al. 2000). The adaptive  immune system 
may play an additional role in engraftment 
and maintenance of allogeneic HSCs. Recent 
studies demonstrated that HSC niches in the 
BM are immune privileged sites (Fujisaki, Wu 
et al. 2011), so that the acceptance of do-
nor HSCs may be maintained through local 
regulatory mechanism even before central 
deletional tolerance has been established.
Engraftment of donor APCs in the thymus is 
required to induce  central tolerance (Fig. 5). 
Since monoclonal antibodies are not very 
efficient in depleting allo-reactive thymo-
cytes, thymic irradiation was introduced to 
inhibit residual intra-thymic alloreactivity in 
19
non-myeloablative protocols (Sykes 2001). In 
rodents this could be replaced by the intro-
duction of costimulation blockers or by a 
short course of CsA (Nikolic, Zhao et al. 
2000), but thymic irradiation is still included 
in mixed chimerism induction protocols in 
clinical evaluation. 
Among the different approaches to induce 
tolerance in rodents very few were success-
ful in large animals and only the  mixed chi-
merism model was translated into the first 
pilot studies in patients, principally by 
two independent groups in the United 
States (Fig. 6) (Fehr and Sykes 2008). The 
group of Samuel Strober at Stanford estab-
lished a mixed chimerism induction protocol 
based on T cell depletion with anti-
thymocyte globulin (ATG) and irradiation of 
lymphoid organs first in dogs and non-
human primates and finally in kidney trans-
plant patients (Strober, Modry et al. 1984; 
Myburgh, Smit et al. 2001). In the  first clini-
cal study with HLA-mismatched cadaveric 
kidney allografts only 3 of 28 patients de-
veloped tolerance and only one patient has 
been reported to be tolerant for more then 
10 years (Strober, Dhillon et al. 1989; 
Strober, Benike et al. 2000). The recently 
reported results of a second trial using an 
intensified protocol and HLA-matched kid-
ney allografts were much more encouraging 
with 8 out of 12 patients that had gone off 
of immunosuppresants for more then one 
year without complications (Scandling, 
Busque et al. 2011).
The group at Massachusetts General 
Hospital (David Sachs, Megan Sykes) was 
involved in the initial studies using the mixed 
chimerism approach in rodents and further 
developed it in pigs and non-human pri-
mates to establish a clinical protocol consist-
ing of T cell depletion using ATG or a de-
pleting monoclonal anti-CD2 antibody, cy-
clophosphamide, a  short course of CsA and 
thymic irradiation (Sachs, Sykes et al. 2011). 
The first clinical study was performed in pa-
tients with renal failure  secondary to multi-
ple myeloma. As allogeneic BM transplan-
tation is the only known cure for multiple 
myeloma, but conventional BM transplanta-
tion was contraindicated in these patients 
because of renal failure, a combination of 
BM and renal transplantation in a HLA-
matched combination was considered the 
ideal option in this particular situation. Only 
one of the 9 patients treated with this pro-
tocol developed acute allograft rejection af-
ter discontinuation of the immunosuppres-
sive  therapy, and only 3 patients presented a 
recurrence on the myeloma (Fudaba, Spitzer 
et al. 2006). The second study was per-
formed with HLA-mismatched renal allo-
graft in patients without complicating neo-
plasia. In 8 of 10 patients immunosuppres-
sion has been discontinued and in 7 of them 
renal allograft function has been stable for a 
follow-up of 10 to 90 months (Kawai, 
Cosimi et al. 2008; Kawai, Sachs et al. 
2011).
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Fig. 6. Clinical protocols to induce mixed chimerism (Dolgin 2012)
Despite the small numbers of patients and 
the partially unsatisfactory results, these 
pioneering studies demonstrated that toler-
ance induction through mixed chimerism is 
feasible  in the  clinic and highlighted several 
limitations that remain to be addressed for 
a broad application of this approach. The 
conditioning protocols required to induce 
mixed chimerism in patients are  character-
ized by major toxicity, related to the fact 
that mixed chimerism induction in large-
animals is much more difficult than in ro-
dents, due to of immunological and phar-
macological differences (Sykes 2001). 
Among the immunological factors, memory 
cells have  been shown to preclude toler-
ance induction particularly in costimulation-
based protocols in mice and non-human 
primates (Nadazdin, Boskovic et al. 2011). 
Interestingly, memory cells generated as a 
result of previous infections can crossreact 
with allo-antigens in a process called heter-
ologous immunity (Adams, Williams et al. 
2003) and provide a major barrier for the 
translation to the clinic of protocols estab-
lished in laboratory mice that have been 
barely exposed to pathogens during their 
life (Ford and Larsen 2011). Pharmacological 
challenges are primarily related to the 
thromboembolic side effects registered in 
non-human primates and in humans after 
treatment with anti-CD154 (Kawai, An-
drews et al. 2000) and to major differences 
in the response to lymphocyte depleting 
therapies among species: particularly, com-
plete T cell depletion is possible in mice 
but is not realistic in humans (Sachs, Sykes 
et al. 2011). For these reasons less sophisti-
cated but much more toxic regimes were 
chosen for the clinical studies, resulting in 
severe morbidity. All recipients developed 
pancytopenia and most of them engraft-
ment syndrome, a systemic inflammatory 
response syndrome (SIRS) accompanied by 
fever, fluid retention and transient renal 
failure.
Moreover, although a  systemic donor-
specific tolerance persisted, non-human 
primates and patients lost chimerism dur-
ing the  first days after transplantation. Pre-
vious studies demonstrated that chimerism 
is needed only in the thymus to maintain 
tolerance in mice. However, thymic APCs 
are continually turning over and true hema-
topoietic chimersm is required to replace 
donor APCs over time in mice (Khan, Tomita 
et al. 1996). Thus, acceptance of the kidney 
graft and simultaneous rejection of the BM, 
determining a state of “split tolerance”, 
occurred only in primates and may represent 
a substantial difference between species in 
this setting (Sachs 2003). Studies in mon-
keys indicate  that the mechanism of toler-
ance may switch from central deletion to a 
peripheral mechanism that may include 
Tregs and in which the renal allograft plays 
a critical role  (Andreola, Chittenden et al. 
2011; Sachs, Sykes et al. 2011). A similar 
role of the allograft in the  maintenance of 
regulatory mechanism has been previously 
described in a  different mouse model 
(Karim, Steger et al. 2002).
An additional issue is provided by the com-
bination of immunosuppressive and tolero-
genic therapies. Because of the excellent 
graft survival obtained with classical immu-
nosuppression, the risk of allograft rejec-
tion cannot be ethically accepted in the 
modern transplantation era and every 
tolerance-inductive therapy should initially 
be combined with immunosuppression in 
clinical studies (Waldmann 2010). However, 
immunosuppressive  drugs can radically alter 
the outcome of the procedure, because of 
pharmacological and immunological interac-
tions. Particularly, CNIs displayed an anti-
tolerogenic effect in costimulation-based 
protocols (Blaha, Bigenzahn et al. 2003).
In summary, the induction of donor-specific 
tolerance is the best option to improve the 
long-term outcome after solid organ trans-
plantation. Among the different strategies 
to induce tolerance in rodents, the  com-
bined transplantation of solid organ and BM 
from the same donor to induce mixed chi-
merism is the only approach that was suc-
cessfully translated to the clinic, but several 
problems remain to be solved for its broad 
clinical application. The introduction of 
costimulation blockers allowed to markedly 
reduce the toxicity of the conditioning re-
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gime in mouse models, changing the strat-
egy for the tolerization of the  pre-exisitng 
immune system from a generalized T cell 
depletion to a selective deletion of alloreac-
tive T cells by apoptosis. The regulation of 
the apoptosis pathway in allo-reactive T cells 
may be  critical for the establishment of tol-
erance and merits further investigations as a 
potential tolerance-promoting pharmacol-
ogical target.
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Chapter 2: Apoptosis in the immune system
Apoptosis
The elimination of superfluous, damaged or 
dangerous cells is pivotal for the  develop-
ment and the survival of multicellular organ-
isms (Vaux and Korsmeyer 1999). For this 
purpose, animals developed a controlled, 
genetically programmed form of cell death 
called apoptosis (from the ancient Greek, 
“leaves falling from a tree”). Apoptosis has 
been evolutionarily conserved in metazoans 
and is characterized by morphological fea-
tures that distinguish it from other forms of 
cell death. In contrast to the cell and organ-
elle swelling and the early disruption of the 
cell membrane typically seen in necrosis, 
apoptotic cells present nuclear chromatin 
condensation, followed by cytoplasmatic 
budding and cell shrinkage. Finally, cell 
fragments called apoptotic bodies are pro-
duced and quickly removed by phagocytic 
cells without inducing an inflammatory re-
sponse or any damage to the surrounding 
tissue (Kumar, Cotran et al. 2003; Green, 
Ferguson et al. 2009). The whole process is 
20 times faster than mitosis and even sub-
stantial apoptosis may be histologically in-
apparent (Melino 2001). Therefore, al-
though morphological features of apoptosis 
have been described since the middle of the 
nineteenth century, the term apoptosis to 
describe a common type of cell death was 
only introduced in 1972 (Kerr, Wyllie  et al. 
1972), but it was not generally credited until 
the 1980s when the group of Robert Horvitz 
first defined the genetics of apoptosis in 
Caenorhabditis elegans (Horvitz, Sternberg 
et al. 1983; Horvitz, Shaham et al. 1994).
Apoptosis is involved in embryonic devel-
opment, playing an important role in mor-
phogenesis, removing vestigial or sexual in-
congruent tissues and generating lacunae 
and separation of tissue layers (Yin and 
Dong 2009). In adult animals, the balance 
between mitosis and apoptosis controls the 
number of cells in different tissues, a par-
ticularly important issue in highly proliferat-
ing tissues (such as in the intestinal epithe-
lium, the endometrium or in the hemato-
poietic system). Furthermore, apoptosis is a 
fundamental effector and regulatory 
mechanism of the immune system and has a 
crucial role in the elimination of cells with an 
irreparable  DNA damage. As a result, apop-
tosis is inevitably involved in the  pathogene-
sis of a  variety of diseases: defects in the 
control of apoptosis notoriously result in 
cancer and autoimmunity, but there is 
growing evidence that apoptosis dysregula-
tion is also critical for ischemic, neurode-
generative and infect ious disorders 
(Hotchkiss, Strasser et al. 2009).
The control of life and death in each single 
cell of a multicellular organism is the result 
of the  integration of a plurality of signals 
generated in the cell itself or provided by 
the environment. The molecular regulation 
of apoptosis in mammalian cells reflects this 
dualistic concept (Fig. 7): two converging 
signaling pathways culminate in the activa-
tion of caspases, a family of aspartate-
specific cystein proteases. Caspases are syn-
thetized in an inactive  form (zymogen) and 
can be activated through three different 
mechanisms. (1) Caspases can activate  cas-
pase zymogens resulting in a “caspase cas-
cade” that enormously amplify the pro-
apoptotic signal. (2) The recruitment of pro-
caspases in protein complexes that lead to a 
clustering of the zymogens leads to their 
self-processing (induced proximity). (3) An 
association with other regulatory proteins 
may be  required for the full activation of the 
enzymatic activity (described for caspase 9 
and Apaf-1). Activation of the caspase cas-
cade leads to the execution of the  apoptosis 
process. Caspases cleave essential cellular 
proteins (such as nuclear lamins and com-
ponents of the cytoskeleton), activate the 
caspase-activated DNase  responsible for the 
generation of the typical DNA ladder and 
other substrates, resulting in cell death and 
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in the morphological changes typically ob-
served in apoptotic cells (Hengartner 2000).
The extrinsic apoptotic pathway is trig-
gered by cell-surface receptors of the tumor 
necrosis factor (TNF) receptor superfamily, 
called death receptors (DRs), and character-
ized by the presence of a cytoplasmatic se-
quence known as death domain, which en-
ables the  initiation of the death signal (Na-
gata  1997). Currently, six DRs have  been 
characterized: Fas (CD95, APO-1), TNF-R1, 
TRAIL-R1, TRAIL-R2, DR3 and DR6. Binding 
of the natural ligand leads to oligomeriza-
tion of the receptor and to the formation of 
large protein complexes at the cell mem-
brane, known as DISC (death-inducing sig-
naling complex). Formation of DISC leads to 
the accumulation of the pro-caspase 8 (and 
pro-caspase 10 in humans) in close proxim-
ity resulting in their activation by induced 
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Fig. 7. A simplified scheme of the apoptosis pathway (Bouillet and O'Reilly 2009)
proximity. As initiators of the  extrinsic 
apoptosis pathway, caspase 8 subsequently 
activates the executioner caspases 3, 6 and 
7 (Krammer, Arnold et al. 2007).
The intrinsic apoptotic pathway (or mito-
chondrial pathway) is induced by the per-
meabilization of the outer mitochondrial 
membrane followed by the release of cyto-
chrome c and other apoptogenic proteins 
such as SMAC into the cytoplasm. Cyto-
chrome c leads to the formation of a  large 
protein complex (called apoptosome) with 
Apaf-1 (apoptotic protease activating factor 
1) and pro-caspase-9, the initiator caspase 
of the intrinsic pathway (Li, Nijhawan et al. 
1997). The Bcl-2 family (B cell lymphoma 2) 
is an evolutionarily conserved family of pro-
teins that control the permeabilization of 
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Tab. 4. Mammalian Bcl-2 family proteins, their expression and function (Yin and 
Dong 2009, modified)
Anti-apoptotic Bcl-2 Lymphocytes
Melanocytes
Kidney
Bcl-xL Lymphocytes
Megakaryocytes
Platelets
Embryonic lethality
Bcl-w Male sterility
Mcl-1 HSCs
Myeloid cells
A1/Bfl-1 Lymphocytes
Granulocytes
Mast cells
Bcl-B ?
Pro-apoptotic
(BH3-only)
Bad Pancreas
Bid Hepatocytes
Myeloid cells
Link extrinsic-intrinsic 
pathway
Bik Spermatogenesis
Bim Lymphocytes
Bmf Lymphocytes
Noxa Lymphocytes Irradiation
PUMA Lymphocytes DNA damage
Hrk/DP5 ?
Pro-apoptotic
(Multi-
domain)
Bax Mitocondrial membrane 
permeabilization
Bak
Bok ?
mitochondrial membrane  and is therefore a 
pivotal regulator of the intrinsic pathway 
(Hengartner and Horvitz 1994; Wei, Zong et 
al. 2001). Bcl-2 family members share se-
quence homology in four domains (BH1-4) 
and can be divided in three groups accord-
ing to their function and structure (Tab. 4). 
Anti-apoptotic Bcl-2 proteins contain all BH 
domains; among the pro-apoptotic factors a 
group contains BH1, BH2 and BH3 (multi-
domain), whereas another group is charac-
terized by the  only presence of the BH3 do-
main (BH3-only proteins) (Strasser 2005). 
Several models have  been proposed to ex-
plain the molecular interactions between 
Bcl-2 proteins. Bax and Bak are  directly in-
volved in the permeabilization of the outer 
mitochondrial membrane and deletion of 
both of them (but not one of them) renders 
the cell completely resistant to the activation 
of the intrinsic apoptosis pathway (Wei, 
Zong et al. 2001). Anti-apoptotic factors in-
hibit Bax and Bak and mutually interact with 
BH3-only proteins. A subgroup of BH3-only 
proteins (including Bid, Bim and PUMA), 
called activators, has been shown to di-
rectly activate Bax and Bak, whereas sensi-
tizers (such as Bad, Noxa and Bmf) exert 
their pro-apoptotic effect through the inac-
tivation of anti-apoptotic factors (Kuwana, 
Bouchier-Hayes et al. 2005; Letai 2008). This 
results in a complex multi-factorial model 
that represents the basis for a dynamic regu-
latory mechanism (Fig. 8) (Strasser, Putha-
lakath et al. 2008).
The activity of the different members of the 
Bcl-2 family is finely regulated at many levels 
in response to disparate stimuli. For exam-
ple, DNA damage induces the transcription 
of PUMA, Noxa, Bid in a p53-dependent 
manner (Oda, Ohki et al. 2000) and UV irra-
diation induces the  translocation of Bim 
from the cytoskeleton to the mitochondrial 
membrane (Puthalakath, Huang et al. 1999). 
A particular function is provided by the BH3-
only factor Bid, which connects the  two 
apoptosis pathways (Fig. 7). Bid is activated 
by caspase 8 and induces an amplification of 
the extrinsic pathway via an indirect activa-
tion in the  instrinsic pathway (Chou, Li et al. 
1999).
Additional levels of complexity are  pro-
vided by regulators of the extrinsic apoptosis 
pathway (such as c-FLIP) (Thome and 
Tschopp 2001), by the role  of caspases and 
Bcl-2 proteins in cellular processes not di-
rectly related to apoptosis (Kennedy, Ka-
taoka et al. 1999), by inhibitors of caspases 
(inhibitors of apoptosis, IAPs) (Jost, Grabow 
et al. 2009; Kaufmann, Strasser et al. 2012) 
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Fig. 8. Molecular interactions of Bcl-2 proteins
and by the  role of other organelles (such as 
the endoplasmatic reticulum) in the modula-
tion of apoptosis. Thus, the regulation of 
apoptosis is tightly interconnected with the 
function of the cell and promptly responds 
to stimuli from the environment. “Such so-
cial control of life and death are vital in 
complex multicellular networks such as the 
immune system and the  nervous system, 
where communication between cells is cru-
cial” (Melino 2001).
Role of apoptosis in the immune system
The regulation of cell survival is essential for 
the correct functioning of the immune sys-
tem: it plays a  pivotal role in the generation 
of immune cells, it exerts important effector 
and regulatory functions and it is required 
for the maintenance of immune homeosta-
sis. 
Apoptosis – and particularly the Bcl-2 family 
- is actively involved in hematopoiesis, the 
process by which HSCs generate mature 
blood and lymphatic cells through multiple 
rounds of division and differentiation. The 
survival of mature blood and lymphatic cells 
is genetically pre-determined during devel-
opment, and all cells are intrinsically pro-
grammed to die in the  absence of external 
stimuli. For this purpose, Bcl-2 factors are 
specifically regulated in different cell linea-
ges during hematopoiesis resulting in a di-
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Fig. 9. The role of Bcl-2 proteins in hematopoiesis (Yin and Dong 2009)
HSC: hematopoietic stem cell, CMP: common myeloid progenitor, MEP: 
megakaryocyte/erythroid progenitor, GMP: granulocyte/macrophage progenitor, 
BFU-E: burst-forming unit-erythroid, MkP: megakaryocyte  progenitor, CFU-G: 
colony-forming unit granulocyte, CFU-M: colony-forming unit macrophage.
verse expression of pro- and anti-apoptotic 
factors among the different cell populations 
(Fig. 9) (Yin and Dong 2009). The survival of 
HSCs critically depends on the expression of 
Mcl-1 (Opferman, Iwasaki et al. 2005) and 
the same factor inhibits the pro-apoptotic 
effect of Bim in neutrophils (Leuenroth, 
Grutkoski et al. 2000), whereas Bcl-xL coun-
teracts the pro-apoptotic effect of Bak in 
platelets (Josefsson, James et al. 2011).
The regulation of the apoptosis pathway in 
lymphocytes is much more complex. Here 
we will focus on T lymphocytes (Starr, 
Jameson et al. 2003) (Fig. 10). T cells origi-
nate  from common lymphoid progenitors 
that migrate  from the bone marrow into the 
thymus, where they proliferate extensively 
and start to differentiate  (Murphy, Travers et 
al. 2008). In the first stages of development 
these cells lack most of the surface  mole-
cules and do not express a  T cell receptor 
(TCR). Their survival depends on the pres-
ence of IL-7, which induces the expression 
of Bcl-2 and Mcl-1 to counteract the  pro-
apoptotic effect of Bim (Pellegrini, Bouillet et 
al. 2004). In the next development steps, 
thymocytes undergo TCR gene rearrange-
ment, first at the β-chain locus, then at the 
α-chain locus. Failure to resolve double-
strand DNA breaks during the rearrange-
ment process leads to p53-dependent apop-
tosis (Jiang, Lenardo et al. 1996). The ex-
pression of a  functional pre-T and T cell re-
ceptor is required for thymocytes to survive 
from the double negative (CD4-CD8-) to the 
double positive  (CD4+CD8+) and finally to 
single positive CD4 or CD8 stage. This last 
step, called positive selection, is mediated 
by the up-regulation of A1 (Mandal, Bor-
owski et al. 2005) and ensures that only 
cells expressing a functional TCR that can 
bind to an MHC/peptide  complex expressed 
by thymic epithelial cells will survive. As dis-
cussed in chaper 1, negative selection is 
the key checkpoint for central tolerance. 
Thymocytes with a high affinity to MHC/self-
peptide complexes are  deleted from the 
repertoire by a Bim-dependent activation of 
the intrinsic apoptosis pathway (Bouillet, 
Purton et al. 2002). As a result, approxi-
mately 95% of developing thymocytes die 
by activation of the intrinsic apoptosis 
pathway during the different stages of dif-
ferentiation.
The CD4 or CD8 single positive T cell that 
survive  this process migrate to the peripheral 
lymphatic organs as naïve T cells until they 
encounter an antigen. The survival of naïve 
T cells depends on the inhibition of the  in-
trinsic apoptosis pathway by Bcl-2, which 
counteracts the pro-apoptotic effect of Bim 
(Wojciechowski, Tripathi et al. 2007). The 
expression of Bcl-2 depends on IL-7 and re-
quires a basal activity of calcineurin (Tan, 
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Fig. 10. Critical role of apoptosis in T cell homeostasis
Dudl et al. 2001; Manicassamy, Gupta et al. 
2008). Interestingly, CD8 T cells are more 
sensitive  to the loss of prosurvival signaling 
than CD4 T cells. The  regulation of apopto-
sis dramatically changes after antigen rec-
ognition: T cell activation triggers the ex-
pression of proteins with anti-apoptotic 
function such as c-FLIP, Bcl-2, Bcl-xL, A1, 
XIAP and with pro-apoptotic function such 
as Fas, TRAIL-R1, Bim and Nur77 (Sandalova, 
Wei et al. 2004; Brenner, Krammer et al. 
2008). The precise regulation of the  intrinsic 
and the  extrinsic apoptosis pathway is under 
the control of costimulatory molecules and 
cytokines, and is required to promote the 
survival of reactive  and proliferating cells 
during the immune response, but also to 
ensure elimination of the majority of them 
after antigen clearance (Rathmell and 
Thompson 2002). T cell contraction is the 
result of cooperation between the extrinsic 
and the intrinsic apoptosis pathway (Weant, 
Michalek et al. 2008). In parallel, a small 
percentage of reactive  T cells survive as 
memory cells. A down-regulation of Bim 
via regulation of its proteosomal degrada-
tion seems to be  crucial for the generation 
of memory cells (Sabbagh, Srokowski et al. 
2006; Sabbagh, Pulle et al. 2008), and the 
balance between Bcl-2, Bcl-xL and Bim is 
critical for their long-term survival (Wo-
jciechowski, Tripathi et al. 2007).
Apart from its role in the development and 
in the  maintenance of immune homeostasis, 
apoptosis is an important effector function 
of cytotoxic cells (principally CD8 T cells 
and natural killer cells). To eliminate intracel-
lular pathogens or potentially dangerous 
cells, cytotoxic lymphocytes induce cell 
death by activation of the extrinsic apoptosis 
pathway (mostly triggering Fas), or releasing 
the content of cytotoxic granules. Although 
the cytotoxic granzymes and perforins in-
duce cell death by creating pores in the 
plasma membrane, the process can be am-
plified by activation of the apoptosis path-
way, for example by the cleavage  of Bid by 
granzyme B (Cullen and Martin 2008). Simi-
lar mechanisms are also important in the 
complex intercellular regulation of the im-
mune system. Regulatory T cells regulate  the 
survival of effector CD4 and CD8 T cells by 
inducing apoptosis through TRAIL or indi-
rectly by a  deprivation of cytokines (Ren, Ye 
et al. 2007). Moreover, Th1 differentiated 
CD4 T cells can kill chronically infected 
macrophages by activation of the Fas signal-
ing to release  bacteria to be destroyed by 
fresh macrophages (Murphy, Travers et al. 
2008).
Because of the critical role of apoptosis in 
the maintenance of immune homeostasis 
and regulation, a  dysregulation of apoptosis 
pathways is a  common cause of autoim-
munity and lymphoproliferative disor-
ders (Rieux-Laucat, Le Deist et al. 2003). 
Studies in transgenic animals have been cru-
cial for the  characterization of these proc-
esses: lpr mice  (mutation in Fas) and mice 
over-expressing Bcl-2 develop a lupus-like 
autoimmune disease (Andrews, Eisenberg et 
al. 1978), and Bim knock-out mice  present 
splenomegaly, a progressive accumulation 
of lymphocytes and are prone to autoim-
munity (Bouillet, Metcalf et al. 1999). On 
the other hand, Bcl-2 knock-out mice are 
characterized by lymphopenia (Veis, Soren-
son et al. 1993). Similar disorders have been 
described in humans: mutations in Fas or 
FasL result in the autoimmune lymphoprolif-
erative syndrome (ALPS), characterized by 
lupus-like autoimmunity, hypergamma-
globulinemia, B-cell lymphocytosis and pre-
disposition to develop lymphomas (Bidere, 
Su et al. 2006). An additional link between 
apoptosis and autoimmunity may result 
from the mechanism involved in the clear-
ance of apoptotic cells. One of the most 
important characteristics of apoptosis con-
sists in the absence of inflammation after 
phagocytosis of apoptotic bodies, and it is 
known that failure  or delay in removing dy-
ing cells can induce autoimmunity. The 
mechanism determining the  tolergenic 
properties of apoptotic cells is uncompletely 
understood (Green, Ferguson et al. 2009).
Pharmacological apoptosis modulation
The apoptosis pathway is a promising phar-
macological target with various potential 
clinical applications (Hotchkiss, Strasser et al. 
2009). In general, diseases with an excessive 
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cell death, such as myocardial or cerebral 
ischemia, cisplatin nephrotoxicity or neuro-
degenerative disorders might be beneficially 
influenced by an inhibition of apoptosis 
(Letai 2005). Currently, the most significant 
clinical application of this approach is repre-
sented by the administration of cyclosporine 
A in patients with acute myocardial infarc-
tion to reduce the infarction size by a modu-
lation of the mitochondrial permeability-
transition pores (Piot, Croisille  et al. 2008), 
but several more selective strategies are be-
ing investigated in different experimental 
models (Kostic, Jackson-Lewis et al. 1997; 
Becattini, Sareth et al. 2004; Hamar, Song et 
al. 2004). 
Apoptosis induction may be favorable to 
treat diseases characterized by a deficient 
cell death machinery. Apart from a potential 
clinical relevance for the rare immunological 
diseases caused by a primary defect in apop-
tosis regulation mentioned before, pro-
apoptotic drugs may be indicated to treat 
cancer (Labi, Grespi et al. 2008). Dysregula-
tion of apoptosis is a  hallmark of cancer 
and neoplastic cells develop various strate-
gies to evade apoptosis: for example, over-
expression of Bcl-2 is present in approxi-
mately 85% of human follicular lymphoma 
(Tsujimoto, Finger et al. 1984). These 
mechanisms are not only involved in tumor 
pathogenesis, they also provide resistance  to 
conventional cancer therapy (chemotherapy 
and radiotherapy), since  these  therapies also 
exert their anti-tumor effect by inducing 
apoptosis in cancer cells (Yin and Dong 
2009). However, pro-apoptotic drugs should 
be used with caution. As a fundamental cel-
lular function, apoptosis is universally func-
tional in animal cells, and an uncontrolled 
activation of apoptosis would inevitably re-
sults in major side effects. This can partially 
be avoided by the development of drugs se-
lectively targeting single molecular players in 
the apoptosis pathway. Several partially re-
dundant mechanisms protect the cell from 
an undesired suicide (Bortner and Cidlowski 
2002), and deletion of a single  anti-
apoptotic gene is mostly not lethal in trans-
genic mice (Veis, Sorenson et al. 1993; Ha-
masaki, Sendo et al. 1998; Harlin, Reffey et 
al. 2001). Therefore, the  selective pharma-
cological modulation of single apoptotic fac-
tors is unlikely to induce generalized apop-
tosis, and because different cell types pro-
tect themselves from apoptosis using differ-
ent mechanisms, a selective deletion of 
defined cell populations is theoretically pos-
sible  using selective  pro-apoptotic drugs. 
Finally, pro-apoptotic drugs can be used to 
interfere with apoptosis-dependent proc-
esses, such as the central and peripheral 
selection of lymphocytes.
Most efforts to develop drugs that trigger 
apoptosis have been made in the field of 
oncology. Stimulation of death receptors is 
an attractive and technically feasible ap-
proach (Ashkenazi 2002). However, the sys-
temic application of Fas-L and TNFα resulted 
in major toxicities (Ogasawara, Watanabe-
Fukunaga et al. 1993). In contrast, TRAIL 
represents a  promising candidate, and hu-
man monoclonal antibodies to stimulate 
TRAIL-R1 or TRAIL-R2 are  currently evalu-
ated in clinical trials (Tolcher, Mita  et al. 
2007). An additional target of interest is the 
family of inhibitor of apoptosis proteins 
(IAPs): particularly, inhibitors of the X-linked 
inhibitor of apoptosis (XIAP) are in early 
clinical evaluation (Lacasse, Kandimalla et al. 
2005). The most promising approach is the 
manipulation of the  Bcl-2 family (Vogler, 
Dinsdale et al. 2009). Initial attempts to in-
hibit the anti-apoptotic function of Bcl-2 us-
ing unmodified BH3 domain peptides failed, 
because of the problem of intracellular de-
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Fig. 11. Chemical structure  of ABT-737 
(Oltersdorf, Elmore et al. 2005) 
livery. However, small molecule Bcl-2 inhibi-
tors were identified by screening of chemical 
libraries or developed by iterative modula-
tion of chemical structure based on NMR 
(Letai 2005). As a result, a series of Bcl-2 in-
hibitors are  currently being tested in pre-
clinical tumor models. Importantly, different 
compounds displayed a different binding 
affinity to the different anti-apoptotic mem-
bers of the  Bcl-2 family, which eventually 
determined their selectivity profile  (Zhai, Jin 
et al. 2006). Three drugs are currently in ad-
vanced clinical evaluation (Khaw, Huang et 
al. 2011).
ABT-737 and navitoclax (ABT-263, Abbott, 
Fig. 11) bind with high affinity to Bcl-2, Bcl-
xL and Bcl-w, but not to Mcl-1 and A1 (Ol-
tersdorf, Elmore et al. 2005; Tse, Shoemaker 
et al. 2008). As a result, ABT-737 triggered 
apoptosis in tumor cells and sensitized them 
to chemotherapy, but tumors expressing 
Mcl-1 and A1 were resistant to the treat-
ment (Yecies, Carlson et al. 2010). ABT-737 
and navitoclax have the same Bcl-2 selectiv-
ity profile  and displayed the  same pharma-
codynamic properties. However, navitoclax 
is characterized by a  better solubility and 
bioavailability and was therefore used for 
clinical studies, whereas ABT-737 was fur-
ther used in the experimental setting. Navi-
toclax has been tested in Phase 1 trials in 
patients with advanced lymphomas, small 
cell lung cancer and chronic lymphocytic 
leukemia (CLL) (tumors with high-level ex-
pression of Bcl-2) (Wilson, O'Connor et al. 
2010; Gandhi, Camidge et al. 2011; Rob-
erts, Seymour et al. 2011). In the CLL trial 9 
of 26 patients achieved a partial response, 
but the  results were less encouraging in 
small cell lung cancer. Patients displayed a 
moderate depletion of CD3 T cells within 14 
days without an increased risk for infections, 
and a dose-dependent thrombocytopenia 
without major bleeding episodes. ABT-737-
induced thrombocytopenia depends on 
the inhibition of Bcl-xL and is primarily due 
to a  direct depletion of circulating platelets 
by apoptosis, although Bcl-xL inhibition can 
also induce a dysfunction in the generation 
of platelets in the bone  marrow (Josefsson, 
James et al. 2011). Platelet survival is deter-
mined by the balance between Bcl-xL and 
Bak. Since platelets are anucleate  cells, they 
receive their stock of both proteins during 
their generation in the bone marrow. Inhib-
iting Bcl-xL inevitably leads to an irreversible 
shift towards the pro-apoptotic side (Mason, 
Carpinelli et al. 2007). Phase 2 trials with 
navitoclax as a single agent and in combina-
tion with conventional chemotherapy are in 
progress.
Clinical studies using the pan-Bcl-2 inhibitor 
obatoclax resulted in major neuro-
psychiatric side effects and in a lack of sig-
nificant single agent activity (Hwang, Kuru-
villa et al. 2010). The Bcl-2 / Bcl-xL / Mcl-1 
inhibitor AT-101 displayed a limited clinical 
activity as single  agent in patients with CLL, 
prostate cancer and small cell lung cancer, 
and induced a high incidence of severe gas-
trointestinal side effects (James, Castro et al. 
2006). Interestingly, in contrast to navito-
clax, neither obatoclax nor AT-101 induced 
the expected Bcl-xL-inhibition dependent 
thrombocytopenia, suggesting that their 
lower binding affinity may not be sufficient 
to achieve a clinically relevant response 
(Khaw, Huang et al. 2011).
Previous studies tried to inhibit undesired 
immune reactions targeting the apoptosis 
pathway. In the 1990s it was recognized 
that up-regulation of Fas occurs in T cells 
after antigen recognition, opening the op-
portunity for a selective depletion of acti-
vated T cells by Fas-L to prevent allograft 
rejection (Owen-Schaub, Yonehara et al. 
1992). Apart from the limitation of this ap-
proach because of toxic side effects 
(Ogasawara, Watanabe-Fukunaga et al. 
1993), the  hypothesized immunosuppressive 
effect could not be achieved, because of an 
inactivation of the extrinsic apoptosis path-
way in early-activated lymphocytes (O'Fla-
herty, Ali et al. 1998). In contrast, an immu-
nosuppressive effect of Bcl-2 inhibitors has 
recently been demonstrated in mouse mod-
els of autoimmunity (Bardwell, Gu et al. 
2009). The immuno-modulatory mechanism 
of this approach and its potential to control 
allograft rejection and induce tolerance have 
been investigated in this project.
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Abstract
Apoptosis controls the adaptive immune system through regulation of central and peripheral 
lymphocyte  deletion. Therefore, substances that selectively interact with the intrinsic apopto-
sis pathway in lymphocytes offer unexplored opportunities to pharmacologically modulate the 
immune response. Here we present evidence that the BH3-mimetic ABT-737 suppresses allo-
geneic immune responses. In vitro, ABT-737 prevented allogeneic T cell activation, prolifera-
tion and cytotoxicity by apoptosis induction, but without impairing the physiological functions 
of remaining viable T cells. In vivo, ABT-737 was highly selective  for lymphoid cells and inhib-
ited allogeneic T and B cell responses after skin transplantation. The immunosuppressive ef-
fect of ABT-737 was markedly increased in combination with low-dose cyclosporine A, as 
shown by the induction of long-term skin graft survival without significant inflammatory infil-
trates in 50% of the recipients in a  MHC class I single antigen mismatched model. Thus, 
pharmacological targeting of Bcl-2 proteins represents a  novel immunosuppressive approach 
to prevent rejection of solid organ allografts.
Introduction
The identification of alternative pharmacol-
ogical targets to suppress allo-specific im-
mune responses is a  fundamental step in the 
development of new drugs aiming at the 
optimization of long-term outcome after 
solid organ transplantation (Halloran 2004). 
It has been shown that the modulation of 
apoptosis in lymphocytes is responsible for 
central and peripheral repertoire selection 
(Bouillet, Purton et al. 2002; Rathmell and 
Thompson 2002) and controls the deletion 
of alloreactive  lymphocytes in the induction 
of peripheral transplantation tolerance 
(Wells, Li et al. 1999). Therefore, targeting 
apoptosis pathways in lymphocytes repre-
sents a  potential novel strategy for immuno-
suppression.
Two distinct but interconnected pathways 
regulate apoptosis in mammalian cells: the 
extrinsic pathway is mediated by death re-
ceptors at the cell surface (e.g. by FAS or 
TNF-receptor), whereas the intrinsic (or mi-
tochondrial) pathway is under the  control of 
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pro- and anti-apoptotic members of the Bcl-
2 family (Hotchkiss, Strasser et al. 2009). Se-
lective  small-molecule Bcl-2 antagonists 
have rationally been developed for the 
treatment of tumors (Oltersdorf, Elmore et 
al. 2005). The Bcl-2 inhibitor ABT-737 and 
its orally bioavailable counterpart ABT-263 
bind the anti-apoptotic proteins Bcl-2, Bcl-
XL and Bcl-w (but not A1 and Mcl-1) and 
activate the intrinsic apoptosis cascade in 
human and murine tumor cells (Hann, Dan-
iel et al. 2008). While research on Bcl-2 in-
hibitors focused on cancer biology, this 
novel class of drugs offers the opportunity 
for selective interaction with a fundamental 
pathway in mammalian cells and could find 
various clinical applications outside of onco-
logical therapy. Interestingly, it has been 
shown that ABT-737 has a favorable  effect 
on various autoimmune diseases in mice and 
inhibits B and T cell immune responses 
(Bardwell, Gu et al. 2009; Carrington, Vik-
strom et al. 2010). Moreover, Carrington et 
al. recently described a beneficial impact of 
ABT-737 on glucose levels after islet trans-
plantation from (C57BL/6 x SJL)F1 to spon-
taneous non-immune diabetic RIP-H-2Kb 
mice (Carrington, Vikstrom et al. 2010). 
However, BH3-mimetics have never been 
tested in stringent models of allograft rejec-
tion.
Here we present evidence that the BH3-
mimetic ABT-737 suppresses allogeneic T 
cell responses in vitro due to a clone  size re-
duction in the alloreactive T cell population 
by apoptosis induction. In vivo, ABT-737 se-
lectively induced apoptosis in lymphatic tis-
sues and potently inhibited allogeneic T and 
B cell responses after skin transplantation in 
mice synergistically with cyclosporine A 
(CsA).
Materials and Methods
Mice. C57BL/6 (B6, H-2b), CBA (H-2k), 
B6.C-H2Kbm1 (bm1, H-2bm1), BALB/c (H-2d) 
and BM3.3 (H-2k) mice were housed in spe-
cific pathogen-free conditions at the Univer-
sity of Zürich. Bm1 mice (7 nucleotides mu-
tation in the H-2Kb locus) were purchased 
from The Jackson Laboratory (Bar Harbor, 
USA) (Schulze, Pease et al. 1983). BM3.3 
mice express on all CD8 T cells a transgenic 
T cell receptor (TCR) selective for a  naturally 
processed octapeptide bound to the alloge-
neic MHC class I molecule H-2Kb (Auphan, 
Curnow et al. 1994; Guimezanes, Barrett-
Wilt et al. 2001). All animal experiments 
were performed according to protocols ap-
proved by the  legal authority (Veterinary Of-
fice of the Canton of Zürich).
In vivo experiments. Full thickness tail skin 
(about 0.5-1.0 cm2) from donor mice was 
grafted. Recipient mice  were treated from 
day 5 before grafting until allograft rejec-
tion. Skin grafts were considered rejected 
when <10% of the  graft remained viable. In 
some experiments recipient mice were sacri-
ficed at day 8 after transplantation and the 
transplanted tissue was harvested for histo-
logical evaluation. ABT-737 was provided by 
Abbott Bioresearch (Worcester, USA) and 
was injected intra-peritoneally (i.p.) at 50 
mg/kg/day. Vehicle  consisted of polyethyl-
ene glycol, Tween 80, dextrose solution and 
DMSO. CsA was purchased from Sigma-
Aldrich (Buchs, CH) and injected subcutane-
ously at 10 mg/kg/day. 
Mixed lymphocyte reaction (MLR) and cell-
mediated lympholysis (CML) assay. MLR 
were performed with BM3.3 splenocytes 
stimulated by irradiated CD8 T cell-depleted 
splenocytes from B6 (allogeneic) and CBA or 
BM3.3 (syngeneic) mice. Splenocytes were 
sorted by magnetic cell separation according 
to the  protocols of Miltenyi Biotec (Bergisch 
Gladbach, D) to allow a selective analysis of 
alloantigen-specific CD8 T cells. ABT-737 or 
DMSO-containing vehicle  were  added to the 
MLR at the beginning of the culture. For the 
CML assay B6 splenocytes were cultured 
with irradiated BALB/c (allogeneic) and B6 
(syngeneic) lymphocytes during 5 days 
(stimulation phase). Thereafter, 51Cr-labelled 
concanavalin-A-stimulated BALB/c lympho-
cytes were added to the  serially diluted cul-
ture for 4 hours (killing phase), and 
alloantigen-specific cytotoxicity was assessed 
by measurement of 51Cr release in the su-
pernatant. For a  compensation of the allore-
active clone size reduction in certain experi-
ments the same number of viable ABT-737 
treated responder cells was used for the kill-
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ing phase as measured in vehicle control cul-
tures. Alloantigen-specific lysis was calcu-
lated as: % specific lysis = (experimental re-
lease – spontaneous release) / (total release 
– spontaneous release)*100.
Flow cytometry (FACS) and detection of allo-
specific antibodies. FACS was performed 
with a  BD-FACSCanto (Becton Dickinson, 
Allschwil, CH). Anti-mouse CD3-FITC, CD4-
PE, CD8-APC, CD8-PE, CD45R/B220 PE-Cy5, 
anti-IgG-FITC, anti-IgM-PE, annexin V-FITC 
and propidium iodide (PI) were purchased 
from eBioscience (Frankfurt, D), anti-mouse 
CD25-PE/Cy7 and interferon-γ (IFN-γ)-APC 
from Biolegend (Uithoorn, NL), carboxyfluo-
rescein succinimidyl ester (CFSE) from 
Promega (Dübendorf, CH). Allospecific anti-
bodies were detected by FACS: after Fc-
receptor blockade, allogeneic splenocytes 
were incubated with recipients’ serum and 
subsequently stained with a secondary anti-
mouse anti-IgG and anti IgM antibody. 
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Fig. 12. ABT-737 suppresses allogeneic T cell responses in vitro.
A) MLR with transgenic BM3.3 splenocytes  stimulated with CD8-depleted irradiated B6 splenocytes. After 3 
days  of MLR, ABT-737 suppressed CD8 T cell  proliferation in a concentration-dependent manner as  shown by 
CFSE-dilution in FACS. Representative results of one of three independent experiments are shown.
B) ABT-737 inhibited IFN-γ synthesis, as  shown by reduction of IFN-γ concentration in the  culture supernatant 
measured by ELISA (3 independent experiments). The effect on allo-reactive  BM3.3 CD8 T cells was confirmed 
determining the  number of IFN-γ positive transgenic CD8 T cells in an additional independent experiment. Per-
cent of values measured in cultures exposed to vehicle are given.
C) B6 lymphocytes  were stimulated with BALB/c splenocytes in the presence of ABT-737 or DMSO-containing 
vehicle  during 5 days. Allo-antigen specific cytotoxicity was  tested in a 51Cr release  assay against concavalin A-
stimulated BALB/c lymphocytes. ABT-737 exposure  during the stimulation phase suppressed alloantigen-specific 
cytotoxicity in a  concentration-dependent manner. Representative results  of one of three  independent experi-
ments are shown (one-way ANOVA comparing the four allogeneic stimulated groups, *  p<0.05, ** p<0.01, 
*** p<0.001).
Mean fluorescence intensity (MFI) was de-
termined in FACS gating on B220 negative 
cells.
ELISA, Western blotting and blood analyses. 
IFN-γ ELISA was performed using a kit pur-
chased from Biolegend (Uithoorn, NL) and 
used according to the manufacturer’s proto-
col. Western blot analysis was performed 
using a rabbit anti-caspase-3 antibody (Cell 
Signaling Technology, Danvers, USA). A 
peroxidase-conjugated donkey anti-rabbit 
IgG (GE Healthcare, Buckinghamshire, UK) 
was used as secondary reagent. Hemato-
logical analyses were  performed in the labo-
ratory of the Division of Hematology at the 
University Hospital Zürich with an ADVIA 
2120 flow cytometer (Siemens, Eschborn, 
D).
Histology, immunohistochemistry, TUNEL 
and analysis of isolated intestinal epithelial 
cells. Histology and immunohistochemistry 
were performed as previously described (Se-
gerer, Hudkins et al. 2002). Monoclonal 
anti-CD3 antibody was purchased from AbD 
Serotec (Düsseldorf, D), anti-CD8a from 
OriGene (Rockville, USA). For detection of 
apoptotic cells by immunohistochemistry the 
monoclonal antibody F7-26 (Chemicon, In-
ternational, Inc. Temecula, USA) was used as 
previously described (Segerer, Eitner et al. 
2002). F7-26 binds to single-stranded DNA 
after thermal denaturation. A peroxidase-
conjugated monoclonal rat anti-mouse IgM 
antibody (Zymed, San Francisco, USA) was 
used as secondary reagent. Apoptosis in in-
testinal mucosa  associated lymphatic tissue 
was quantified by TUNEL technology with 
the In Situ Cell Death Detection Kit (Roche, 
Basel, CH) as described by the manufac-
turer. Intestinal epithelial cells were isolated 
and analyzed by FACS as previously de-
scribed (Grossmann, Walther et al. 2003). 
Statistics. Student t-test, Mann-Whitney 
test, ANOVA-test or Fisher’s exact test were 
used to compare values between groups as 
appropriate; skin graft survival was com-
pared by log-rank test. Graph Pad Prism 
Software Version 5.0 was used for calcula-
tions.
Results
Bcl-2 inhibition suppresses allogeneic T cell 
responses in vitro.
The Bcl-2 inhibitor ABT-737 was first tested 
in vitro in a  mixed lymphocyte reaction 
(MLR) model. To analyze  the immunosup-
pressive effect of ABT-737 on a homogene-
ous population of alloreactive T cells we 
used the transgenic mouse  model BM3.3. 
The BM3.3 mouse expresses on all CD8 T 
cells a transgenic TCR specific for a naturally 
processed octapeptide bound to the alloge-
neic MHC class I molecule H-2Kb (Auphan, 
Curnow et al. 1994; Guimezanes, Barrett-
Wilt et al. 2001). After 3 days of a classical 
MLR culture  with BM3.3 responders and ir-
radiated B6 stimulators we registered a po-
tent, concentration-dependent inhibition of 
transgenic CD8 T cell activation (data not 
shown), proliferation (CFSE dilution, Fig. 
12A) and IFN-γ synthesis (ELISA of culture 
supernatant and intracellular IFN-γ staining 
in transgenic CD8 T cells, Fig. 12B) in cul-
tures exposed to ABT-737. Analogous re-
sults were observed at the cytotoxicity level 
in a cell-mediated lympholysis (CML) assay 
using the BM3.3 transgenic model (data  not 
shown), and in the non-transgenic fully 
MHC-mismatched combination B6 to BALB/
c (Fig. 12C).
Mechanism of immunosuppression by Bcl-2 
inhibition in vitro.
Previous studies have  shown that ABT-737 
initiates the  intrinsic apoptosis cascade by 
mitochondrial release  of cytochrome c (Ol-
tersdorf, Elmore et al. 2005). However, 
apart from their role as apoptosis regulators, 
Bcl-2 proteins seem to be  involved in addi-
tional cellular functions in lymphocytes (Shi-
basaki, Kondo et al. 1997; Ludwinski, Sun et 
al. 2009). Here we show that the immuno-
suppressive effect of ABT-737 results from 
clone size reduction in the alloreactive T cell 
population by apoptosis induction. How-
ever, the  fraction of alloreactive CD8 T cells 
that remained viable  after exposure to a 
concentration of ABT-737 that did not in-
duce a complete  T cell deletion were not 
impaired in their physiological effector func-
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tions. For this purpose, we  analyzed the fate 
of alloreactive lymphocytes in culture after 
treatment with ABT-737. Within hours ABT-
737 induced apoptosis in resting lympho-
cytes as shown by phosphatidylserine  expo-
sure (annexin V positivity) in PI negative cells 
by FACS analysis (Fig. 13A) and by caspase 3 
activation in Western blot (Fig. 13B). Similar 
results were obtained for wild type and for 
transgenic BM3.3 lymphocytes. The  specific 
examination of transgenic alloreactive CD8 T 
cells in the BM3.3 to B6 model revealed that 
ABT-737 markedly increased the number of 
apoptotic cells in this population after 3 
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days of MLR in a concentration dependent 
manner (data not shown). However, the 
small fraction of alloreactive CD8 T cells that 
survived exposure to ABT-737 (PI negative 
population) was not altered in its activation 
status (CD25 expression, Fig. 13C) and pro-
liferation capacity (CFSE dilution, Fig. 13D, 
ABT-737 plots) even at high ABT-737 con-
centrations. Moreover, the cytotoxicity of 
surviving lymphocytes was not reduced 
compared to control, as shown in experi-
ments, in which after activation under the 
effect of ABT-737 the  number of viable  cells 
was adjusted before starting the killing 
phase (Fig. 13E). The relevance of such ob-
servations was confirmed with an ex vivo 
experiment. After 5 daily injections of ABT-
737 (50 mg/kg/day) BM3.3 mice presented 
marked lymphopenia in blood compared 
with control animals (Fig. 13F). The mice 
were sacrificed and their splenocytes used 
for MLR with irradiated B6 lymphocytes 
stimulators. Ex vivo CD8 T cell activation 
(data not shown) and proliferation (Fig. 13F) 
were not reduced by the previous exposure 
to ABT-737. Therefore, the immunosuppres-
sive  effect of ABT-737 appears to be ex-
plained by clone size reduction in the allore-
active lymphocyte population by apoptosis, 
sparing the physiological functions of re-
maining viable CD8 T cells. This contrasted 
with the mechanism of action of established 
small-molecule immunosuppressive drugs: in 
the same experimental setting CsA, rapamy-
cin and mycophenolic acid directly sup-
pressed proliferation, whereas ABT-737 re-
duced the alloreactive clone size (Fig. 13D).
ABT-737 is highly selective for lymphatic tis-
sues.
The intrinsic apoptosis pathway is funda-
mental and universal in mammalian cells. 
Therefore, systemic toxicity might limit the 
clinical application of Bcl-2 inhibition as an 
immunosuppressive  principle. It has been 
shown that the  relevance of different apop-
tosis regulatory mechanisms varies among 
tissues, eventually determining the selectivity 
of different Bcl-2 inhibitors (Vogler, Dinsdale 
et al. 2009) and – as a consequence – the 
toxicity of the  treatment. To assess the tis-
sue selectivity of ABT-737 we analyzed by 
immunohistochemistry the  number of apop-
totic cells in different organs after injection 
of ABT-737 (50 mg/kg) or DMSO-containing 
vehicle. Six hours after injection, ABT-737 
treated mice  presented a 10-fold increase  in 
the number of apoptotic cells in spleen and 
a 2-fold increase in the  thymus compared to 
vehicle-treated controls (Fig. 14A-B). Paren-
chymal organs such as kidney, liver or heart 
were minimally affected by the treatment. 
To exclude a  role  of a  possible variability in 
ABT-737 exposure among different organs, 
the selectivity of ABT-737 was further as-
sessed by a specific analysis of epithelial and 
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Fig. 13. The immunosuppressive mechanism of ABT-737.
A-B) ABT-737 (5 µM) induced apoptosis in B6 splenocytes  within hours as shown by exposure  of phosphati-
dylserine in propidium iodide negative cells (FACS) (A) and caspase 3 activation (Western blot) (B). 
C-D) In MLR with BM3.3 splenocytes  stimulated by irradiated CD8-depleted B6 splenocytes  ABT-737 inhibited 
CD8 T cell  activation (C) and proliferation (D) in a concentration-dependent manner if all responder BM3.3 TCR 
cells  were considered. In contrast, activation and proliferation were  not impaired by ABT-737 in a selective 
analysis of viable  (PI negative) responder BM3.3 TCR. Similar  results were obtained from several experiments 
with different MLR conditions. Representative  data obtained after 3 days  of MLR are  shown and compared with 
the effect of cyclosporin A, rapamycin and mycophenolate  mofetil  (MMF) in the same experimental setting for 
CD8 T cell proliferation (D). 
E) Modified CML assay to compensate the reduced number of viable  responder cells after the stimulation phase 
under the  effect of ABT-737. The inhibitory effect of ABT-737 on cytotoxicity  was completely  compensated if 
the same number of viable  treated cells was added to the 51Cr-labelled target cells  during the killing phase. 
Data from a CML in the  full-MHC mismatched combination B6 to BALB/c are shown (no statistical difference 
between allogeneic control and ABT-737 1 uM adjusted in all dilutions of standard culture). 
F) BM3.3 mice were  treated with ABT-737 or  vehicle during 5 days. Treatment efficacy was demonstrated by 
lymphocyte  depletion in blood (FACS). Splenocytes from ABT-737 and vehicle  treated mice  did not differ  in 
their proliferation capacity after 4 days of MLR against B6 lymphocytes, as shown by CFSE dilution.
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Fig. 14. The pro-apoptotic effect of ABT-737 is selective for lymphocytes.
A-B) B6 mice  were  sacrificed 6h after injection of ABT-737 (50 mg/kg) or vehicle. Apoptosis  detection by im-
munohistochemistry for single-stranded DNA revealed a 10-fold increase  in the number of apoptotic cells  in the 
spleen and a 2-fold increase in the thymus. Kidney and liver tissue presented a low number of apoptotic cells 
and were  minimally  affected by the  treatment (mean number of F7-26 positive cells  per 10 high power fields 
[HPF], n = 5 mice/group; * p<0.05, ** p<0.01).
C) After 5 daily injections of ABT-737 (50 mg/kg/day) the intestine of B6 mice  was  harvested. Treatment with 
ABT-737 significantly increased the number of apoptotic cells  in the mucosa  associated lymphatic tissue (MALT) 
as  shown by TUNEL staining (mean number of apoptotic cells  per HPF), but had no impact on the  frequency of 
apoptotic cells in isolated intestinal epithelial cells as measured in FACS (n = 6-9 mice/group, * p<0.05).
D) Analysis  of splenocyte subpopulations by FACS  after  5 daily injections  revealed that B and T cells were  simi-
larly affected by ABT-737 (number of cells/spleen, n = 4 mice/group; ** p<0.01).
E) After  18 daily injections  of ABT-737 (50 mg/kg/day) B6 mice  presented a  significant lymphopenia and a 
moderate thrombocytopenia compared to control  animals. Erythrocytes and neutrophils  were not affected by 
the treatment (n = 5-7 mice/group).
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lymphatic cells from one and same organ: 
the intestine. We found that after 5 daily 
injections of ABT-737 (50 mg/kg/day) B6 
mice presented a significant increase in the 
number of apoptotic cells in the mucosa as-
sociated lymphatic tissue (Peyer’s patches), 
but not in the epithelium (TUNEL staining). 
FACS analysis of isolated intestinal epithelial 
cells from colonic mucosa confirmed that 
ABT-737 did not increase the  fraction of 
apoptotic cells in this tissue (Fig. 14C).
Spleen FACS analyses after 5 daily injections 
revealed that ABT-737 exposure resulted in 
a 60-65% reduction in the number of total 
splenocytes, and that different lymphocyte 
subpopulations were similarly affected by 
the treatment (Fig. 14D).
In addition, hematological analyses were 
performed. After 18 daily injections of ABT-
737 (50 mg/kg/day) B6 mice showed a sig-
nificant reduction of lymphocyte and plate-
let counts compared to vehicle-treated con-
trols, but erythrocytes and neutrophils were 
not affected (Fig. 14E). 
ABT-737 inhibits skin graft rejection syner-
gistically with low-dose cyclosporine A.
The immunosuppressive  effect of ABT-737 
on T cell mediated rejection was assessed in 
vivo in a mouse skin graft model. In the fully 
MHC-mismatched combination BALB/c to 
B6 neither ABT-737 (50 mg/kg/day), nor 
low-dose CsA (10 mg/kg/day) or a combina-
tion of ABT-737 and low-dose CsA were 
sufficient to significantly prolong skin graft 
survival (Fig. 15A). However, in the MHC 
class I single antigen mismatched combina-
tion bm1 to B6, daily injections with ABT-
737 from day 5 before transplantation until 
rejection significantly prolonged skin graft 
survival compared to vehicle control (median 
graft survival vehicle vs. ABT-737: 13 vs. 18 
days, p=0.03, Fig. 15B). Notably, ABT-737 
and CsA displayed a similar, significant but 
rather modest, effect as single agents in this 
model, but their immunosuppressive po-
tency was markedly increased in combina-
tion: a long-term graft survival was achieved 
in 50% of recipients treated with ABT-737 
(50 mg/kg/day, i.p.) and CsA (10 mg/kg/day, 
s.c.) from day 5 before  transplantation (me-
dian graft survival CsA vs. ABT-737+CsA: 18 
days vs. undefined, p=0.008; vehicle vs. 
ABT-737+CsA, p=0.001, Fig. 15B). Fifty days 
after transplantation recipients that had not 
rejected their grafts were sacrificed. The his-
tological analysis revealed an almost com-
plete absence of inflammatory infiltrates 
(Fig. 15C), supporting the hypothesis of a 
suppression of the allospecific immune re-
sponse. Moreover, the immunosuppressive 
effect of ABT-737 and the synergistic effect 
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Fig. 15. ABT-737 inhibits allospecific T cell responses in vivo.
A) In the fully  MHC-mismatched combination BALB/c to B6 neither ABT-737 (50 mg/kg/day), nor CsA (10 mg/
kg/day) or  a  combination of both prolonged skin graft survival  (data  pooled from two identical experiments, 
n=7-12 mice/group).
B-C) In the single MHC-mismatched model bm1 to B6 ABT-737 inhibited skin graft rejection synergistically with 
CsA (Log-rank test in comparison to the  vehicle group, * p<0.05, ** p<0.01, n=7-8 mice/group). As  a result, 
long-term graft survival was  observed in 50% of the  recipients  in the combination group. Biopsies of the  non-
rejected skin grafts  did not present any histological  sign for rejection at day 50 after  transplantation, as  shown 
by the comparison of transplanted (left to the dashed line) and native skin (right to the dashed line) in one  rep-
resentative example.
D-E) Histological analysis of bm1 skin grafts  at day 8 after transplantation onto B6 recipients confirmed a 
marked inhibition of T cell mediated rejection by ABT-737 in synergism with CsA. Representative  examples  of 
the morphological evaluation by routine histology (haematoxylin eosin staining, HE) and immunohistochemistry 
for CD3 and CD8 from mice  treated with vehicle, CsA (10 mg/kg/day), ABT-737 (50 mg/kg/day) or a  combina-
tion of both drugs  are shown. Please  note the prominent thickening of the  epidermis  and cellular infiltration in 
the vehicle  treated mice (HE, upper left). A marked reduction of the CD3 positive infiltrating cells  (arrows in 
second row, third and fourth column) could be demonstrated. The  number of CD8 positive cells was  low as 
compared to the CD3 positive cells  (arrows in the  lower panels). Semi-quantitative analyses for CD3 are pre-
sented in Fig. 15D according to a  3 degree score (white: no infiltration, gray: infiltration in less then 50% of the 
graft, black: infiltration in more then 50% of the graft; Fisher’s exact test comparing no infiltration vs. any infil-
tration, * p<0.05; n = 3-4 mice/group).
in combination with CsA were confirmed in 
an additional experiment, in which skin 
grafts were analyzed histologically 8 days 
after transplantation. At that time point a 
prominent reduction of CD3 positive T cells 
was seen in mice treated either with ABT-
737 or the  combination of ABT-737 and 
CsA (vehicle vs. ABT-737+CsA, p=0.03, Fig. 
15D). CD8 positive T cells were  low in num-
ber but also demonstrated a  trend towards 
a reduced infiltration (Fig. 15E). Notably, 
syngeneic skin grafts were not affected by 
ABT-737 treatment with or without CsA 
(follow up of more  than 150 days, data not 
shown), indicating that ABT-737 did not 
negatively interfere  with the  healing process 
after surgery.
ABT-737 inhibits allo-specific humoral re-
sponses.
The serum level of allo-specific antibodies 
was measured 15 days after transplantation 
of BALB/c skin grafts onto B6 recipients. Al-
though not sufficient to prolong skin graft 
survival in this setting (Fig. 15A), ABT-737 
significantly inhibited the production of allo-
specific antibodies as measured by indirect 
FACS (vehicle vs. ABT-737, IgG, p=0.002, 
Fig. 16). Interestingly, also the B cell re-
sponse was further inhibited in the group 
treated with a combination of ABT-737 (50 
mg/kg/day) and low-dose CsA (10mg/kg/
day). Similar results were obtained for IgG 
and IgM allo-specific antibodies (vehicle vs. 
ABT-737 + CsA, IgG p=0.001, IgM p=0.001; 
CsA vs. ABT-737 + CsA, IgG p=0.003, IgM 
p=0.028). Thus, ABT-737 potently inhibited 
allospecific T and B cell responses in vivo 
and displayed a marked synergistic effect 
with the calcineurin inhibitor CsA. 
Discussion
BH3-mimetics represent a new class of 
drugs to inhibit detrimental immune re-
sponses such as in autoimmunity (Bardwell, 
Gu et al. 2009), allergy (Karlberg, Ekoff et 
al. 2010) and chronic inflammation. Here 
we report that ABT-737 potently suppressed 
allospecific T and B cell responses. The im-
munosuppressive effect of ABT-737 was 
markedly increased in combination with 
low-dose CsA.
In our in vitro and ex vivo models, immuno-
suppression by ABT-737 was a sole manifes-
tation of clone size reduction in the alloreac-
tive T cell population induced by apoptosis. 
Although T cell depletion represents a well 
established immunosuppressive approach 
(Halloran 2004), the mechanism of action 
described here differs from strategies in cur-
rent clinical protocols. In contrast to deplet-
ing antibodies such as antithymocyte globu-
lin or cytotoxic drugs such as cyclophos-
phamide, Bcl-2-antagonists interact with 
pathways physiologically regulating periph-
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Fig. 16. ABT-737 inhibits allospecific B cell 
responses in vivo.
Serum levels of allospecific  IgG and IgM antibodies 
were measured 15 days  after skin transplantation in 
the BALB/c to B6 combination. ABT-737 (50 mg/kg/
day) synergistically with CsA (10 mg/kg/day) inhib-
ited allospecifc humoral response  (MFI: mean fluo-
rescence  intensity; * p<0.05, ** p< 0.01, n = 6-8 
mice/group). Representative  results of one of two 
experiments are shown.
eral T cell deletion and offer opportunities to 
better understand and to modulate  these 
fundamental mechanisms as a  novel immu-
nosuppressive approach.
The efficacy of this concept was confirmed 
in vivo in a skin transplantation model. As a 
single agent ABT-737 significantly pro-
longed skin graft survival, but was not suffi-
cient to fully prevent rejection in a MHC 
class I mismatched model. As ABT-737 did 
not completely deplete lymphocytes in vivo 
(Fig. 14D), we speculate that a subpopula-
tion of alloreactive lymphocytes survived the 
pro-apoptotic effect of ABT-737 and was 
responsible for graft rejection. In contrast, in 
combination with low dose CsA ABT-737 
completely prevented rejection in 50% of 
the recipients, as shown in the histological 
analysis of the grafts at day 50 after trans-
plantation (Fig. 15B-C). Because of the high 
immunogenicity of the skin it is not surpris-
ing that a pharmacological combination was 
required to completely exploit the  immuno-
suppressive potential of ABT-737. Of par-
ticular interest, the addition of a  Bcl-2 inhibi-
tor increased the immunosuppressive  po-
tency of CsA at a dosage  that by its own 
was not sufficient to prevent graft rejection. 
We hypothesize that in the setting of a re-
duced clone size by ABT-737 a lower con-
centration of CsA was sufficient to control 
the pool of alloreactive T cells. This hypothe-
sis is supported by the fact that the combi-
nation therapy was not sufficient to inhibit 
the larger pool of allo-reactive cells in the 
fully-MHC mismatched combination. How-
ever, additional interactions between the 
calcineurin and the intrinsic apoptosis path-
ways have been previously described and 
might play a role  in this setting (Shibasaki, 
Kondo et al. 1997).
Bcl-2 inhibitors suppress immune responses 
through a novel pharmacological target and 
open new options for pharmacological 
combinations. Because of the favorable syn-
ergism with CsA, ABT-737 might find a 
clinical application as part of a low dose cal-
cineurin inhibitor (CNI) based regime and 
help reducing CNI long-term toxicity. 
Moreover, based on its well-established anti-
neoplastic properties, we expect that ABT-
737 would reduce the incidence of tumors 
in transplant recipients. This aspect would 
differentiate  Bcl-2 inhibitors from most cur-
rent immunosuppressive drugs, and might 
have a major impact on survival in this high-
risk situation for cancer development.
Apoptosis is a fundamental cellular mecha-
nism, and tissue selectivity of Bcl-2 inhibitors 
is crucial to limit systemic toxicity. Although 
a detailed analysis of the mechanisms de-
termining tissue selectivity of ABT-737 was 
beyond the objectives of this study, our ex-
periments showed that ABT-737 is selective 
for lymphatic cells and tissues. These results, 
which are supported by data from clinical 
trials using the  ABT-737 orally bioavailable 
counterpart ABT-263 (Wilson, Tulpule et al. 
2007), suggest a favorable toxicity profile 
for ABT-737. Further analyses are required 
for a  better understanding of the regulation 
of Bcl-2 proteins in inflamed tissues and to 
better assess the  selectivity of ABT-737 after 
surgery. In this context, the  normal survival 
and wound healing of syngeneic grafts in 
ABT-737 treated mice represent a promising 
result, thereby distinguishing ABT-737 from 
anti-proliferative drugs such as mTOR inhibi-
tors.
Currently available therapeutical options to 
control humoral rejection are limited. ABT-
737 as a  single agent and particularly in 
combination with CsA suppressed the  allo-
antibody response in a fully MHC mis-
matched skin graft model. Although our 
mechanistic studies primarily focused on T 
cell responses, we observed that B and T 
cells were similarly depleted by ABT-737 
(Fig. 14D). Therefore, we suggest B cell de-
pletion as the principal explanation for this 
effect of ABT-737, but a concomitant T cell 
help inhibition is likely to be  involved and 
may explain the synergistic effect with CsA. 
Further studies are  required to better assess 
the effect of ABT-737 on plasma cells.
Thus, our data strongly support further 
evaluation of Bcl-2 inhibitors as novel class 
of immunosuppressive  drugs with potential 
broad clinical application in the field of allo-
transplantation.
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Abstract
Dynamic regulation of the intrinsic apoptosis pathway controls central and peripheral lympho-
cyte  deletion and may interfere with the pro-apoptotic potency of Bcl-2 inhibitors such as 
ABT-737. By following a T cell receptor-transgenic population of alloantigen-specific T cells, 
we found that sensitivity to ABT-737 radically changed during the  course of allo-specific im-
mune responses. Particularly, activated T cells were fully resistant to ABT-737 during the first 
days after antigen recognition. This phenomenon was caused by a T cell receptor-calcineurin-
NFAT-dependent up-regulation of A1 and was therefore prevented by cyclosporine A. As a 
result, exposure to ABT-737 after alloantigen recognition induced selection of alloreactive T 
cells in vivo, whereas in combination with low-dose cyclosporine  A ABT-737 efficiently de-
pleted allo-reactive T cells in mouse host-versus-graft and graft-versus-host models. Thus, 
ABT-737 resistance is not a prerogative of neoplastic cells, but it physiologically occurs in T 
cells after antigen recognition. Reversibility of this process by calcineurin inhibitors opens new 
pharmacological opportunities to modulate this process in the context of cancer, autoimmu-
nity and transplantation. 
Introduction
Bcl-2 inhibition represents a  novel pharma-
cological principle to control lymphoid ma-
lignancies and detrimental immune re-
sponses (Vogler, Dinsdale et al. 2009; Car-
rington, Vikstrom et al. 2010). Of particular 
scientific and potential clinical interest are 
the small-molecule Bcl-2 inhibitors ABT-737 
and its bioavailable counterpart navitoclax 
(ABT-263) (Oltersdorf, Elmore  et al. 2005; 
Tse, Shoemaker et al. 2008). ABT-737 binds 
with high affinity to the  anti-apoptotic Bcl-2 
family members Bcl-2, Bcl-xL and Bcl-w. By 
this mechanism it prevents them from se-
questering pro-apoptotic BH3 proteins and 
therefore indirectly initiates the apoptotic 
cascade. In contrast, ABT-737 has a low af-
finity to Bcl-2-A1 (A1, Bfl-1), Mcl-1 and Bcl-
B. These particular molecular binding char-
acteristics may be important for tissue selec-
tivity and - as a consequence – for the  fa-
vorable toxicity profile  of ABT-737 and ABT-
263 (Wilson, Tulpule et al. 2007), but limits 
their therapeutic potency on lymphoma cells 
expressing A1 and Mcl-1 (Del Gaizo Moore, 
Schlis et al. 2008; Yecies, Carlson et al. 
2010).
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The physiological regulation of apoptosis in 
lymphocytes has been extensively investi-
gated (Marsden and Strasser 2003) and may 
assume a new relevance in the  context of 
therapeutic approaches selectively targeting 
Bcl-2 proteins. Focusing on the T cell com-
partment, it has been shown that the fate of 
a T cell is linked to the expression of a func-
tional T cell receptor (TCR) (Cho, Kim et al. 
2010) and its interaction with antigen pre-
senting cells (APCs). The combination of 
signals through the TCR, co-stimulatory 
molecules (such as CD28 and 4-1BB) and 
cytokines (such as IL-2 and IL-15) dynami-
cally modulates the intrinsic and the extrinsic 
apoptosis pathway in T lymphocytes and 
eventually controls central and peripheral T 
cell selection (Wojciechowski, Tripathi et al. 
2007; Fischer, Belz et al. 2008; Hughes, Belz 
et al. 2008; Sabbagh, Pulle et al. 2008; 
Bouillet and O'Reilly 2009; Fehr, Lucas et al. 
2010). Of particular interest are previous re-
ports on a  TCR-dependent up-regulation of 
A1 in the early phase after antigen recogni-
tion, which protects activated thymocytes 
and splenocytes from apoptosis without in-
terfering with cell proliferation (Gonzalez, 
Orlofsky et al. 2003; Verschelde, Walzer et 
al. 2003). These mechanisms are crucial for 
the development and the maintenance of a 
functional immune system (Hughes, Belz et 
al. 2008) and might be  influenced by drugs 
targeting the apoptosis pathway.
This hypothesis is supported by previous re-
ports about the immunomodulatory proper-
ties of ABT-737 in several experimental 
models: ABT-737 had a beneficial effect on 
autoimmunity (Bardwell, Gu et al. 2009) and 
significantly inhibited solid allograft rejection 
in the  mouse (Carrington, Vikstrom et al. 
2010; Cippa, Kraus et al. 2011). However, 
immunosuppression by ABT-737 in a 
collagen-induced arthritis model was only 
effective in a preventive setting, but not in 
mice with established disease (Lawlor, Smith 
et al. 2011). Furthermore, the immunosup-
pressive effect of ABT-737 in a mouse skin 
graft model was rather limited as a  single 
agent, but markedly increased in combina-
tion with cyclosporine A (CsA) (Cippa, Kraus 
et al. 2011). These data suggest that the 
pro-apoptotic potency of ABT-737 on lym-
phoid cells is altered in the context of in-
flammation and T cell activation. 
Thus, in this study we examined the effect 
of ABT-737 on alloreactive  T cells in the set-
ting of host-versus-graft and graft-versus-
host immune reactions. We found a unique 
selectivity profile of ABT-737 on T lympho-
cytes over the course of the immune re-
sponse as a  result of a transient, calci-
neurin-, NFAT- and A1-dependent resistance 
to ABT-737 after antigen recognition. The 
calcineurin inhibitor CsA blocked A1 up-
regulation and prevented resistance to ABT-
737 in activated T cells, thereby offering 
new options for effective combination 
therapies.
Material and Methods
Mice. C57BL/6 (B6, H-2b), CBA (H-2k), 
(CBAxB6)F1 (F1, H-2b/k) and BM3.3 (CBA, H-
2k) mice  were housed in specific pathogen-
free conditions at the University of Zürich. 
The BM3.3 mouse (Auphan, Curnow et al. 
1994), which expresses on all CD8 T cells a 
transgenic T cell receptor (TCR) selective for 
a naturally processed octapeptide bound to 
the allogeneic MHC class I molecule H-2Kb, 
was kindly provided by A.-M. Schmitt-
Verhulst (Guimezanes, Barrett-Wilt et al. 
2001). All animal experiments were per-
formed according to protocols approved by 
the legal authority (Veterinary Office, Can-
ton of Zürich, Switzerland).
Synchimeras and graft-versus-host reaction 
model. Synchimeric animals were  generated 
as previously described (Fehr, Takeuchi et al. 
2005; Haspot, Fehr et al. 2008). Briefly, 
5x106 bone marrow cells from BM3.3 mice 
were transplanted into naive CBA mice irra-
diated with 3 Gy on the same day. After 6-
10 weeks, B6 splenocytes were  injected and 
treatment with ABT-737 (50 mg/kg/d i.p.) or 
vehicle  was started according to the experi-
mental protocol. Donor-reactive BM3.3 CD8 
T cells were monitored in blood using the 
Ti98 antibody, which selectively binds to the 
BM3.3 TCR (Buferne, Luton et al. 1992).
Graft-versus-host (GvH) reactions were stud-
ied in a parent to F1 model. F1 mice were 
generated by breeding CBA females and B6 
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males and expressed H-2k and H-2b. After 
adoptive transfer of 20-25x106 BM3.3 sple-
nocytes (H-2k background and therefore  not 
rejected by the host, and selectively reacting 
against H-2Kb) GvH reactive  cells were ana-
lyzed in the spleen using the Ti98 antibody.
Fluorescence activated cell sorting (FACS). 
FACS analyses were  performed with a  BD-
FACSCanto (Becton Dickinson, Basel, Swit-
zerland). Anti-mouse  CD3-FITC, CD4-PE, 
CD8-APC, and propidium iodide (PI) were 
purchased from eBioscience (Frankfurt, D), 
anti-mouse CD25-PE/Cy7 from Biolegend 
(Uithoorn, NL). The Ti98 antibody was kindly 
provided by A.-M. Schmitt-Verhulst 
(Buferne, Luton et al. 1992). A secondary PE 
rat anti-mouse IgG was purchased from Bec-
ton Dickinson (Basel, CH). 
Mixed lymphocyte reaction (MLR). MLR were 
performed in 96 wells plates with responder 
splenocytes stimulated by T cell-depleted (or 
CD8 T cell-depleted) splenocytes from allo-
geneic and syngeneic mice at a final concen-
tration of 4 x106 cells/ml in RPMI medium 
containing, 10% fetal bovine serum, penicil-
lin 100 U/ml, streptomycin 100 µg/ml, 2-
mercaptoethanol 50 µM. Splenocytes were 
sorted by automatic magnetic cell separa-
tion using an autoMACS pro separator ac-
cording to the protocols of Miltenyi Biotec 
(Bergisch Gladbach, D) to allow a  selective 
analysis of responder CD4 and CD8 T cells in 
FACS.
Reagents and Drugs. ABT-737 was provided 
by Abbott Bioresearch (Worcester, USA): for 
in vitro experiments ABT-737 was dissolved 
in DMSO at a concentration of 5 mM and 
then diluted in culture medium. For in vivo 
applications ABT-737 was dissolved in poly-
ethylene glycol, Tween 80, dextrose solution 
and DMSO and injected intra-peritoneally 
(i.p.) at 50 mg/kg/day. Antimycin A, CsA, 
Rapamycin and Tacrolimus were purchased 
from EnzoBiochem (Farmingdale, New York, 
USA), Cycloheximide from Sigma-Aldrich 
(Buchs, CH), VIVIT-R from Calbiochem 
(Merck, Darmstadt, D), Obatoclax (GX15-
070) from Selleck (Houston, USA). CTLA4Ig 
(abatacept) was provided by Bristol-Myers 
Squibb. The anti-CD154 (CD40L) antibody 
MR1 was purchased from BioXCell (West 
Lebanon, USA). For in vivo application CsA 
was dissolved in ethanol and cremaphor EL 
(Sigma-Aldrich), then diluted in PBS and in-
jected subcutaneously (s.c.).
Quantitative RT-PCR (qRT-PCR). Reverse tran-
scription and qPCR were performed as re-
ported earlier (Lindenmeyer, Eichinger et al. 
2010). Pre-developed TaqMan reagents 
w e r e u s e d f o r m o u s e B c l - 2 
( M m 0 0 4 7 7 6 3 1 _ m 1 ) , B c l - X L 
( M m 0 0 4 3 7 7 8 3 _ m 1 ) , M c l - 1 
(Mm01257352_g1) and for the house-
keeper gene 18S rRNA (Applied Biosystems 
Europe, Rotkreuz, CH). For mouse A1, the 
following oligonucleotide primers and probe 
were designed to simultaneously detect Bcl-
2A1a, Bcl-2A1b and Bcl-2A1d: sense primer 
5’-ATG GAG GTT GGG AAG ATG G-3’, anti-
sense primer 5’-GAG CCA AGG TTC TCT 
CTG GTC-3’, fluorescence labeled probe 
(FAM) 5’-GGC TGG CTG ACT TTT CTG CAG 
ATG A-3’. The expression of candidate 
genes in alloantigen-stimulated cells of cul-
ture  was normalized by 18S rRNA and com-
pared with syngeneically stimulated cells.
Western blot. For Western blot allo- and 
syngeneically stimulated lymphocytes were 
harvested with Ripa buffer and complete 
protease inhibitor cocktail (Roche, Mann-
heim, D) at different time points after stimu-
lation in vitro. Extracted proteins were 
boiled in loading buffer for 5 minutes, re-
solved by 15% SDS-PAGE and transferred to 
an Immobilon-P membrane (Millipore, Esch-
born, D). Membranes were blocked over-
night with Tris-buffered saline (TBS)/5% fat-
free skim milk, then incubated with a poly-
clonal anti-A1 antibody (Cell Signaling 
Technology, Danvers, USA) diluted 1:1000 
overnight at 4°C and rinsed with TBS that 
contained 0.1% Tween 20. For detection a 
HRP-linked goat anti-rabbit antibody 
(1:4000, 30 min at room temperature; Cell 
Signaling Technology, Danvers, USA) and 
enhanced chemiluminescence substrate 
(Proteinsimple, Santa Clara, USA) were used. 
Membranes were also probed with anti-
actin antibody (A2066, 1:1000, Sigma-
Aldrich) as internal loading control.
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Statistics. Student t-test, Mann-Whitney test 
and paired t-test were used to compare val-
ues between groups as appropriate. IC50-
values were calculated using a log(inhibitor) 
vs. response model. P<0.05 was considered 
significant. Graph Pad Prism Software Ver-
sion 5.0 was used for calculations.
Results
Activated T cells are resistant to ABT-737
To investigate the impact of allogeneic T cell 
activation on the sensitivity to the Bcl-2 in-
hibitor ABT-737, we used the transgenic 
mouse strain BM3.3, which expresses on all 
CD8 T cells a  transgenic TCR specific for the 
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Fig. 17. Allo-reactive CD8 T cells are resistant to ABT-737 after donor specific transfusion
(A) Characterization of the BM3.3 model: after 48h of MLR with BM3.3 responders  and CD8-depleted B6 stimu-
lators all  responder (Ti98+) CD8 T cells were activated, as measured by CD25 expression in FACS. (B) Experimen-
tal setup: Synchimeric mice were generated by bone  marrow (BM) transplantation from BM3.3 mice into CBA 
recipients  after non-lethal total  body irradiation (3Gy). After 6 weeks, synchimeras expressed the BM3.3 TCR 
(Ti98+) on about 6% of the whole CD8 positive  population. The mice were primed by i.v. injection of B6 spleno-
cytes, and two days later treatment with ABT-737 was started. (C-D) Exposure to ABT-737 induced a  relative and 
absolute reduction of CD3+ cells  in peripheral blood and similarly affected CD4+ and CD8+ T cells. (E) The in-
crease  of the percentage of Ti98+ cells  among CD8 T cells  was  significantly higher in mice exposed to ABT-737 
(p<0.01). Statistical comparison of data registered at baseline and at day 5 by paired t-test; *p<0.05, **p<0.01; 
n=5. Representative results of one of two independent experiments are shown.
MHC class I molecule H-2Kb and can be de-
tected by the clonotypic antibody Ti98. In a 
first experiment we transplanted BM3.3 
bone marrow (BM) into non-lethally irradi-
ated CBA mice in order to create synchi-
meric mice  that express the BM3.3-TCR only 
on a fraction of the CD8 T cell pool. This 
well-defined homogeneous population of 
alloreactive CD8 T cells could then be fol-
lowed during the course of a host-versus-
graft (HvG) response in the context of an 
otherwise physiological immune system (Fig. 
17A-B). Synchimeras received a donor spe-
cific transfusion (20x106 B6 splenocytes, i.v., 
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Fig. 18. Activated CD8 T cells are resistant to ABT-737 in a graft-versus-host model
BM3.3 splenocytes were adoptively transferred to CBA (syngeneic) or (CBAxB6)F1 (allogeneic) recipients  to assess 
the effect of ABT-737 on GvH reactive cells. After 3 daily injections  of ABT-737 (filled circles) or vehicle  (open 
circles), splenocytes  were analyzed by FACS. (A-B) Allogeneic CD8 T cell activation was confirmed by CD25 ex-
pression and (B-C) a selective analysis of Ti98+ cells indicated that ABT-737 did not substantially influence this 
process. (E-F) A similar reduction in the number  of total  splenocytes was registered in both groups (about 30% 
reduction, please note the different total number of splenocytes  in different recipient strains). (G-H) The  total 
number of Ti98 positive cells  decreased in the  syngeneic, but not in the allogeneic combination, indicating resis-
tance to ABT-737 in allo-activated CD8 T cells. Statistical  comparison ABT-737 vs. vehicle; *p<0.05, **p<0.01, 
***p<0.001; n=5. Representative results of one of two independent experiments are shown.
DST) and treatment with either ABT-737 (50 
mg/kg/day) or vehicle, starting at day 2 after 
DST. At day 5 after priming, mice treated 
with ABT-737 presented a 75% reduction of 
T cells in peripheral blood (Fig. 17C); CD4 
and CD8 T cells were similarly affected by 
the treatment (Fig. 17D). After antigen rec-
ognition the percentage of Ti98 positive 
cells among CD8 T cells increased in both 
groups, but this effect was markedly en-
hanced in the ABT-737 group compared to 
control (Fig. 17E). This observation is ex-
plained by a  selection of activated Ti98+ 
cells among CD8 T cells under the effect of 
ABT-737, which may be further enhanced 
by homeostatic proliferation in a lym-
phopenic environment.
To limit the confounding effect of homeo-
static proliferation we performed an analo-
gous experiment in a GvH model. The  com-
bination of a parent to F1 model with the 
BM3.3 transgenic system allowed us to spe-
cifically analyze a homogeneous population 
of host-reactive CD8 T cells in the absence 
of rejection by the recipient and without the 
effect of any conditioning regime (such as 
total body irradiation), that may alter the 
immune response and apoptosis regulation. 
We minimized the effect of T cell prolifera-
tion by choosing a short protocol: BM3.3 
splenocytes were adoptively transferred into 
(CBAxB6)F1 (allogeneic stimulation) or CBA 
recipients (syngeneic control). On day 1 after 
transfer treatment with ABT-737 (50 mg/kg/
day) or vehicle was started, and two days 
later recipient mice were sacrificed for FACS 
analysis. ABT-737 minimally influenced the 
activation of Ti98 cells (Fig. 18C and D) and 
similarly reduced the number of total sple-
nocytes in F1 and CBA recipients by about 
30% reduction (Fig. 18E and F). However, in 
the syngeneic combination, Ti98+ cells were 
similarly reduced as total T cells and total 
splenocytes (Fig. 18G), whereas in F1 recipi-
ents alloactivated donor-reactive CD8+Ti98+ 
cells were resistant to ABT-737 (Fig. 18H). 
As a result, the total number of Ti98+ cells 
in CBA recipients was markedly reduced af-
ter ABT-737 treatment, but no difference in 
the total number of Ti98 positive  cells be-
tween the two groups was registered after 
allogeneic stimulation (Fig. 18G and H). 
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Fig. 19. Allo-activated T cells are resistant to ABT-737 in vitro
(A) BM3.3 splenocytes  were stimulated with CD8-depleted B6 (allogeneic, filled circles) or  CBA (syngeneic, open 
circles) splenocytes during 48h MLR and then treated with ABT-737 during additional 12h of MLR. Much higher 
concentrations  of ABT-737 (1’000- to 10’000-fold) were required to induce apoptotis in allo-activated CD8 T 
cells  compared to non-activated T cells. (B) Similarly, B6 splenocytes  were stimulated with T cell-depleted CBA 
splenocytes  during 48h MLR and then treated with ABT-737 during additional 12h of MLR. FACS  analysis  of re-
sponder CD4 and CD8 T cells  revealed that activated (CD25+, filled circles) cells  were resistant to ABT-737 com-
pared to non-activated (CD25-, filled squares) cells  in the same culture  and also with syngeneically stimulated 
cells  (open circles). Cell viability was assessed by PI exclusion in FACS in at least 3 independent experiments. Per-
centage of cells  treated with vehicle  is  given. Statistical comparison of allo vs. syn: *p<0.05, **p<0.01, 
***p<0.001.
These data strongly suggest that resistance 
of activated Ti98+ T cells to ABT-737 had 
developed in both HvG and GvH experi-
ments.
This hypothesis was further tested in vitro in 
a mixed lymphocytes reaction (MLR) model. 
BM3.3 splenocytes were cultured with CD8-
depleted allogeneic B6 or syngeneic CBA 
splenocytes during 48h and then treated 
with ABT-737 for additional 12h. Cell viabil-
ity analysis by propidium iodide exclusion in 
FACS revealed that a 1’000- to 10’000-fold 
higher concentration of ABT-737 was re-
quired to induce  apoptosis in CD8 T cells 
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after allogeneic stimulation (Fig. 19A). To 
exclude a transgenic artifact the  same ex-
periment was repeated with B6 responders 
and T-cell depleted CBA stimulators. Acti-
vated (CD25+) CD8 T cells were much more 
resistant to ABT-737 compared to non-
activated (CD25-) cells in the  same culture 
and to syngeneically stimulated (non-
activated) T cells. The same phenomenon 
was observed for CD4 T cells (Fig. 19B). 
Thus, T cell activation induces resistance to 
ABT-737 in vitro and in vivo. 
Molecular mechanism of resistance to ABT-
737 in activated T cells
The regulation of apoptosis is complex, and 
several mechanisms may be involved in resis-
tance to ABT-737 after T cell activation. In 
MLR experiments using the  BM3.3 system, 
we found that exposure to the  ribosome 
blocker cycloheximide during the stimulation 
phase prevented the establishment of ABT-
737 resistance, indicating that protein syn-
thesis was required to induce this anti-
apoptotic state (Fig. 20A). Previous studies 
in tumor models revealed that the expres-
sion of anti-apoptotic Bcl-2 proteins with a 
low binding affinity to ABT-737, such as A1 
and Mcl-1, resulted in resistance to this 
compound (Al-Harbi, Hill et al. 2011). There-
fore, we first assessed the impact of T cell 
activation on the expression of various anti-
apoptotic Bcl-2 proteins in our system. 
Analyses by qRT-PCR revealed that T cell ac-
tivation rapidly influenced the gene expres-
sion pattern of Bcl-2 family members (Fig. 
20B): among the Bcl-2 members that are 
not inhibited by ABT-737, expression of A1 
was 9-fold higher in alloantigen-stimulated 
than in non-activated cells. In contrast, ex-
pression of Mcl-1 did not change. When 
looking at time  kinetics we found that resis-
tance to ABT-737 is a transient phenome-
non: it rapidly develops after T cell stimula-
tion, but progressively vanished after 4-5 
days of culture (Fig. 20C). This evolution 
strongly correlated with expression of A1 
protein over time (Fig. 20D), supporting the 
hypothesis of a crucial role of this particular 
factor. A selective inhibition of A1 in mouse 
cells is complicated due to the presence of 4 
homologous genes for A1 in the mouse ge-
nome. Just one of them – A1-a – was suc-
cessfully targeted in a knock-out mouse 
(Hamasaki, Sendo et al. 1998) and selective 
pharmacological A1 inhibitors are  currently 
not available (Cashman, MacDonald et al. 
2010). Therefore, we applied a reversed ap-
proach using different Bcl-2 inhibitors with a 
defined binding profile. We found that T cell 
activation induced resistance to Bcl-2 inhibi-
tion by ABT-737 (no binding of A1 and Mcl-
1) and by Antimycin A (no binding of A1 
only), but had no impact on the pro-
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Fig. 20. Up-regulation of A1 is crucial for resistance to ABT-737
(A) BM3.3 splenocytes were stimulated with CD8 T cell-depleted splenocytes from B6 (allo) or CBA (syn) donors 
during 24h of MLR under different concentration of cycloheximide  and then treated with ABT-737 (1 uM) or 
vehicle. Alloantigen-stimulated cells  without cycloheximide  were resistant to ABT-737, but cycloheximide  pre-
vented this  process  in a concentration-dependent manner. (B) After 6h of MLR the expression of Bcl-2 family 
genes was  analyzed in BM3.3 CD8 cells  by qRT-PCR: we registered a  9-fold up-regulation in the expression of A1 
and a small increase of Bcl-2 and Bcl-xL in comparison to syngeneically stimulated cells. (C) For a  time course 
analysis BM3.3 splenocytes were stimulated for up to 6 days with B6 or CBA splenocytes and then treated with 
ABT-737 for  additional 12h. Resistance  to ABT-737 dynamically changed over time after allogeneic stimulation, 
reaching a  maximum 2-3 days after stimulation and rapidly declining thereafter, whereas  syngeneically stimu-
lated cells remained sensitive to ABT-737 over time (one representative  time  point is  shown). Cell  viability of 
BM3.3 CD8 T cell was assessed by PI exclusion in FACS  in at least 3 independent experiments. Percentage  of cells 
treated with DMSO-containing vehicle  is given. Statistical comparison of allo vs. syn: *p<0.05, **p<0.01, 
***p<0.001. (D) A parallel  analysis  of A1 by Western blot revealed that ABT-737 resistance  and A1 expression 
strongly correlated over time. (E) The role  of different anti-apoptotic  Bcl-2 factors  in determining resistance to 
ABT-737 was  investigated comparing the  pro-apoptotic effect of ABT-737, antimycin A and Obatoclax on acti-
vated (filled circles) and non-activated (open circles) BM3.3 CD8 T cells. T cell  activation induced resistance to 
ABT-737 and to antimycin A but not to Obatoclax, demonstrating a  crucial  role of A1 in this  phenomenon. Per-
centage of cells  treated with DMSO-containing vehicle is given. Half maximal inhibitory concentration (IC50) and 
95% confidence interval (95% CI) are reported in the table.
apoptotic potency of the pan-Bcl-2 inhibitor 
Obatoclax (Fig. 20E). Thus, A1 up-regulation 
is the crucial factor determining resistance 
to ABT-737 in activated T cells.
T cell activation signaling and resistance to 
ABT-737
According to the 3-signal concept, physio-
logical T cell activation is determined by the 
concurrent stimulation of the TCR (signal 1) 
together with a costimulatory signal through 
CD28 and CD154 (signal 2) and by the ef-
fect of cytokines such as IL-2 and IL-15 (sig-
nal 3) (Matzinger and Kamala 2011). The 
link between resistance to ABT-737 and the 
different pathways involved in T cell activa-
tion was investigated dissecting the T cell 
activation process by blockade of different 
pathways during the stimulation phase 
(24h). We found that resistance to ABT-737 
was prevented by blocking signal 1 with the 
calcineurin inhibitor CsA. In contrast, block-
ing of CD28 signaling by CTLA4Ig or of 
CD40 signaling by MR1 or using CD40-
knock out stimulators (data not shown), and 
blocking of mTOR signaling by rapamycin at 
a concentration that efficiently inhibited 
MLR in the same combination, did not influ-
ence resistance to ABT-737 (Fig. 21A). An 
important role of the TCR-calcineurin-NFAT 
(signal 1) cascade was further confirmed by 
using the  alternative calcineurin inhibitor 
tacrolimus and the cell permeable NFAT-
inhibitor VIVIT-R (Aramburu, Yaffe et al. 
1999). The blockade of this pathway at any 
level increased the percentage  of apoptotic 
cells in allogeneic, but not in syngeneic cul-
tures (data not shown), and it prevented re-
sistance to ABT-737 (Fig. 21B), excluding an 
off-target effect of CsA and indicating a 
crucial role for NFAT in preventing T cell 
apoptosis in the early phase  after antigen 
recognition. The correlation of these find-
ings with the inhibition of up-regulation of 
A1 by CsA was confirmed at the mRNA and 
protein level (Fig. 21C-D). Thus, antigen rec-
ognition induced an NFAT-dependent up-
regulation of A1 that determined resistance 
to ABT-737 in allo-antigen activated CD8 T 
cells, and CsA completely prevented this re-
sistance to ABT-737 in activated cells in vi-
tro.
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Fig. 21. Signal 1 determines resistance to ABT-737 in activated T cells
(A) Selective inhibitors  of signal  1, 2 and 3 were added to an MLR during the stimulation phase  with BM3.3 
splenocytes  reacting against CD8 T cell-depleted B6 splenocytes to investigate the role of the  different T cell  acti-
vation pathways  for resistance to ABT-737 (1 uM, during additional 12h of culture). The calcineurin inhibitor  and 
signal 1 blocker cyclosporine A prevented resistance  to ABT-737 in a concentration-dependent manner, whereas 
inhibition of signal  2 by CTLA4Ig and signal 3 by rapamycin did not influence this process. (B) The  results  ob-
tained with CsA were  confirmed by other inhibitors  of this same  pathway, namely the alternative  calcineurin in-
hibitor tacrolimus  and the NFAT-inhibitor VIVIT-R. Cell viability of BM3.3 CD8 T cells  was assessed by PI exclusion 
in FACS in at least 3 independent experiments. Percentage  of cells treated with vehicle is  given. Statistical  com-
parison of ABT-737 vs. vehicle: *p<0.05, **p<0.01. (C, D) Exposure to CsA during the stimulation phase inhib-
ited the up-regulation of A1 as assessed by qRT-PCR (C) and Western blot (D). 
Reversibility of ABT-737 resistance by cyclo-
sporine A in vivo 
The critical role of signal 1 for ABT-737 re-
sistance offers the opportunity to prevent 
resistance to ABT-737 using clinically well-
established calcineurin inhibitors. We tested 
this option using a combination of CsA and 
ABT-737 in the GvH and HvG models intro-
duced before. For the GvH experiments 
BM3.3 splenocytes were transferred to F1 
mice under treatment with low doses of 
CsA (10 mg/kg/day). Similarly to the previ-
ous experiment (Fig. 18), ABT-737 (50 mg/
kg/day) was administered at day 1 and 2 af-
ter cell transfer, and on day 3 mice were 
sacrificed for spleen FACS analysis. Concur-
rent with the in vitro results, the selection of 
activated donor reactive CD8+Ti98+ cells 
observed in mice treated with ABT-737 
alone was completely prevented by the ad-
dition of CsA (Fig. 22A). Because of the 
general lymphopenia induced by ABT-737, 
this resulted in a  much more pronounced 
depletion of alloreactive  T cells in the com-
bination group (Fig. 22B). This effect was 
even more pronounced in the  HvG model, 
where treatment was continued for 5 days 
after DST and the immunosuppressive  effect 
of CsA simultaneously contributed to the 
inhibition of the allogeneic immune re-
sponse (Fig. 22C). Thus, resistance to ABT-
737 after antigen recognition was success-
fully overcome by combination with low 
doses of CsA.
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Fig. 22. Cyclosporine A prevents resistance to ABT-737 in vivo
(A-B) (CBAxB6)F1 mice  were injected with BM3.3 splenocytes  to induce a  GvH reaction and treated with ABT-
737 (50 mg/kg/day, i.p.) with or without CsA (10 mg/kg/day, s.c.). After  3 days  the mice were sacrificed and the 
spleens analyzed by FACS. (A) Treatment with ABT-737 alone resulted in the selection of allo-reactive  Ti98+ cells. 
However, this  phenomenon was completely prevented in combination with CsA (statistical comparison to vehicle 
or  CsA alone respectively). (B) As a  result, the total number of allo-reactive CD8+Ti98+ cells per spleen was 
markedly reduced in the combination therapy group, compared to CsA or ABT-737 alone.
(C) Similarly, in an HvG combination using synchimeric mice  (s. Fig. 17 for experimental setup), the combination 
of ABT-737 and CsA strongly reduced the number of donor-reactive  Ti98+ cells  as  measured in spleens  at day 5 
after  injection of B6 splenocytes. Statistical  comparison to vehicle group: n.s. p>0.05, *p<0.05, **p<0.01, 
***p<0.001.
Discussion
The regulation of the intrinsic apoptosis 
pathway in lymphocytes assumes a novel 
relevance after the advent of small-molecule 
Bcl-2 inhibitors. Here we present evidence 
that sensitivity to ABT-737 in lymphocytes 
dynamically changes during the course of 
immune responses, and activated T cells are 
transiently resistant to ABT-737 during the 
first days after antigen recognition because 
of a signal 1-dependent NFAT-dependent 
up-regulation of A1. As a result, ABT-737 
displayed a  unique selectivity profile in its 
pro-apoptotic potency, depleting naïve lym-
phocytes, but sparing T cells after antigen-
specific activation.
A1 is up-regulated in the first hours after T 
cell activation and protects activated thymo-
cytes and splenocyes from premature death 
(Gonzalez, Orlofsky et al. 2003; Verschelde, 
Walzer et al. 2003). A1-dependent resis-
tance to ABT-737 has been previously re-
ported in lymphoma cells (Del Gaizo Moore, 
Schlis et al. 2008; Vogler, Butterworth et al. 
2009; Yecies, Carlson et al. 2010). Here we 
show for the first time that physiological up-
regulation of A1 after antigen recognition 
and ABT-737 resistance in normal (non-
neoplastic) T cells are linked. More precisely, 
T cell activation resulted in a 1’000- to 
10’000-fold resistance to ABT-737, a finding 
reminiscent of the  results obtained by Vo-
gler et al. in B cell lymphoma cells cultured 
with CD154-expressing fibroblasts and IL-2 
(Vogler, Butterworth et al. 2009). Mechanis-
tic analyses revealed that the TCR-
calcineurin pathway controlled A1 up-
regulation and that NFAT was the crucial 
transcription factor in this context (Ver-
schelde, Walzer et al. 2003), thereby mim-
icking the  mechanism regulating A1 in mast 
cells after IgE receptor stimulation (Ulleras, 
Karlberg et al. 2008). Interestingly, funda-
mentally different pathways were involved 
in resistance to ABT-737 in CLL cells (which 
was signal 2- and 3-dependent and NFκB-
mediated) suggesting a different regulation 
of A1 in B and T lymphocytes. In the com-
plex system of apoptosis regulation it is pos-
sible  that additional factors may influence 
the sensitivity of T cells to Bcl-2 inhibition 
during the course  of the immune response 
(e.g. Mcl-1 protein stabilization (Wensveen, 
van Gisbergen et al. 2010)). However, we 
demonstrated that blocking A1 was critical 
to prevent resistance to ABT-737, and inhib-
iting signal 1 of T cell activation achieves this 
goal.
The synergistic effect of CsA and ABT-737 is 
partially paradoxical because of the anti-
apoptotic properties of CsA, which have 
been previously related to a  stabilization of 
the mitochondrial membrane (Zamzami, 
Marchetti et al. 1996; Hotchkiss, Strasser et 
al. 2009). This effect is presumably of lim-
ited relevance in combination with ABT-737. 
In contrast, the inhibition of the A1-
dependent strong anti-apoptotic signal pro-
vided by the Ca2+-calcineurin-NFAT pathway 
was crucial to prevent resistance to ABT-737 
in activated T cells, as shown by the  similar 
effect obtained with tacrolimus and VIVIT-R. 
Interestingly, a dysregulation of the Ca2+-
calcineurin-NFAT pathway has been de-
scribed in several lymphatic and solid tumors 
and may therefore influence the anti-
neoplastic effect of Bcl-2 inhibitors (Muller 
and Rao 2010). The most important conse-
quence of the signal 1 dependency of ABT-
737 resistance described here is the possibil-
ity to easily prevent it by well-established 
drugs such as calcineurin inhibitors. Charac-
terization of ABT-737 resistance in physio-
logical processes is relevant to find pharma-
cological strategies to potentiate the effect 
of Bcl-2 inhibitors, and, although the  use of 
immunosuppressive  drugs to control cancer 
may be counterintuitive and potentially 
dangerous, we speculate that the combina-
tion of calcineurin inhibitors with ABT-737 
might be beneficial in selected cases.
Because of the different molecular affinities 
of small-molecule Bcl-2 inhibitors to differ-
ent members of the Bcl-2 family (Vogler, 
Dinsdale et al. 2009), their immuno-
modulatory effect strictly depends on the 
expression of different members of the Bcl-2 
family in distinct lymphocytes subpopula-
tions and during the different phases of an 
immune response. Myeloid cells express 
high levels of Mcl-1 and are not affected by 
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ABT-737; in contrast, ABT-737 efficiently 
induces apoptosis in naive lymphocytes 
(Cippa, Kraus et al. 2011). Here we demon-
strate  that the physiological mechanisms 
that protect T cells from apoptosis in the ini-
tial phase after antigen recognition dramati-
cally influence  their sensitivity to ABT-737. 
Particularly, the low affinity of ABT-737 to 
A1 determines a  selection of antigen-
specific T cells in the first days after activa-
tion. Thus, ABT-737 is not effective as an 
immunosuppressive  agent during the first 
days after transplantation and in the  acute 
phase of an autoimmune disease  (Lawlor, 
Smith et al. 2011), but may find a clinical 
application for induction therapy before 
solid organ or stem cell transplantation. In 
contrast, we speculate that an opposite re-
sult would be  obtained with a  selective A1 
inhibitor, but none of the currently available 
Bcl-2 inhibitors selectively binds to A1. 
However, the fact that ABT-737 in combina-
tion with CsA efficiently depleted activated 
T cells in a GvH and an HvG model explains 
the synergistic effect of ABT-737 and CsA, 
that we previously observed in a skin graft 
model (Cippa, Kraus et al. 2011), and is a 
reasonable option to potentiate the immu-
nosuppressive effect of Bcl-2 inhibitors.
Finally, the  unique selectivity profile of ABT-
737 may find a useful application for cell-
based immunotherapy. The experimental 
selection of antigen-specific cells after a 
short activation time is difficult to achieve 
and largely limited to the use of transgenic 
systems. ABT-737 allows selecting polyclonal 
antigen-specific cells after antigen recogni-
tion in vitro and in vivo with a  wide experi-
mental application in the field of infection 
and cancer immunology, i.e. for the  genera-
tion of virus- or tumor-antigen specific T 
cells presented by the host MHC. As resis-
tance to ABT-737 depends only on signal 1 
activation, antigen-specific T cells can be 
further influenced by interleukins to gener-
ate particular subsets of T cells in vitro, such 
as donor-reactive  regulatory T cells or CMV-
reactive cytotoxic T cells (Sagoo, Ali et al. 
2011).
Thus, in this study we first described, char-
acterized and found a way to overcome re-
sistance to ABT-737 in activated T lympho-
cytes. Moreover, we propose a link between 
the well-established resistance to ABT-737 
in tumor cells and physiological lymphocyte 
activation after antigen recognition. These 
findings are relevant for a potential clinical 
application of Bcl-2 inhibitors as immuno-
modulatory and anti-neoplastic agents.
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Abstract
Deletion of donor-reactive T cells is the most reliable mechanism to induce allograft tolerance. 
Apoptosis determines central and peripheral lymphocyte selection and is required to induce 
deletional tolerance through costimulation blockade. Here, we used a small molecule Bcl-2 
inhibitor (ABT-737) to induce mixed chimerism through a direct pharmacological modulation 
of the  intrinsic apoptosis pathway in peripheral T cells. Using a short conditioning therapy 
with ABT-737 in combination with costimulation blockade (anti-CD154) and low-dose cyclo-
sporine A we established a novel protocol to induce robust systemic deletional tolerance with 
long-term acceptance of secondary donor-type allografts without any myelosuppressive  con-
ditioning. ABT-737 reversed the well-known anti-tolerogenic effect of calcineurin inhibitors in 
costimulation-blockade-dependent protocols by boosting the role of the  pro-apoptotic factor 
Bim, which was identified here as a critical factor for mixed chimerism induction, and whose 
expression was dysregulated by cyclosporine A. Thus, tolerance  across full MHC can be 
achieved targeting the apoptosis pathway, without myelosuppressive  condition, without risk 
of graft-versus-host disease  and using moderate  doses of bone marrow cells. This low toxicity 
regimen represents a promising option for a potential clinical application.
Introduction
Induction of operational allograft tolerance, 
a state in which the  immune system accepts 
donor organs without any immunosuppres-
sion but normally responds to foreign anti-
gens, represents the  ideal solution for 
c h r o n i c g r a f t r e j e c t i o n a n d 
immunosuppression-related toxicity after 
solid organ transplantation (Pascual, 
Theruvath et al. 2002; Fehr and Sykes 
2008). Among the different ways to induce 
tolerance in rodents, very few were  success-
ful in large animal models and only one 
strategy – namely the induction of mixed 
chimerism by a combined transplantation of 
solid organ and hematopoietic stem cells 
from the same donor – was successful in 
clinical pilot studies (Fudaba, Spitzer et al. 
2006; Kawai, Cosimi et al. 2008; Scandling, 
Busque et al. 2011). However, the high tox-
icity of currently available conditioning pro-
tocols to induce mixed chimerism in humans 
has precluded a broad clinical application 
(Pilat and Wekerle 2010). Recent discoveries 
on the mechanisms involved in tolerance 
induction might lead to more selective and 
less toxic protocols for translation of this 
concept to the clinic.
56
Deletion of allo-reactive T cells is the  fun-
damental mechanism of tolerance in mixed 
chimeras (Sykes 2001; Wekerle, Kurtz et al. 
2002). After engraftment of donor-derived 
cells in the bone marrow (BM) and in the 
thymus, tolerance is maintained by central 
deletion of nascent donor-reactive lympho-
cytes (Wekerle, Sayegh et al. 1998). How-
ever, to prevent rejection in the  initial phase 
after transplantation, therapeutic interven-
tions targeting pre-existing allo-reactive T 
cells in the periphery and in the thymus are 
required (Fehr, Takeuchi et al. 2005; Fehr, 
Lucas et al. 2010). This can be achieved by a 
profound generalized lymphopenia (Sykes, 
Szot et al. 1997) or by a more selective tol-
erization of allo-reactive  T cells through 
costimulation blockade combined with allo-
antigen (Wekerle, Kurtz et al. 2000; Seung, 
Mordes et al. 2003). Blocking CD28/CD80/
CD86 and CD154/CD40 signaling was suffi-
cient to induce tolerance in several mouse 
models (Larsen, Elwood et al. 1996; Seung, 
Mordes et al. 2003), but the efficacy of this 
approach was reduced in case of a high T 
cell precursor frequency (Ford, Wagener et 
al. 2008). Therefore, cytotoxic therapies 
aiming at a general T cell clone size reduc-
tion are usually included in conditioning pro-
tocols, resulting in higher toxicity and lim-
ited clinical applicability. 
Tolerance by costimulation blockade is the 
result of anergy, regulation and deletion of 
allo-reactive T cells (Wekerle, Kurtz et al. 
2002). After BMT under the effect of anti-
CD154, selective deletion of alloreactive 
CD4 and CD8 T cells occurs by activation of 
the apoptosis cascade (Li, Li et al. 1999). 
This process is regulated by two intercon-
nected pathways: the extrinsic apoptosis 
pathway is mediated by cell surface recep-
tors, whereas the intrinsic (or mitochondrial) 
apoptosis pathway by pro- and anti-
apoptotic factors of the Bcl-2 family 
(Marsden and Strasser 2003). Resistance to 
anti-CD154 or CTLA4Ig induced tolerance in 
mice over-expressing the anti-apoptotic fac-
tor Bcl-xL in a heart transplantation model 
(Wells, Li et al. 1999) indicates that the 
regulation of the  intrinsic pathway is pivotal 
in this setting. The recent advent of selective 
Bcl-2 inhibitors offers new options to phar-
macologically modulate these processes. Of 
particular clinical interest are  the  small-
molecules ABT-737 and ABT-263 (navito-
clax)(Oltersdorf, Elmore et al. 2005), ration-
ally designed molecules with antineoplastic 
(Vogler, Dinsdale et al. 2009) and immuno-
modulatory properties (Bardwell, Gu et al. 
2009; Carrington, Vikstrom et al. 2010; 
Cippa, Kraus et al. 2011). ABT-737 acts as a 
“sensitizer BH3-only protein”: it inhibits the 
anti-apoptotic Bcl-2 factors Bcl-2, Bcl-xL and 
Bcl-w and enhances the effect of pro-
apoptotic endogenous “activator BH3-only 
proteins”, such as Bid or Bim (Oltersdorf, 
Elmore et al. 2005). Importantly, ABT-737 
and ABT-263 were selective for lymphocytes 
and platelets (Cippa, Kraus et al. 2011), and 
did not induce myelosuppression, resulting 
in a favorable  toxicity profile in first clinical 
trials (Wilson, O'Connor et al. 2010).
In this study we investigated the  potential 
role of Bcl-2 inhibitors in combination with 
costimulation blockade to induce  mixed 
chimerism. The  BH3-mimetic ABT-737 dis-
played a marked tolerogenic effect and re-
versed the  previously described anti-
tolerogenic effect of calcineurin inhibitors. 
Thus, we identified a new pharmacological 
target to induce tolerance using a  low toxic-
ity approach that may find a clinical applica-
tion in the near future.
Materials and Methods
Mice. C57BL/6 (B6, H-2b), CBA (H-2k), BALB/
c (H-2d), BM3.3 (CBA, H-2k) and Bim knock 
out mice  (Bim-/-, H-2b) were housed in spe-
cific pathogen-free conditions at the Univer-
sity of Zürich. The BM3.3 mouse (Auphan, 
Curnow et al. 1994), which expresses on all 
CD8 T cells a transgenic T cell receptor (TCR) 
selective  for a naturally processed octapep-
tide bound to the allogeneic MHC class I 
molecule H-2Kb, was kindly provided by 
A.-M. Schmitt-Verhulst (Guimezanes, 
Barrett-Wilt et al. 2001). Bim-/- mice were 
kindly provided by Andreas Strasser 
(Bouillet, Metcalf et al. 1999). All animal ex-
periments were performed according to pro-
tocols approved by the legal authority (Vet-
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erinary Office, Canton of Zürich, Switzer-
land).
Conditioning and BM procedures. Different 
conditioning protocols were  tested as indi-
cated. In general, B6 recipient mice received 
1.5 or 3 Gy total body irradiation (TBI) from 
a 137Cesium irradiator on day -1 with respect 
to BMT. Hamster anti-mouse CD154 (MR1, 
2 mg, purchased from Bio-X-cell, West 
Lebanon, USA) was administered i.p. 6-12 h 
before transplantation with 25 x 106 (50 x 
106 where  indicated) fully MHC-mismatched 
CBA BM-cells by tail vein injection. In some 
experiments, CTLA4Ig (abatacept, 0.5 mg, 
provided by Bristol-Myers Squibb) was ad-
ministered at day 2 after BMT. ABT-737 was 
provided by Abbott Bioresearch (Worcester, 
USA), was dissolved in polyethylene glycol, 
Tween 80, dextrose solution and DMSO and 
injected intra-peritoneally (i.p.) at 50 mg/kg. 
CsA (Sigma-Aldrich, Buchs, CH) was dis-
solved in ethanol and cremaphor EL (Sigma-
Aldrich), then diluted in PBS and injected 
subcutaneously (s.c.) at 10 mg/kg. Both 
ABT-737 and CsA were administered daily 
from day -3 to day 12, on day -2 and day -1 
two mice received two injections for a total 
of 100 mg/kg of ABT-737 and 20 mg/kg of 
CsA, on day 0 ABT-737 and CsA were  not 
administered. To monitor the deletion of 
donor-reactive CD8 T cells, 20x106 synge-
neic BM3.3 splenocytes were adoptively 
transferred to CBA recipients before starting 
the conditioning protocol with B6 BM cells. 
The transgenic H-2Kb reactive  BM3.3 CD8 T 
cells were  monitored over time in peripheral 
blood in FACS using the clonotypic antibody 
Ti98 (Buferne, Luton et al. 1992), kindly 
provided by A.-M. Schmitt-Verhulst, and 
stained with a secondary PE rat anti-mouse 
IgG purchased from Becton Dickinson 
(Basel, CH). 
Flow cytometric analysis of chimerism and 
detection of allospecific antibodies. FACS 
analyses were performed with a BD-
FACSCanto (Becton Dickinson, Basel, CH). 
Chimerism was analyzed in white blood cells 
at different time points after BMT, in spleen 
and thymus as indicated. Donor-derived cells 
were identified by FITC-conjugated anti-H-
2Dk (Becton Dickinson, Basel, CH). The cells 
were counterstained with anti-CD4-PE, anti-
CD8-APC, anti-B220-PE, anti-CD11b-APC, 
anti-CD11c-APC antibodies purchased from 
eBioscience (Frankfurt, D). Background sig-
nal measured in a  naïve B6 mouse was sub-
tracted to determine the % of donor-
derived cells. Depletion of CD25 cells was 
monitored using an anti-CD25-PE antibody 
(eBioscience, Frankfurt, D). Allospecific anti-
bodies were measured in indirect FACS: 
CBA and BALB/c splenocytes were incubated 
with recipients’ serum (1:5 dilution in FACS 
buffer) and subsequently stained with a sec-
ondary anti-mouse FITC-conjugated IgG an-
tibody (eBioscience, Frankfurt, D). Mean 
fluorescence intensity was determined in 
FACS gating on CD8 positive cells.
Skin grafting. Mice were shaved and anes-
thetized with ketamine/xylazine. Full thick-
ness tail skin (about 1 cm2) from CBA (do-
nor) or BALB/c (3rd party) mice were grafted 
3 to 6 weeks after BMT and considered re-
jected when <10% of the graft remained 
viable. In some experiments a second skin 
grafting was performed using the same pro-
cedure. In one experiment before  the sec-
ond skin transplantation, regulatory T cells 
were depleted using the anti-CD25 mono-
clonal antibody PC61 (0.25 mg for 2 week 
every second day, purchased from Bio-X-
cell, West Lebanon, USA).
Mixed lymphocyte reaction (MLR). MLR were 
performed in 96 wells plates with responder 
splenocytes stimulated by splenocytes from 
donor, 3rd party or syngeneic mice  at a  final 
concentration of 4 x106 cells/ml in RPMI 
medium containing 10% fetal bovine se-
rum, penicillin 100 U/ml, streptomycin 100 
µg/ml, 2-mercaptoethanol 50 µM. T cell 
proliferation was measured by incorporation 
of 3H-thymidine (Perkin Elmer, Waltham, 
USA) added to the culture on day 4 after 
stimulation. For the selective analysis of al-
loreactive  CD8 T cells in vitro, BM3.3 speno-
cytes were stimulated with CD8 T cell de-
pleted splenocytes from B6 (allogeneic) or 
CBA (syngeneic) mice  and analyzed in FACS 
gating on CD8 T cells. After cell permeabili-
zation, the level of Bim in alloreactive CD8 T 
cells was detected in FACS using a  poly-
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clonal rabbit antibody detecting total Bim 
(EL, L and S isoforms) purchased from Cell 
Signaling (Danvers, USA) and then stained 
with a FITC anti-rabbit IgG  (eBioscience, 
Frankfurt, D). Splenocytes were sorted by 
automatic magnetic cell separation using an 
autoMACS pro separator according to the 
protocols of Miltenyi Biotec (Bergisch Glad-
bach, D). For polyclonal stimulation of sple-
nocytes anti-CD3 and anti-CD28 antibodies 
were used (eBioscience, Frankfurt, D). Cell 
viability was measured by propidium iodide 
exclusion in FACS.
Statistics. Student t-test was used to com-
pare  values between groups. A p-value 
<0.05 was considered significant. Graph Pad 
Prism Software Version 5.0 was used for 
calculations.
Results
Bcl-2 inhibition allows mixed chimerism in-
duction with reduced conditioning
The effect of Bcl-2 inhibitors on mixed chi-
merism and tolerance induction was first 
assessed adding the BH3-mimetic ABT-737 
(50 mg/kg/day) to an established minimal 
conditioning protocol consisting of low-dose 
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Fig. 23. The tolerogenic effect of ABT-737
ABT-737 was  added to a  standard conditioning protocol (TBI, MR1, 25 x 106 BM-cells). (A) In combination with 3 
Gy of TBI similar results were obtained in mice  treated with vehicle  (white) or ABT-737 (black). Twenty weeks  
after  BMT we measured a similar  level of chimerism in both group. After  skin transplantation all chimeric mice 
accepted donor grafts and promptly rejected 3rd party grafts, demonstrating that donor-specific tolerance had 
been induced. (B) When reducing the dose  of TBI to 1.5 Gy, the standard protocol was  successful  in 5/7 of the 
recipients. Addition of ABT-737 increased the number of tolerant mice  to 8/8 and significantly increased the level 
of chimerism in blood (week 20 after  BMT). (C) In an irradiation free protocol, ABT-737 induced a  pronounced 
donor-specific  hyporesponsiveness, but tolerance was  not achieved, as shown by the  slow rejection of donor skin 
grafts over time. * p<0.05, **p<0.01.
total body irradiation (TBI, 3 Gy) on the  day 
before BM transplantation, a  single  injection 
of anti-CD154 (MR1, 2 mg) and 25x106 of 
fully MHC-mismatched CBA bone marrow 
cells to B6 recipients. Similar levels of hema-
topoietic chimerism were obtained in mice 
treated with ABT-737 or vehicle, and all 
chimeric animals presented a donor-specific 
tolerance after skin transplantation (Fig. 
23A), indicating that inhibition of Bcl-2, Bcl-
xL and Bcl-w was not detrimental for sur-
vival and engraftment of donor-derived he-
matopoietic stem cells (HSCs). To demon-
strate  a  benefit for ABT-737 for mixed chi-
merism induction, in a second experiment, 
TBI was progressively reduced to obtain a 
sub-therapeutic conditioning protocol. In 
combination with 1.5 Gy TBI, ABT-737 in-
creased the percentage of chimeric mice 
and induced a higher level of chimerism in 
all hematopoietic cell lines. All chimeric ani-
mals accepted donor-type  skin grafts for 
more than 120 days and promptly rejected 
third party grafts (Fig. 23B). Mice treated 
only with ABT-737, MR1 and BM cells but 
without TBI did not develop significant chi-
merism (not shown), but skin transplanta-
tion (performed 6 weeks after BMT) re-
vealed that this conditioning protocol had 
induced a marked and lasting donor-specific 
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Fig. 24. ABT-737 reverses the anti-tolerogenic effect of CsA
CsA had a  deleterious  impact on mixed chimerism induction using a standard conditioning protocol (1.5 Gy TBI, 
MR1, 25 x 106 BM-cells). This effect was reversed in combination with ABT-737, as shown in the chimerism ki-
netics  for CD4 T cells  (A), in the level of chimerism in different hematopoietic  cell lineages 20 weeks  after BMT 
(B) and in the rejection of donor  skin grafts (C). Notably in the combination group the  chimerism level  was  even 
higher than in the group treated with ABT-737 and 1.5 Gy TBI (B). *p<0.05, **p<0.01, ***p<0.001.
hyporesponsiveness (Fig. 23C). Nevertheless, 
donor grafts were  eventually rejected (me-
dian survival time 96 days). Thus ABT-737 in 
combination with CD154 blockade  had a 
tolerogenic effect, but was not sufficient to 
induce mixed chimerism and stable toler-
ance in an irradiation-free conditioning pro-
tocol.
ABT-737 reverses the anti-tolerogenic effect 
of calcineurin inhibitors 
Reduction of the precursor frequency of 
donor-reactive T cells is a prerequisite to in-
duce tolerance using costimulation blockade 
(Ford, Wagener et al. 2008). We hypothe-
sized that a combination with calcineurin 
inhibitors, which increased the pro-
apoptotic potency of ABT-737 on lympho-
cytes (Cippà et al, submitted), might in-
crease the  tolerogenic effect of ABT-737. 
On the other hand, signal 1 inhibition by 
itself had an anti-tolerogenic effect in 
costimulation blockade-dependent tolerance 
induction protocols and interfered with 
clonal deletion of donor-reactive CD8 T cells 
(Li, Li et al. 1999; Fehr, Lucas et al. 2010). 
The above mentioned combination therapy 
was tested experimentally by adding a short 
course of low dose CsA (10 mg/kg/day s.c.) 
to a mixed chimerism protocol using re-
duced conditioning of 1.5 Gy TBI, MR1, 
25x106 BM cells with or without ABT-737. 
According to previous observations (Blaha, 
Bigenzahn et al. 2003; Fehr, Lucas et al. 
2010), treatment with CsA alone resulted in 
a reduced number of tolerant mice  and 
lower chimerism levels. However, the  com-
bination with ABT-737 completely pre-
vented this phenomenon and induced a 
high level of chimerism and donor-specific 
tolerance in all recipients. Importantly, the 
combination of ABT-737 and CsA not only 
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Fig. 25. Regulation of Bim in alloreactive CD8 T cells
(A-B) BM3.3 splenocytes were stimulated with CD8-depleted B6 (allo) or CBA (syn) splenocytes. Allogeneic 
stimulation induced a transient up-regulation of Bim, with a  peak after 2 days of culture. (C) CsA and MR1 sub-
stantially influenced the regulation of Bim after antigen recognition: CsA inhibited its  initial up-regulation and 
MR1 prevented its  downregulation in the late activation phase. As  a result, after  4 days  of culture the level of 
Bim was  lower in cells  stimulated in the presence of CsA and significantly higher with MR1. (D) Wild type  (wt) B6 
splenocytes  polyclonally  stimulated in the presence of MR1 presented a  reduced viability of CD8 T cells after 4 
days  of culture, but the same  phenomenon was  not observed using Bim-/- cells, suggesting that the  reduced 
down-regulation of Bim determined by MR1 results in cell death in activated CD8 T cells. *p<0.05, **p<0.01.
prevented the anti-tolerogenic effect of cal-
cineurin inhibitors, it even resulted in a 
higher chimerism level compared to ABT-
737 alone, reversing the  anti-tolerogenic 
effect of CsA in a paradoxical synergnism 
(Fig. 24).
ABT-737 boosts the critical role of Bim in 
synergism with costimulation blockade
Signal 1 activation leads to an up-regulation 
of Bim in CD8 T cells (Sandalova, Wei et al. 
2004). Therefore, inhibition of this process 
might explain the anti-tolerogenic of calci-
neurin inhibitors in anti-CD154 dependent 
tolerance protocols (Blaha, Bigenzahn et al. 
2003; Fehr, Lucas et al. 2010). To further 
investigate  this mechanism, we first estab-
lished an in vitro model to monitor the 
regulation of Bim in CD8 T cells after alloan-
tigen recognition using a T cell receptor 
(TCR) transgenic system. BM3.3 CD8 T cells, 
which express a transgenic TCR specific for 
the MHC class I molecule H-2Kb (Auphan, 
Curnow et a l . 1994; Guimezanes , 
Barrett-Wilt et al. 2001), were stimulated 
with CD8-depleted B6 splenocytes under 
the effect of CsA or MR1. Expression of Bim 
was monitored by intracellular FACS over 
time and correlated with cell viability. Allo-
antigen stimulation induced a transitory up-
regulation of Bim in CD8 T cells (Fig. 25A-B). 
The initial up-regulation phase was depend-
ent on signal 1 (which can be blocked by 
CsA), whereas the subsequent down-
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Fig. 26. Resistance to mixed chimerism induction in Bim-/- mice
A standard conditioning protocol (3 Gy TBI, MR1, 25x106 BM-cells) induced mixed chimerism in all wild type (wt) 
B6 mice, but was  not successful  in most Bim-/- mice, as shown in the  chimerism-kinetics  for CD4 T cells (A), in 
the level  of chimerism in different hematopoietic cell lineages  15 weeks  after BMT (B) and in the rejection of do-
nor skin grafts (C). *p<0.05, **p<0.01, ***p<0.001.
regulation was influenced by costimulatory 
signals. As a  result, the level of Bim re-
mained low in cells activated in the presence 
of CsA, and – starting at day 3 after stimula-
tion – was significantly higher in CD8 T cells 
treated with MR1 (Fig. 25C). This correlated 
with the viability of polyclonally stimulated 
alloreactive CD8 T cells in vitro: MR1 did not 
influence alloreactive CD8 T cell viability in 
culture during the first two days of culture 
(data not shown), but a progressive  loss of 
viability in alloreactive  CD8 T cells stimulated 
in presence of MR1 was registered at day 3 
and 4 after stimulation. This process was 
completely dependent on Bim, as MR1 did 
not influence the viability of Bim-/- CD8 in 
the same experimental conditions (Fig. 25D).
To investigate the  role  of Bim in the particu-
lar situation of mixed chimerism induction, 
we applied the initially described mixed chi-
merism conditioning protocol (TBI 3Gy, 
MR1) to Bim-/- recipients. Compared to wild 
type animals, Bim-/- mice  displayed a 
marked resistance to mixed chimerism in-
duction, and tolerance was not achieved in 
most Bim-/- mice (Fig. 26). Thus, in consid-
eration of previous reports about a similar 
resistance to tolerance  induction in trans-
genic mice over-expressing anti-apoptotic 
Bcl-xL (Wells, Li et al. 1999), we conclude 
that the  balance between pro- and anti-
apoptotic Bcl-2 factors determines deletion 
of allo-reactive T cells and the anti-
tolerogenic effect of CsA in costimulation-
blockade depending protocols is indeed re-
lated to a dysregulation of the intrinsic 
apoptosis pathway. More precisely, CsA 
blocks the initial up-regulation of Bim in al-
loreactive  T cells and prevents a complete 
deletion of donor-reactive T cells in the late 
activation phase  under the effect of 
costimulation blockade. In this context, a 
pharmacological boosting of Bim by ABT-
737 might promote  the deletion of alloreac-
tive T cells in synergism with costimulation 
blockade and therefore promote tolerance 
induction and compensate the anti-
tolerogenic effect of CsA. This is confirmed 
by the fact, that treatment with ABT-737 
did not influence  the resistance to mixed 
chimerism induction in Bim-/- mice, further 
emphasizing the role  of Bim in peripheral 
deletion of allo-reactive T cells as a  critical 
“activator BH3-only protein” in lymphocytes 
(Fig. 27). 
Low toxicity irradiation-free mixed chimer-
ism induction by targeting the apoptosis 
pathway
The above described synergistic effect of 
ABT-737 and CsA to induce mixed chimer-
ism was exploited to eventually establish an 
irradiation-free conditioning protocol. Wild-
type B6 mice were treated with ABT-737 (50 
mg/kg/day) and low-dose CsA (10 mg/kg/
day) for two weeks starting at day -3 with 
respect to BMT, and an additional dose of 
both drugs was administered on day -2 in 
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Fig. 27: ABT-737 does not reverse resistance to mixed chimerism induction in Bim-/- mice.
In Bim-/- mice, adding ABT-737 to a  standard conditioning protocol (3 Gy TBI, MR1, 25x106 BM-cells) we  ob-
tained similar results than without ABT-737 (compare with figure 26).
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Fig. 28. Irradiation-free mixed chimerism induction with ABT-737 and CsA
An irradiation-free  tolerance induction protocol  consisting of a two weeks treatment with CsA and ABT-737, 
MR1 and 25 x 106 BM-cells  induced donor-specific tolerance. (A) Donor  skin grafts  were indefinitely accepted by 
20/21 mice in 3 independent experiments (max observation time 133 days), and 3rd party grafts  were promptly 
rejected. (B-C) A low level of granulocytes and T cell chimerism was  measured in peripheral blood (week 24 after 
BMT) and in the  spleen (33 weeks  after BMT). (D) In the  thymus double  negative  (DN), double positive  (DP), 
single-positive CD4 and CD8 lymphocytes  did not showed a significant chimerism, but donor derived cells  were 
measured in the CD11c positive fraction.
(E) BM3.3 splenocytes  were adoptively transferred to CBA recipients before starting the conditioning protocol 
with ABT-737, CsA and MR1, 25x106 BM cells  from B6 donors (full protocol, black dots). In a  control group BM 
cells  were  not administered (white  dots). Donor-reactive  BM3.3 CD8 T cells  (Ti98+) were reduced in both groups 
but only in mice receiving the  full protocol  a  complete depletion was achieved: (F-G) after  re-challenging with 
donor antigens  (106 B6 splenocytes i.v. at day 37) Ti98+ cells were clearly detectable  in the  control group but 
had completely disappeared from the peripheral  T cell repertoire after exposure to the full conditioning protocol. 
(H) The conditioning protocol with ABT-737 and CsA was  successful in combination with double costimulation 
blockade with MR1 and CTLA4Ig, but not if MR1 was substituted by CTLA4Ig.
order to achieve a  more pronounced pe-
ripheral lymphocyte depletion. Subse-
quently, MR1 was injected 6-12h before 
25x106 of BM cells from fully MHC-
mismatched CBA donors. This tolerance in-
duction protocol was successful in 20 out of 
21 mice in three  independent experiments. 
Donor-type CBA skin grafts were accepted 
indefinitely with a maximal observation time 
of >130 days (n=6), whereas all third party 
grafts (BALB/c) were promptly rejected, 
therefore demonstrating robust systemic 
donor-specific tolerance (Fig. 28A). Similarly 
to previous reports of successful mixed chi-
merism induction without myelosuppressive 
conditioning (Wekerle, Kurtz et al. 2000), 
the level of donor chimerism was rather low 
compared to protocols including TBI. How-
ever this level was stable  over time: 33 
weeks after BMT we measured a  4.37% of 
donor-derived CD4, 2.73% CD8 and 
15.58% granulocytes in the  spleen. Interest-
ingly, the B cell compartment did not show 
any macrochimerism in the  spleen nor in pe-
ripheral blood at any time point after BMT 
(Fig. 28B-C).
Establishment of mixed chimerism with ABT-
737, MR1 and CsA leads to robust central 
and peripheral deletional tolerance
The initial tolerization of peripheral alloreac-
tive T cells was further investigated in an 
adoptive transfer experiment. Before start-
ing the tolerance induction protocol 20x106 
BM3.3 splenocytes were transferred into 
syngeneic CBA recipients; alloreactive 
BM3.3 CD8 T cells were monitored in blood 
over time using the clontypic antibody Ti98. 
In mice treated with the  full conditioning 
protocol including 25x106 BM-cell from B6 
donors, transgenic allo-reactive CD8 T cells 
completely disappeared from the peripheral 
T cell repertoire during two weeks and did 
not recover after resolution of the lym-
phopenia (Fig. 28E). In contrast, in mice 
treated with the  same pharmacological 
therapy but without B6 derived BM, Ti98+ 
cells were markedly reduced but still detect-
able in peripheral blood. The  complete  dele-
tion of Ti98+ cells in mice  exposed to the 
full protocol was confirmed by FACS analysis 
of the spleen after re-challenging the recipi-
ent mice with B6 splenocytes (106 cells, i.v.) 
(Fig. 28F-G). Thus, despite the inhibition of 
signal 1 by CsA, exposure to donor-derived 
cells was required to induce a complete pe-
ripheral deletion of alloreactive T cells.
The success of this conditioning regimen 
was strictly dependent on inhibition of the 
CD40/CD154 signal. ABT-737 and CsA 
alone were not sufficient to induce BM en-
graftment (data not shown). Adding 
CTLA4Ig to the conditioning protocol (0.5 
mg on day 2 after BMT) resulted in the same 
positive  outcome in terms of donor-specific 
tolerance and a similar levels of chimerism, 
whereas CTLA4Ig alone was not sufficient to 
induce tolerance in this setting (Fig. 28H). By 
increasing the  dose of BM from 25 x106 to 
50 x106 BM-cells, we obtained a minimal, 
not significant increase in the chimerism 
level (data not shown).
Mixed chimeras maintain donor-specific tol-
erance through central deletion of donor-
reactive T cells. The presence of donor-
derived antigen presenting cells in the  thy-
mus is therefore critical in this setting. Using 
the above mentioned irradiation-free proto-
col including ABT-737, we  consistently de-
tected about 5% of donor-derived antigen 
presenting cells (CD11c+) in the thymus (as 
demonstrated by thymic FACS analysis 33 
weeks after BMT; Fig. 28D), a finding consis-
tent with a central clonal deletion mecha-
nism.
The establishment of a sustained systemic 
tolerance was further confirmed using dif-
ferent immunological tests: donor-specific B 
cell tolerance was demonstrated by the ab-
sence of donor-specific IgG, whereas 3rd 
party-reactive IgG was readly detected sev-
eral weeks after skin grafting (Fig. 29A). 
Non-responsiveness of donor reactive T cells 
was proven in a classical mixed lymphocyte 
reaction (Fig. 29B). Finally, 60 days after the 
first skin transplantation tolerant mice were 
rechallenged with a second skin graft from 
donor and 3rd party control. All mice ac-
cepted the secondary CBA graft and re-
jected the BALB/c graft (Fig. 29C-D). The 
same result was obtained if regulatory T 
cells were depleted using an anti-CD25 an-
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tibody before re-grafting, indicating that 
long-term tolerance was independent of 
classical regulatory T cells (data not shown). 
The success of this experiment definitively 
demonstrates that a 2 weeks conditioning 
protocol with ABT-737 and CsA in combina-
tion with MR1 induced mixed chimerism 
and stable systemic tolerance without mye-
losuppressive treatment and with clinically 
relevant doses of BM cells.
Discussion
In this study we identified the intrinsic apop-
tosis pathway as a novel pharmacological 
target to induce mixed chimerism and toler-
ance. More precisely, the balance between 
pro- and anti-apoptotic factors of the  Bcl-2 
family was recognized as a  critical mecha-
nism for alloreactive CD8 T cell deletion in 
the context of mixed chimerism and toler-
ance induction using costimulation block-
ade. This concept was therapeutically ex-
ploited using ABT-737 – a  Bcl-2, Bcl-xL and 
Bcl-w inhibitor – to establish a new 
irradiation-free protocol to induce robust 
tolerance with a clinically relevant dose of 
BM cells.
The regulation of the apoptosis pathway in 
lymphocytes after antigen recognition is 
complex. The interaction between T cells 
and antigen presenting cells influences both 
branches of the apoptosis pathway and 
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Fig. 29. Robust, systemic tolerance after mixed chimerism induction with ABT-737 and CsA
(A) Sixty days after  skin transplantation from CBA and BALB/c donors, mice previously treated with our condi-
tioning protocol (ABT-737, CsA, MR1 and 25 x 106 BM-cells) did not present any IgG antibodies  reactive with B6 
cells, but a normal  seroconversion towards BALB/c as  measured in indirect FACS. (B) Mixed lymphocyte reaction 
with splenocytes  responders  from tolerized mice showed donor-specific non-responsiveness. *p<0.05, 
**p<0.01, ***p<0.001. (C) A second transplantation at day 58 after first grafting resulted in rapid rejection of 
3rd party grafts  and acceptance of donor grafts. (D) Picture  of a mouse  after double  skin transplantation. The 
second two grafts were transplanted, crossed-over, 58 days after  the initial transplantation. Both BALB/c grafts 
were rejected (scar), but the  CBA grafts were accepted without signs  for rejection. Please note the fur graying 
(normal phenotype: black), typically observed after combined treatment with CsA and ABT-737.
eventually controls T cell survival (Bouillet 
and O'Reilly 2009). Focusing on the intrinsic 
pathway, it has been shown that in the early 
phase of the immune response signal 1 
leads to an up-regulation of the  anti-
apoptotic Bcl2-A1 that protects the cell from 
apoptosis without influencing proliferation 
and induces resistance to ABT-737 ((Ver-
schelde, Walzer et al. 2003), Cippà et al, 
submitted). The initial up-regulation of Bim 
is counteracted by simultaneous regulation 
of anti-apoptotic factors and is required for 
T cell activation (Ludwinski, Sun et al. 2009). 
Three to four days after antigen-recognition 
A1 is progressively down-regulated and ad-
ditional stimuli by costimulatory molecules 
and interleukins are  required to maintain cell 
survival by a down-regulation of Bim and an 
up-regulation of Bcl-xL (Sabbagh, Pulle et al. 
2008; Watts 2010). In the absence of an 
adequate anti-apoptotic signal through 
costimulation, Bim prevails and activated T 
cells die by apoptosis. This mechanism is 
crucial to prevent autoimmunity and lym-
phoproliferative  disorders, and – according 
to previous observations (Li, Li et al. 1999; 
Wells, Li et al. 1999) and to the data pre-
sented here  – is critical for deletion of al-
loreactive  T cells in tolerance induction pro-
tocols.
Bcl-2 inhibitors offer the opportunity to se-
lectively interact with these  mechanisms. In 
our model ABT-737 promoted peripheral T 
cell tolerization by at least two complemen-
tary effects. First, it boosted the critical role 
of Bim leading to a more efficient deletion 
of alloantigen-specific T cells. Second, ABT-
737 reduced the precursor frequency by a 
peripheral deletion of lymphocytes, but 
avoiding any myelosuppressive effect. Addi-
tional effects of Bcl-2 inhibitors on regula-
tory T cells or directly on BM or thymic en-
graftment cannot be excluded. The  benefi-
cial effect of the combination of ABT-737 
and CsA is multi-factorial. CsA potentiated 
the pro-apoptotic effect of ABT-737 on 
lymphocytes by a synergistic inhibition of 
Bcl-2, the  crucial survival factor in mature 
naïve  lymphocytes (Veis, Sorenson et al. 
1993). Moreover, CsA blocked the up-
regulation of A1 preventing resistance to 
ABT-737 in activated T cells (Cippà et al, 
submitted). On the other hand ABT-737 re-
versed the anti-tolerogenic effect of CsA by 
compensating the missing up-regulation of 
Bim after allostimulation under calcineurin 
blockade. As a  result, the combination of 
CsA and ABT-737 resulted in a paradoxical 
synergistic effect and was sufficient to in-
duce tolerance together with MR1 and clini-
cally relevant doses of BM-cells, but without 
any myelosuppressive treatment. 
Apart from the peculiarity of this model to 
investigate  the role of the intrinsic apoptosis 
pathway in mixed chimerism, this finding is 
of clinical relevance. As graft loss due to 
acute rejection cannot be ethically accepted 
in the modern transplantation era, each 
clinically applicable tolerance induction pro-
tocol has to foresee  a combination of initial 
standard immunosuppressive and tolerance 
induction regimes in a preventive or thera-
peutic setting, ideally without a priori exclu-
sion of calcineurin inhibitors (Waldmann 
2010). Moreover, the option to include CsA 
to prevent or control GvHD after BMT to in-
duce tolerance, without precluding the effi-
cacy of the tolerance induction regime may 
be useful in selected clinical cases. Unfortu-
nately, CsA increased the  pro-apoptotic po-
tency of ABT-737 not only on lymphocytes: 
a more pronounced thrombocytopenia and 
a generalized hair depigmentation were ob-
served in mice treated with ABT-737 and 
CsA (Cippà et al, submitted), but these side 
effects may be limited when applying a 
short treatment course only during a toler-
ance induction protocol.
Our irradiation free protocol induced a low, 
but stable hematopoietic chimerism at simi-
lar level as previously reported in protocols 
without myelosuppressive conditioning 
(Wekerle, Kurtz et al. 2000). Because hema-
topoietic stem cells express high levels of 
Mcl-1 (Opferman, Iwasaki et al. 2005), ABT-
737 does not induce apoptosis in this cell 
population. Therefore, ABT-737 fails to 
“create space” in the  stem cell niches in the 
bone marrow, a  factor that was originally 
thought to be required for BM engraftment 
(Tomita, Sachs et al. 1994). Our data sup-
port the hypothesis that depletion of stem 
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cells is dispensable to induce  mixed chimer-
ism. The sustained detection of donor-
derived granulocytes over more than 8 
months clearly indicates that engraftment of 
donor stem cells or very early progenitor 
cells had occurred. However, the  level of 
hematopoietic chimerism was not uniform 
among different cell lineages with an ab-
sence of donor-derived B cells and higher 
levels of granulocytes. This could be ex-
plained by the engraftment of myeloid-
biased HSCs (Muller-Sieburg, Cho et al. 
2004). This myeloid-biased donor-derived 
hematopoiesis was sufficient to maintain a 
pool of donor-derived antigen presenting 
cells in the thymus to establish central dele-
tional tolerance. In a clinical perspective, this 
low level of chimerism may be favorable, 
since it completely avoids the risk of full 
chimerism induction and graft versus host 
disease.
The tolerance induction protocol described 
here  provides a solution to several problems 
currently precluding a broad clinical applica-
tion of the mixed chimerism approach 
(Dolgin 2012). The general toxicity of the 
conditioning regimen is low compared to 
protocols including myelosuppressive drugs 
or total lymphoid irradiation (Scandling, 
Busque et al. 2011). In phase  I clinical trials 
ABT-737 displayed a favorable toxicity pro-
file and its application for a  short condition-
ing therapy seems to be adequate  also for 
non-mal ignant cond i t ions (Wi l son, 
O'Connor et al. 2010). Depleting antibodies 
– notably more efficient in mice than in hu-
mans (Sachs, Sykes et al. 2011) – are not 
required, but a blockade of CD40/CD154 
was critical in our model. The recent report 
of antibodies blocking CD40 in advanced 
pre-clinical studies may represent an ideal 
solution to block this pathway without the 
thromboembolic side effect reported in pri-
mates after exposure to anti-CD154 (Kawai, 
Andrews et al. 2000; Page, Srinivasan et al. 
2012). Importantly, in contrast to previous 
reports of mixed chimerism induction with-
out myelosuppression (Wekerle, Kurtz et al. 
2000; Pilat, Baranyi et al. 2010), our condi-
tioning protocol was successful using a clini-
cally relevant dose of BM cells and without 
additional cell-based therapy.
In summary, we describe a novel approach 
to reliably induce allograft tolerance using 
the mixed chimerism model and selective 
targeting of the apoptosis pathway. This 
approach allowed to establish a  non-toxic, 
non-myelosuppressive  conditioning protocol 
with potential clinical application.
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Abstract
Memory T cells are recognized as a major barrier for costimulation blockade and tolerance  
induction, but currently available  therapeutic options have a limited impact on their survival or 
immunological activity. The intrinsic apoptosis pathway regulates memory T cell survival 
through the  interaction of the pro-apoptotic factor Bim and the anti-apoptotic factors Bcl-2 
and Bcl-xL. In this study we investigated the effect the  Bcl-2 inhibitor ABT-737 on alloreactive 
memory T cells. ABT-737 induced apoptosis in memory T cells at very low concentrations in 
vitro and prolonged skin graft survival to the level of a primary response in sensitized mice in 
a fully MHC-mismatched combination. Moreover, a short induction therapy with ABT-737  in 
combination with donor-specific transfusion and costimulation blockade with anti-CD154 
overcame resistance to costimulation blockade determined by adoptive  transfer of memory T 
cells in naïve mice in a skin graft model and promoted the establishment of donor-specific 
hyporesponsiveness. Thus, apoptosis induction in memory T cells by Bcl-2 inhibition is a prom-
ising approach for immunosuppression and induction of tolerance in sensitized recipients and 
recipients displaying heterologous immunity such as non-human primates and patients.
Introduction
Costimulation blockade is a promising ap-
proach to prevent allograft rejection and in-
duce donor specific tolerance (Ford and 
Larsen 2009). Blockade of CD28/CD80/
CD86 and CD40/CD154 signaling pro-
longed survival of skin and vascularized allo-
grafts (Larsen, Elwood et al. 1996) and al-
lowed to markedly reduce the toxicity of 
mixed chimerism conditioning protocols in 
rodents (Wekerle, Kurtz et al. 2000). How-
ever, translation of the same protocols to 
non-human-primates and humans was par-
ticularly challenging, suggesting the pres-
ence of a  substantial difference between the 
immune system of laboratory mice and hu-
mans in this particular context (Ford and 
Larsen 2011).
Memory T cells are considered one of the 
most important barrier to costimulation 
blockade: the adaptive immune system of 
laboratory mice, young animals that have 
barely been exposed to pathogens, mostly 
consists of naïve lymphocytes, whereas in 
humans a  progressive shift from naïve cells 
to memory cells occurs during life as a result 
of previous infections and of a progressive 
decline in thymus function, a processes gen-
erally summarized as immune senescence 
(McElhaney and Effros 2009). Although 
memory cells primarily recognize pathogen-
related antigens, it has been demonstrated 
that cross-reactive memory cells can recog-
nize  alloantigens in a process called heter-
ologous immunity, and therefore assume a 
critical relevance not only in donor-
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sensitized recipients (Adams, Williams et al. 
2003).
Memory T cells are characterized by a lower 
activation threshold, are less dependent on 
costimulation and are  not efficiently inhib-
ited by regulatory T cells (Lanzavecchia  and 
Sallusto 2000; London, Lodge et al. 2000; 
Yang, Brook et al. 2007). As a result, the 
efficacy of costimulation blockers is limited 
in the context of a secondary immune re-
sponse. Anti-CD154 dependent experimen-
tal tolerance protocols are not effective  in 
sensitized mice or after adoptive transfer of 
memory T cells (Adams, Williams et al. 
2003), and the  presence  of high numbers of 
memory cells correlated to resistance to tol-
erance in primates (Nadazdin, Boskovic et al. 
2011). Moreover, it is presumed that the 
higher incidence of acute rejection episodes 
in patients on a  belatacept-based immuno-
suppression is the direct consequence of the 
same phenomenon (Vincenti, Larsen et al. 
2005; Vincenti, Dritselis et al. 2011).
Compared to naïve cells, memory T cells are 
more resistant to immunosuppression and 
depleting antibodies, so that induction ther-
apy with alemtuzumab or rabbit anti-
thymocyte globulin resulted in the  selection 
and accumulation of functional T cells with 
a memory-like phenotype (Pearl, Parris et al. 
2005). Recent studies demonstrated a fa-
vorable inhibition of memory T cells by tar-
geting adhesion molecules such as CD2 (no-
tably, an anti-CD2 antibody was also used in 
the first successful tolerance induction clini-
cal study (Kawai, Cosimi et al. 2008)) 
(Weaver, Charafeddine et al. 2009) and LFA-
1 (Badell, Russell et al. 2010), but the effi-
cacy and safety of these  agents in humans 
remains to be proven. 
Apoptosis controls T cell contraction and 
generation of memory cells at the  end of 
the immune response (Weant, Michalek et 
al. 2008). Particularly, the balance between 
the pro-apoptotic BH3-only protein Bim and 
the anti-apoptotic Bcl-2 and Bcl-xL controls 
long-term memory T cell survival (Schluns 
and Lefrancois 2003; Sabbagh, Srokowski et 
al. 2006; Wojciechowski, Tripathi et al. 
2007) and pharmacological Bcl-2 inhibition 
induced memory T cell depletion in naïve 
mice (Wojciechowski, Tripathi et al. 2007; 
Carrington, Vikstrom et al. 2010). ABT-737 
and ABT-263 (navitoclax) are small molecule 
Bcl-2 inhibitors, which bind to anti-apoptotic 
Bcl-2 family factors Bcl-2, Bcl-xL and Bcl-w 
and indirectly activate the  apoptotic cascade 
(Oltersdorf, Elmore et al. 2005). ABT-737 
showed a  marked antineoplastic effect 
(Khaw, Huang et al. 2011), inhibited auto-
immunity and allograft rejection in mouse 
models (Bardwell, Gu et al. 2009; Cippa, 
Kraus et al. 2011). Interestingly, the  pro-
apoptotic effect of these drugs was rather 
selective  for lymphocytes, resulting in a  fa-
vorable toxicity profile, principally related to 
lymphopenia and thrombocytopenia in 
phase I clinical trials with navitoclax (Wilson, 
O'Connor et al. 2010). 
This study was designed to assess the effect 
of ABT-737 on alloreactive memory T cells. 
ABT-737 efficiently induced apoptosis in al-
loreactive  memory T cells and prolonged 
skin graft survival in sensitized recipients. 
Furthermore, induction therapy with ABT-
737 restored sensitivity to costimulation 
blockade after memory T cell transfer. Thus, 
depletion of memory cells targeting Bcl-2 
overcomes costimulatory resistance in trans-
plantation.
Materials and methods
Mice. C57BL/6 (B6, H-2b), CBA (H-2k), BALB/
c (H-2d) and BM3.3 (CBA, H-2k) mice were 
housed in specific pathogen-free conditions 
at the University of Zürich. The BM3.3 
mouse, which expresses on all CD8 T cells a 
transgenic T cell receptor (TCR) selective for 
a naturally processed octapeptide bound to 
the allogeneic MHC class I molecule H-2Kb, 
was kindly provided by A.-M. Schmitt-
Verhulst (Auphan, Curnow et al. 1994; 
Guimezanes, Barrett-Wilt et al. 2001). All 
animal experiments were performed accord-
ing to protocols approved by the legal 
authority (Veterinary Office, Canton of 
Zürich, CH).
Fluorescence activated cell sorting (FACS). 
FACS analyses were  performed with a  BD-
FACSCanto (Becton Dickinson, Basel, CH). 
Anti-mouse CD3-FITC, CD3-PECy7, CD4-PE, 
CD8-APC, CD25-FITC, CD25-PE, CD44-FITC, 
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CD44-PECy7, CD62L-PE and propidium io-
dide (PI) were purchased from eBioscience 
(Frankfurt, D). BM3.3 CD8 T cells were de-
tected using the clonotypic antibody Ti98, 
which selectively binds to the BM3.3 TCR 
and was kindly provided by A.-M. Schmitt-
Verhulst (Buferne, Luton et al. 1992). A sec-
ondary PE rat anti-mouse IgG was pur-
chased from Becton Dickinson (Basel, CH). 
Generation of alloreactive memory T cells in 
vitro. BM3.3 splenocytes were  stimulated 
with CD8-depleted B6 splenocytes in tissue-
culture flasks in RPMI medium containing, 
10% fetal bovine serum, Penicillin 100 U/ml, 
Streptomycin 100 ug/ml, 2-mercaptoethanol 
50 uM. Two days later, CD8 T cells were 
positively selected by magnetic cell sorting, 
washed and cultured in fresh tissue-culture 
flasks in the same medium supplemented 
with 20 ng/ml rIL-15 (R&D systems Inc., 
Minneapolis, USA) for additional 5 days and 
then used for further analyses. All cell sepa-
rations were performed by automatic mag-
netic cell sorting using an autoMACS pro 
separator according to the protocols of Mil-
tenyiBiotec (BergischGladbach, D).
Generation of alloreactive memory cells in 
vivo. Six to 8 weeks old CBA mice were 
adoptively transferred with 107 syngeneic 
BM3.3 splenocytes to monitor priming in 
blood over time. Two days later 107 alloge-
neic B6 splenocytes were injected i.v. for 
priming. After 5-8 weeks Ti98+ cells dis-
played the typical phenotype of central 
memory cells and were used for further in-
vestigations in vitro or – after no-touch 
magnetic T cell sorting – transferred to other 
naïve CBA mice.
ABT-737 sensitivity in vitro. Splenocytes or in 
vitro generated memory cells were cultured 
in 96-wells plates in medium (s. above) at a 
final concentration of 4x106 cells/ml in the 
presence of different concentrations of ABT-
737 or vehicle. After 12h of culture cell vi-
ability was assessed by PI exclusion in FACS 
and % of values measured in corresponding 
vehicle  exposed cultures was calculated. 
ABT-737 was provided by Abbott Biore-
search (Worcester, USA): for in vitro experi-
ments ABT-737 was dissolved in DMSO at a 
concentration of 5 mM and then diluted in 
culture medium.
Skin grafting, donor specific transfusion and 
in vivo treatments. For skin transplantation 
mice were shaved and anesthetized with 
ketamine/xylazine. Full thickness tail skin 
(about 1 cm2) was grafted and considered 
rejected when <10% of the graft remained 
viable. DST was performed by i.v. injection 
of 107 splenocytes. Hamster anti-mouse 
CD154 (MR1, purchased from Bio-X-cell, 
West Lebanon, USA) was administered i.p. 
as indicated. ABT-737 was provided by Ab-
bott Bioresearch (Worcester, USA), was dis-
solved in polyethylene glycol, Tween 80, 
dextrose solution and DMSO and injected 
i.p. at 50 mg/kg.
Statistics. IC50-values were calculated using 
a log(inhibitor) vs. response model. Skin 
graft survival was compared using log-rank 
test. P<0.05 was considered significant. 
Graph Pad Prism Software Version 5.0 was 
used for calculations.
Results
Apoptosis induction in allo-reactive memory 
T cells
The pro-apoptotic effect of ABT-737 on al-
loreactive  memory T cells was assessed in 
two models. First, allo-specific CD8 T cells 
were generated in vitro using a  modified 
version of a previously reported protocol to 
generate virus-specific memory cells using 
TCR-transgenic CD8 T cells (Manjunath, 
Shankar et al. 2001). In our allo-specific sys-
tem, we used the BM3.3 mouse, which ex-
presses a transgenic TCR specific for the 
MHC class I molecule H-2Kb on all CD8 T 
cells (Auphan, Curnow et al. 1994; Gui-
mezanes, Barrett-Wilt et al. 2001). BM3.3 
splenocytes were stimulated with CD8-
depleted B6 splenocytes for two days. 
Thereafter, CD8 T cells were positively se-
lected from the mixed lymphocyte reaction 
culture by magnetic cell sorting and further 
cultivated in the presence of IL-15 to gener-
ate central memory cells. After 5 days we 
obtained CD8+ transgenic (Ti98+) cells with 
the phenotypic characteristics of central 
memory cells (CD25-CD69-CD44+CD62L+) 
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that allowed us to precisely investigate the 
pro-apoptotic effect of ABT-737 on a ho-
mogeneous population of alloreactive 
memory cells (Fig. 30A). The sensitivity to 
ABT-737 was assessed by testing viability by 
propidium iodide exclusion after 12h incu-
bation with different concentration of ABT-
737 compared to DMSO-containing vehicle 
(Fig. 30B-C). In vitro generated central 
memory CD8 T cells were as sensitive to 
ABT-737 as naïve CD8 T cells and were 
killed by nanomolar concentrations of ABT-
737. In contrast, in accordance to our previ-
ous observations (Cippà et al., submitted), 
CD8 T cells were  much more resistant to 
ABT-737 in the first days after allostimula-
tion, as shown by a 1’000-10’000 higher 
IC50 measured for cells that were treated 
with ABT-737 after 2 days of stimulation, 
but without additional IL-15 incubation (ac-
tivated cells in Fig. 30).
These results were validated in an ex vivo 
model. After adoptive transfer of BM3.3 
splenocytes, CBA mice were  primed with 
transfusion of B6 splenocytes. Eight weeks 
after priming >80% of Ti98+ cells in the 
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Fig. 30. In vitro generated alloreactive memory CD8 T cells are sensitive to ABT-737
BM3.3 splenocytes  were stimulated with CD8-depleted B6 splenocytes. Two days later activated CD8 T cells 
(“activated”) were  positively selected and further  cultured for additional 5 days  to obtain memory CD8 T cells 
(“memory”). (A) Phenotype characterization of naïve, activated and memory T cells  by FACS. (B-C) After incuba-
tion with different concentrations  of ABT-737 or vehicle  for  12h cell  viability was  assessed by PI  exclusion in 
FACS. Naïve and memory cells  displayed a  similar sensitivity to ABT-737, whereas 1’000-10’000 fold higher con-
centrations of ABT-737 were required to induce apoptosis in early activated CD8 T cells.
spleen displayed the typical memory phe-
notype (CD25-CD69-CD44+), confirming 
that allospecific priming had occurred (not 
shown). ABT-737 sensitivity in different T 
cell populations in these primed mice was 
then assessed by measuring viability in FACS 
after 12h of incubation with different con-
centrations of ABT-737. Naïve (CD44-) and 
memory (CD44+) CD4 and CD8 T cells dis-
played a  similar sensitivity to ABT-737 (Fig. 
31). Thus, in vitro and in vivo generated 
memory T cells are sensitive  to Bcl-2 inhibi-
tion.
Skin transplantation in primed mice
In consideration of the high sensitivity to 
Bcl-2 inhibition measured in memory T cells, 
we hypothesized that induction therapy 
with ABT-737 might prolong skin graft sur-
vival in sensitized mice. ABT-737 inhibited 
allogeneic immune responses in naïve mice, 
but ABT-737 as a single agent was not suffi-
cient to prolong skin graft survival in a fully 
MHC-mismatch combination. This was re-
lated to the up-regulation of the anti-
apoptotic factor Bcl-2A1 in early-activated T 
cells, which dramatically reduced the pro-
apoptotic potency and therefore  the immu-
nosuppressive effect of ABT-737 in the first 
days after antigen recognition (Cippà  et al., 
submitted). However, this phenomenon 
should not compromise the effect of ABT-
737 used for induction therapy.  Therefore, 
in a fully MHC-mismatched skin graft 
model, ABT-737 was administered to allo-
sensitized mice  to reduce the alloreactive 
memory T cell frequency before  re-
transplantation. B6 mice were primed with 
BALB/c skin and 7 weeks later re-
transplanted with BALB/c skin under treat-
ment with ABT-737 or vehicle, started 5 
days before  transplantation. As expected, 
ABT-737 did not influence skin graft survival 
in naïve  mice. In contrast, ABT-737 pro-
longed skin graft survival in primed mice, 
resulting in a similar skin graft survival in 
primed mice treated with ABT-737 and in 
naïve  mice (Fig. 32). This confirms that de-
pletion of memory T cells by ABT-737 also 
occurs in vivo and is functionally relevant in 
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Fig. 31. In vivo generated alloreactive memory T cells are sensitive to ABT-737
CBA mice  were primed with B6 splenocytes. Eight weeks after priming sensitivity to ABT-737 in vitro as  deter-
mined by measurement of cell viability after 12h incubation with ABT-737. Naïve  (CD44-) and memory (CD44+) 
CD4 and CD8 T cells were  similarly sensitive  to ABT-737. Similar  results  were obtained as for  in vitro generated 
memory cells (Fig. 30).
a strong immunogenic allo-specific model. 
The kinetics of skin rejection suggests that 
depletion of memory cells by ABT-737 re-
converted a  secondary to a primary immune 
response.
Response to costimulation blockade after 
transfer of memory cells
The depleting effect of ABT-737 on memory 
cells may restore sensitivity to costimulation 
blockade in sensitized recipients. This hy-
pothesis was tested in a fully MHC-
mismatched combination using a previously 
described model including donor specific 
transfusion (DST), costimulation blockade 
with anti-CD154 (MR1) and skin transplan-
tation (Markees, Phillips et al. 1997). As an-
tibody removal is not feasible in mice, to ob-
viate the problem of antibody-mediated re-
jection, an adoptive transfer strategy was 
chosen. CBA mice were transferred with 107 
BM3.3 splenocytes and primed with a  single 
transfusion of B6 cells. Priming was con-
firmed by expression of CD44 in alloreactive 
Ti98 CD8 T cells (Fig. 33A). After 12 weeks, 
these mice were euthanized, T cells were 
isolated from the spleens by no-touch mag-
netic cell sorting and transferred to naïve 
CBA recipients (5x106 cells/mouse). An in-
tensified 2-day induction therapy with ABT-
737 was started on the  same day. At day 2 
after adoptive transfer, DST (B6 splenocytes) 
and MR1 were administered according to 
previous reports. MR1 and DST induced a 
donor-specific hyporesponsiveness with a 
prolonged mean skin graft survival of 17 
days compared to 9 days in the control 
group (Fig. 33B). However, in analogy to 
previous observations (Adams, Williams et 
al. 2003), this effect was lost after transfer 
of memory T cells. The short induction ther-
apy with ABT-737 dramatically prolonged 
B6 skin graft survival in mice transferred 
with naïve  T cells and completely prevented 
resistance to costimulation blockade in mice 
transferred with memory T cells. Thus, a 
short induction therapy with ABT-737 
greatly amplified the donor-specific hypore-
sponsiveness induced by DST and MR1.
Discussion
In this study we showed that the Bcl-2 in-
hibitor ABT-737 induced apoptosis in mem-
ory T cells and prolonged skin graft survival 
in sensitized recipients. Induction therapy 
with ABT-737 markedly promoted the  in-
duction of donor-specific  hyporesponsive-
ness in combination with DST and anti-
CD154 and prevented resistance to costimu-
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Fig. 32. ABT-737 prolongs skin graft survival in primed mice
Seven weeks after  priming with BALB/c skin grafts, B6 recipients  were re-transplanted with BALB/c skin on the 
contra-lateral site. ABT-737 or DMSO-containing vehicle  were  administered starting on day 5 before transplanta-
tion with a daily i.p. injection at 50 mg/kg/day. ABT-737 was not efficient in naïve mice, but significantly pro-
longed skin graft survival in primed recipients (n=5-9 mice/group).
lation blockade determined by memory T 
cells.
The immuno-modulatory effect of Bcl-2 in-
hibitors is principally related to their selectiv-
ity profile among different lymphocyte sub-
populations. ABT-737 (and its bioavailable 
counterpart navitoclax) induces apoptosis in 
cells whose survival depends on the anti-
apoptotic effect of Bcl-2, Bcl-xL or Bcl-w (Ol-
tersdorf, Elmore et al. 2005). Generation 
and maintenance of memory T cells is the 
result of a  tight regulation of the  intrinsic 
apoptosis pathway. Particularly, down-
regulation of Bim is crucial for CD8 memory 
T cell generation (Sabbagh, Srokowski et al. 
2006), and the anti-apoptotic factors Bcl-2 
and Bcl-xL are the most important determi-
nants of memory T cell survival (Schluns and 
Lefrancois 2003; Wojciechowski, Tripathi et 
al. 2007). By inhibiting both Bcl-2 and Bcl-
xL, ABT-737 efficiently induced apoptosis in 
memory T cells. Previous studies demon-
strated that ABT-737 reduced the number 
of naïve  and memory cells in non-sensitized 
mice in vivo (Wojciechowski, Tripathi et al. 
2007; Carrington, Vikstrom et al. 2010). Our 
data  complete  this information with a quan-
titative  analysis about the sensitivity to ABT-
737 in allo-reactive memory T cells in vitro 
and with functional tests in vivo. We dem-
onstrate that sensitivity to ABT-737 is similar 
for naïve and memory cells and that the de-
pleting effect of ABT-737 on memory cells is 
sufficient to inhibit secondary immune re-
sponses.
Apoptosis induction in memory T cells might 
represent an innovative option to prevent 
allograft rejection in sensitized patients. Al-
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Fig. 33. ABT-737 restores sensitivity to costimulation blockade after transfer of memory T cells
Naïve CBA mice were  transferred with syngeneic  BM3.3 splenocytes and primed with B6 splenocytes (107 cells, 
i.v. injection). (A) Priming was monitored analyzing the  phenotype of alloreactive CD8+Ti98+ T cells  in FACS. 
Twelve weeks  after priming Ti98 cells  displayed the typical  phenotype of memory T cells  (CD25-CD44+CD69-). 
(B) CBA mice  were  euthanized, T cells isolated from the spleen by negative T cell  sorting and transferred to naïve 
CBA mice (day -9 before skin transplantation). Control mice  transferred with naïve T cells  were  included. Induc-
tion therapy with ABT-737 was started at the  same day of adoptive transfer  and continued at the  following day 
with two injections  of ABT-737 (50/mg/kg/injection). At day -7 recipient mice received donor specific transfusion 
(DST, 107 B6 splenocytes). Anti-CD154 (MR1, 0.25 mg/injection, i.p.) was  administered at day -7, -3, -1, 3 and 7. 
Skin transplantation from B6 and BALB/c donors  was performed at day 0. Donor-specific hyporesponsiveness  
induced by DST and MR1 was prevented by adoptive transfer of memory cells, but ABT-737 reversed this  phe-
nomenon and induced a much more  pronounced hyporesponsiveness in both groups  transferred with naïve  and 
memory cells (n=7 mice/group).
though immunological risk evaluation and 
therapy of sensitized recipients are mostly 
focused on B cells and donor specific anti-
bodies (Gloor and Stegall 2010), T cells are 
surely involved in these mechanisms and 
therapeutic strategies to inhibit memory T 
cells are of clinical relevance. Further investi-
gations are required to assess the effect of 
ABT-737 on B cells and particularly on 
plama cells and memory B cells to fully ex-
ploit this approach. Furthermore, because of 
the critical role of heterologous immunity, 
memory T cell depletion is also relevant for 
the treatment of patients without a detect-
able donor-specific sensitization in the con-
text of costimulation blockade or immuno-
modulatory approaches based on regulatory 
T cells, both notoriously not very efficient in 
controlling secondary immune responses. 
We recently showed that ABT-737 promotes 
mixed chimerism and tolerance  induction in 
naïve  mice (Cippà  et al, unpublished). The 
data  presented here represent a step toward 
a broad clinical application of this approach. 
Memory T cells are more and more recog-
nized as a critical resistance factor to toler-
ance in primates and humans (Ford and 
Larsen 2011; Yamada, Boskovic et al. 2011). 
Previous studies indicate that not only intrin-
sic characteristics of memory T cells are  im-
portant in determining resistance to toler-
ance, but that quantitative aspects may be 
relevant too (Adams, Williams et al. 2003; 
Nadazdin, Boskovic et al. 2011). The intrinsic 
properties of memory cells did not represent 
a barrier for the pro-apoptotic effect of ABT-
737, but we cannot assume that a complete 
deletion of the  alloreactive T cell pool had 
occurred after a short induction therapy. It 
seems rather that ABT-737 induced a suffi-
cient clone size reduction in the alloreactive 
memory T cell pool to restore sensitivity to 
costimulation blockade. Thus, donor-specific 
hyporesponsiveness is primarily the  result of 
antigen recognition under the  effect of 
costimulation blockade, but this effect was 
promoted after clone  size reduction by ABT-
737 in both situations of a naïve and a 
primed mouse. Furthermore, an additional 
direct interaction with the process of 
alloantigen-specific peripheral lymphocyte 
selection may also be involved.
This consideration is important also for the 
potential side effects: if a complete deletion 
of memory T cells does not occur, a reactiva-
tion of infectious diseases as a result of im-
paired immunological memory seems very 
unlikely. In consideration of phase  I clinical 
trials with navitoclax, it seems that an induc-
tion therapy with Bcl-2 inhibitors should 
have an acceptable  toxicity also in the con-
text of a non-malignant condition.
Thus, apoptosis induction in memory T cells 
by Bcl-2 inhibition represents a promising 
strategy to inhibit secondary immune re-
sponses and to increase sensitivity to 
costimulation blockade. This approach 
might be important for the translation of 
tolerance induction protocols in models with 
a high impact of memory cells and toward 
the clinic.
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Section III: Discussion
Chapter 7: A new class of immunomodulatory drugs
In this study I identified and characterized 
previously unknown immunomodulatory ef-
fects of Bcl-2 inhibitors on allogeneic im-
mune responses. As a  single agent, ABT-737 
had a limited effect on skin allograft rejec-
tion, but a strong immunosuppression was 
obtained if resistance to ABT-737 in early-
activated T cells was prevented by calci-
neurin inhibition. Moreover, ABT-737 dis-
played a marked tolerogenic effect in com-
bination with costimulation blockade and 
allowed us to establish a novel mixed chi-
merism induction protocol selectively target-
ing the apoptosis pathway to achieve trans-
plantation tolerance without any myelosup-
pressive treatment. Finally, the depleting ef-
fect of ABT-737 on memory T cells was ex-
ploited to overcome resistance to costimula-
tory blockade in transplantation. Thus, the 
apoptosis pathway represents a new phar-
macological target to prevent allograft rejec-
tion.
Why Bcl-2 inhibitors? Why ABT-737?
Because of the fundamental function of 
apoptosis in animal cells, the first important 
issue to be considered for the  development 
of therapeutic strategies targeting the apop-
tosis pathway is the tissue selectivity of 
the candidate drug, which eventually de-
termines its toxicity profile. This aspect is 
particularly important in the context of 
transplantation, a non-malignant condition 
with an alternative therapeutic option. The 
negative experience of previous attempts to 
trigger Fas to induce apoptosis in alloreac-
tive T cells, finally abandoned because of 
major side effects in preclinical studies, is an 
instructive example in this setting (Owen-
Schaub, Yonehara et al. 1992; Ogasawara, 
Watanabe-Fukunaga et al. 1993). 
Among the different approach to activate 
the apoptosis pathway for the  treatment of 
cancer, the most advanced studies are re-
lated to the inhibition of Bcl-2 proteins (s. 
chapter 2). Moreover, studies in transgenic 
mice showed that deletion of Bcl-2 genes 
mostly results in a phenotype in the immune 
system, but that the effect on other organs 
is quite limited, giving the hope for selectiv-
ity for immune cells and an acceptable sys-
temic toxicity after treatment with selective 
Bcl-2 inhibitors (Veis, Sorenson et al. 1993; 
Bouillet, Metcalf et al. 1999). This was con-
firmed in animal studies and in the first clini-
cal trials.
The selectivity profile  of Bcl-2 inhibitors de-
pends in large  part on their binding affinity 
to different Bcl-2 family proteins correlated 
with the expression of pro- and anti-
apoptotic factors by different cell popula-
tions. The most favorable toxicity profile, 
characterized by lymphopenia and thrombo-
cytopenia, was registered after treatment 
with ABT-737 and its bioavailable counter-
part navitoclax (Wilson, O'Connor et al. 
2010). Depletion of lymphocytes is inevitably 
related to the  immunomodulatory effect of 
ABT-737 (s. below), but thrombocytopenia 
might represent a limiting side effect in a 
clinical setting, particularly if treatment with 
ABT-737 would occur at the time of surgical 
procedures. Moreover, mice treated with 
ABT-737 showed a discoloration of the fur, 
because of a progressive melanocyte loss, 
that was increased in combination with CsA 
(Cippa, Kamarachev et al.). Although this 
side effect should be expected in considera-
tion of the phenotype of Bcl-2 deficient 
mice (Veis, Sorenson et al. 1993), it has 
never been reported in patients.
Apart from their favorable  toxicity profile, 
ABT-737 and navitoclax are of particular 
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clinical relevance  because of their selectivity 
and uniquely high binding affinity to Bcl-2 
proteins, which may explain their particular 
efficacy in vivo (Oltersdorf, Elmore  et al. 
2005). Furthermore, preclinical and clinical 
studies showed a high similarity of the (side) 
effect profile of navitoclax in mice and pa-
tients, confirming that – because these fac-
tors are highly conserved throughout 
evolution – results obtained in animal 
models can probably directly be translated 
into the clinic (Khaw, Huang et al. 2011).
Thus, although drugs targeting other factors 
of the  apoptosis pathway may provide  a 
good alternative in this setting, the Bcl-2 in-
hibitors ABT-737 and navitoclax with their 
high selectivity and acceptable toxicity pro-
file are the most promising drugs in ad-
vanced clinical evaluation to modulate the 
immune system by targeting apoptosis.
The immunomodulatory mechanism of 
Bcl-2 inhibitors
From our results in an allospecific model we 
can extrapolate some general considerations 
about the characteristics of Bcl-2 inhibitors 
as a novel class of immunomodulatory 
drugs. As mentioned in the introduction, 
pro-apoptotic drugs may find a therapeutic 
application (1) to treat diseases with a pri-
mary dysfunction of apoptosis (such a tu-
mors or genetic deficiencies), (2) to elimi-
nate  “dangerous cells” or (3) to modulate 
apoptosis-dependent processes. In our set-
ting the second and the third mechanism 
are important.
The first immunomodulatory mechanism of 
action of Bcl-2 inhibitors is related to the 
depletion of lymphocytes. Depletion of 
harmful immune cells is a fundamental 
process in the maintenance of self-tolerance 
and is physiologically mediated by apoptosis. 
The general idea to deplete lymphocytes to 
inhibit undesired immune reactions is not 
new. Depleting antibodies have been used 
for many years in the clinic. Through 
complement-dependent lysis or phagocyto-
sis stimulation, depleting antibodies lead to 
a sustained but incomplete  lymphopenia, 
which is associated with an increased risk 
for infections and lymphomas (Morris and 
Knechtle  2008). Moreover, memory cells are 
more resistant to antibody-induced deple-
tion, and recovery after exposure to deplet-
ing antibodies is in part mediated by ho-
meostatic proliferation of this cell popula-
tion (which may be particularly detrimental 
for the induction of tolerance) (Pearl, Parris 
et al. 2005). Innovative is however the idea 
to try to modulate the physiological mecha-
nisms regulating lymphocyte  survival – 
namely the apoptosis pathway – to modu-
late the immune response.
The immunomodulatory outcome of such a 
depletional strategy inevitably depends on 
its selectivity among different lymphocyte 
subpopulations. This can be exemplified by 
two extreme situations: an efficient deple-
tion of allo-reactive CD8 T cells induces tol-
erance in the mixed chimerism model (Kurtz, 
Ito et al. 2001), whereas a depletion of 
Tregs induces autoimmunity (Kim, Ras-
mussen et al. 2007). We found that the sen-
sitivity to different Bcl-2 inhibitors varies sig-
nificantly during the course of the immune 
response. This process is related to a dy-
namic regulation of the intrinsic apoptosis 
pathway in response to intrinsic and extrin-
sic stimuli (Fig. 34). Thus, naïve T cells, 
whose survival depends on Bcl-2, were  effi-
ciently depleted by ABT-737, but early acti-
vated T cells expressing A1 were completely 
resistant to the treatment. As a result, the 
combination of donor specific transfusion 
and ABT-737 did not induce the desired se-
lective depletion of allo-reactive T cells, but 
rather their selection among the T cell pool, 
in a kind of reversed alloselectivity, 
whereas the  pro-apoptotic potency of the 
pan-inhibitor obatoclax was not influenced 
by T cell activation in vitro. To selectively in-
duce apoptosis in early-activated T cells an 
A1 inhibitor may be appropriate, but none 
of the currently available Bcl-2 inhibitors 
displayed these particular binding affinity. 
The  characterization of the molecular 
mechanisms leading to the A1-dependent 
resistance to ABT-737 in early-activated T 
cells allowed us to overcome this problem 
by inhibiting the calcineurin-NFAT pathway. 
Notably, because of the general sensitivity of 
naïve  T cells to ABT-737, allo-selectivity can-
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Fig. 34. Simplified model of Bcl-2 regulation in activated T cells
In the early phase after antigen recognition (about 2 days) signal  1 induces  an up-regulation of 
the anti-apoptotic  A1 (Verschelde, Walzer et al. 2003) and the pro-apoptotic Bim (Sandalova, 
Wei et al. 2004). In the later phase  (day 3-5 after antigen recognition) costimulation signals  in-
duce  an up-regulation of Bcl-xL (Watts  2010) and a down-regulation of Bim (Sabbagh, 
Srokowski et al. 2006). In parallel, the regulation of Mcl-1 and Noxa  interacts  with these mecha-
nisms and is involved in the competitive selection of T cell clones  (Wensveen, van Gisbergen et 
al. 2010). Costimulation blockade  inhibits the up-regulation of Bcl-xL and prevents the down-
regulation of Bim leading to apoptosis  of the T cell. These mechanisms  have a  major impact on 
the pro-apoptotic potency of ABT-737 during the course of an immune response.
Green: anti-apoptotic, red: pro-apoptotic.
not be achieved by ABT-737, but its deplet-
ing potency is not impaired by T cell activa-
tion in combination with CsA. These obser-
vations are  important for the application of 
ABT-737 as an immunosuppressive and as a 
tolerogenic drug (s. chapter 8). 
The pro-apoptotic potency of ABT-737 was 
not only modulated by T cell activation. We 
observed that also in steady-state conditions 
different T cell populations displayed a dif-
ferent sensitivity to ABT-737. Particularly in-
teresting are preliminary data  demonstrating 
that Tregs are partially resistant to ABT-737. 
If these data will be confirmed, Bcl-2 inhibi-
tors may find a role for the development of 
new strategies to generate or select Tregs in 
vitro and in vivo.
The second important mechanism of action 
of Bcl-2 inhibitors is related to the critical 
role of the intrinsic apoptosis pathway in 
peripheral lymphocyte selection. This 
process appears to occur later after T cell 
activation, when signal 2 and 3 modulate 
the expression of pro- and anti-apoptotic 
Bcl-2 factors to delete auto-reactive  T cells 
(Strasser, Puthalakath et al. 2008), to regu-
late  the competitive  selection of high affinity 
T cell clones (Wensveen, van Gisbergen et 
al. 2010) and to determine the contraction 
phase and the generation of memory cells at 
the end of the immune  response (Wo-
jciechowski, Tripathi et al. 2007). Bcl-2 in-
hibitors directly interact with these  molecu-
lar processes, and our data  strongly suggest 
that the tolerogenic effect of ABT-737 in 
combination with costimulation blockade is 
at least in part the consequence of a in-
creased peripheral deletion of antigen-
specific T cells. By boosting the role  of Bim, 
ABT-737 shifts the balance between the 
anti-apoptotic (mainly Bcl-xL) and the pro-
apoptotic factors (mainly Bim) towards the 
pro-apoptotic side promoting the elimina-
tion of reactive T cells in synergism with 
costimulation blockers. The impact of ABT-
737 on central T cell selection remains to 
be evaluated.
The effect of ABT-737 on B cells was not 
directly investigated in this project. Analo-
gous mechanisms as described here for the 
T cell compartment control B cell homeosta-
sis (Marsden and Strasser 2003). Bcl-2, Bcl-
xL and A1 are induced after B cell activation 
and the balance between Bim and Bcl-2 / 
Bcl-xL regulates the  selection of B cells dur-
ing the process of high affinity maturation in 
the germinal center (Kuss, Knodel et al. 
1999; Do, Hatada et al. 2000; Smith, Light 
et al. 2000). In line with data  showing an 
inhibition of plasma cell generation in mice 
immunized under ABT-737 (Carrington, 
Vikstrom et al. 2010), we observed a  lower 
level of donor-specific antibodies in mice 
treated with ABT-737 after skin transplanta-
tion (Fig. 16). Memory B cells were signifi-
cantly affected by ABT-737, whereas plasma 
cells in the BM seem to be more resistant to 
Bcl-2 inhibition (Carrington, Vikstrom et al. 
2010). A better characterization of the ef-
fect of Bcl-2 inhibitors on the B cell com-
partment is required to exploit the immu-
nomodulatory potential of these  drugs in 
transplantation and tolerance (Kirk, Turgeon 
et al. 2010).
Additional mechanisms are likely to be  in-
volved in the immunomodulatory effect of 
Bcl-2 inhibitors. Apoptotic cells have tole-
rogenic properties, and the massive  number 
of apoptotic cells observed in the lymphatic 
organs of mice treated with ABT-737 is 
likely to modulate the licensing of dendritic 
cells and may contribute to the  tolerogenic 
effect of ABT-737 (Green, Ferguson et al. 
2009). Moreover, Bcl-2 factors are increas-
ingly recognized as important players in cel-
lular processes not directly involved in 
apoptosis regulation, such as in T cell activa-
tion (Ludwinski, Sun et al. 2009). Bcl-2 in-
hibitors may disturb these mechanisms with 
different possible functional consequences. 
In summary, the immunomodulatory effect 
of ABT-737 is multi-factorial and complex. 
The most important mechanisms of action 
of ABT-737 on the immune system are 
probably related to selection processes de-
termined by the expression of pro- and anti-
apoptotic factors during the course of the 
immune response  and – in general – by dif-
ferent lymphocyte  populations. As a result, a 
Bcl-2 inhibitor such as ABT-737 can deplete 
or select lymphocytes with the same antigen 
specificity depending on their differentiation 
80
and activation state. To my knowledge, 
these properties have never been described 
for other drugs before. Although this project 
was focused on allogeneic immune re-
sponses, the  same mechanisms are  likely to 
generally occur in lymphocytes, so that Bcl-2 
inhibitors can be  considered as a new class 
of immunomodulatory agents with poten-
tially broad experimental and clinical appli-
cations.
Potential applications
Because of its particular selectivity profile 
among lymphocytes, ABT-737 might assume 
immunosuppressive  or immunostimulatory 
properties. This project was primarily fo-
cused on transplantation immunology, and 
a possible stimulation of the immune re-
sponse using Bcl-2 inhibitors was not further 
investigated. However, the results obtained 
by a short course of ABT-737 treatment in 
the initial phase of the immune response 
suggest that resistance to ABT-737 in acti-
vated T cells can be used to select a  popula-
tion of antigen-specific T cells after antigen 
recognition. This phenomenon was detri-
mental for the application of ABT-737 as an 
immunosuppressive  drug, but may be  ex-
ploited for the generation and expansion of 
antigen-specific T cells in vitro and in vivo, 
with broad possible applications for tumor- 
and infection-immunology.
The multifactorial immunosuppressive and 
tolerogenic effect of ABT-737 might find 
multiple applications to control undesired 
immune responses. ABT-737 had a benefi-
cial effect in different models of autoim-
munity in mice (Bardwell, Gu et al. 2009). 
Interestingly, the  immunosuppressive effect 
was evident if the  treatment was started be-
fore  inducing autoimmunity, but was very 
limited in a curative approach (Lawlor, Smith 
et al. 2011). This observation is perfectly in 
line with our mechanistic studies in alloge-
neic models, and I speculate  that the effi-
cacy of ABT-737 could be significantly in-
creased in combination with low-dose CsA 
in most autoimmunity models. Similar re-
sults might be  obtained in models for 
chronic inflammatory bowel diseases, 
currently in preclinical investigation (M. 
Hausmann, personal communication). Fur-
thermore, a possible application of Bcl-2 in-
hibitors to inhibit allergic reactions has 
been proposed in consideration of the  sensi-
tivity of mast cells to ABT-737 (Karlberg, Ek-
off et al. 2010). The relevance of our find-
ings for transplantation is discussed in de-
tails in the next chapter.
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Chapter 8: Bcl-2 inhibitors in transplantation
Immunosuppression
Currently available  immunosuppressive 
drugs are  very effective to prevent and treat 
acute rejection, but minimally ameliorated 
the long-term outcome after solid organ 
transplantation, because  of side effects and 
of their limited impact on chronic rejection 
(chapter 1). Therefore, the development of 
novel immunosuppressive strategies is surely 
necessary, but the introduction of new im-
munosuppressive drugs only makes sense if 
these will assure a long-term efficacy and 
a reduced systemic toxicity. In general, 
immunosuppressive  drugs can be used for 
induction therapy, for maintenance immu-
nosuppression or as a  rescue therapy in case 
of rejection. The  potential role of Bcl-2 in-
hibitors for these  therpeutical modalities is 
discussed here.
Because activated T cells are  resistant to 
ABT-737, this drug is surely not indicated for 
the treatment of acute rejection epi-
sodes. In contrast, because of the critical 
role of A1 in early-activated T cells, a  selec-
tive  A1 inhibitor may deplete alloreactive T 
cells and therefore inhibit acute rejection 
without leading to a generalized lym-
phopenia. The  same approach may be  indi-
cated in the early phase  after transplanta-
tion to prevent rejection or in combination 
with DST. These hypotheses need to be  con-
firmed experimentally as soon as a  selective 
A1 inhibitor will be available.
According to our observations in a skin graft 
model, ABT-737 may find a  role for main-
tenance immunosuppression. Impor-
tantly, the  immunosuppressive  effect of 
ABT-737 was markedly increased in combi-
nation with low-dose CsA. The combination 
of low doses of immunosuppressive drugs 
with different pharmacological targets is 
generally considered a  good option to re-
duce the overall toxicity and therefore im-
prove long-term outcome. Bcl-2 inhibitors 
might represent a valid combination partner 
for immunosuppressive therapies with a re-
duced CNI-exposure. However, although 
ABT-737 and navitoclax displayed a  favor-
able toxicity profile in the short-term, we 
have to be very cautious about their poten-
tial side effects in the long-term. A sus-
tained lymphopenia is generally associated 
with an increased risk for infections and tu-
mors, and although an increased thrombo-
poiesis may partially compensate the loss of 
platelets in the long-term, an increased risk 
for bleeding is probable. The  effect of a 
long-term exposure to ABT-737 on tumor 
pathogenesis is controversial. An increased 
apoptosis rate is generally associated with 
an anti-neoplastic effect in the  short term, 
but a  compensatory hyper-proliferation may 
even lead to cancer in the affected tissues in 
the long term (Weber, Boger et al. 2010). 
Finally, particularly in combination with CsA, 
ABT-737 is likely to accelerate the process of 
hair graying (Cippa, Kamarachev et al., 
submitted).
In my opinion, induction therapy is the 
most promising application of ABT-737 in 
transplantation. A short course of ABT-737 
before transplantation will be  well tolerated 
by the patients and is likely to promote  the 
process of “host-graft-adaptation” by re-
ducing the clone size  of allo-reactive T cells, 
by the generation of tolerogenic apoptotic 
bodies in lymphatic tissues and – probably – 
by selection of regulatory T cells. Compared 
to the currently available  induction therapy, 
which is principally based on the  injection of 
anti-CD25 or depleting antibodies, Bcl-2 in-
hibitors are likely to induce a better deple-
tion of memory cells and may find an appli-
cation in sensitized patients. Moreover, 
lymphopenia after ABT-737 treatment re-
covers during a few days after treatment 
discontinuation whereas a  single  injection of 
ATG leads to a sustained lymphopenia over 
months. Therefore, induction by Bcl-2 inhibi-
tion may be favorable  because it allows the 
physician to control the treatment depend-
ing on the clinical situation and for example 
to reduce the treatment duration in case of 
life-threatening infections. Furthermore, the 
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application of a  small molecule such as 
ABT-737 is usually better tolerated and is 
associated with fewer risks compared with 
antibody therapy.
To take full advantage of all the immuno-
modulatory properties of ABT-737 the in-
duction therapy should be combined with 
DST and costimulation blockade. In our 
model, the combination of a  short course of 
ABT-737, MR1 and DST induced donor-
specific hyporesponsiveness, as shown by 
a dramatic skin graft survival prolongation, 
and allowed to completely overcome the 
barrier to costimulation blockade provided 
by memory cells. This approach may find a 
near-term clinical application as an induction 
therapy followed by standard immunosup-
pression, but can also represent the  basis for 
the development of tolerance induction pro-
tocols.
Tolerance induction 
Tolerance induction is often considered as 
the holy grail of transplantation. Despite the 
major advantages achieved in the last dec-
ades, translation of established experimental 
models to primates and patients has not 
been uniformly successful. I propose a 
“three compartment model” to explain 
the disparities encountered in different ani-
mal models and to characterize the potential 
role of ABT-737 as a tolerogenic drug (Fig. 
35).
The induction of allospecific tolerance con-
sists in a fundamental re-setting of the im-
mune system with a re-definition of the im-
mune self (chapter 1). This process depends 
on the tolerization of three compartments 
of the adaptive immune system: (1) newly-
arising lymphocytes, (2) naïve lymphocytes 
and (3) memory lymphocytes. “Tolerization” 
has to be  considered as a combination of 
deletion and regulatory mechanisms that 
leads to the elimination or to the functional 
inactivation of allo-reactive T cells. The his-
tory of tolerance induction – from the semi-
nal experiment of Medawar in mouse em-
bryos, through the first mixed chimerism in-
duction protocols in mice until the recent 
clinical applications – nicely reflects the dis-
parities in these  compartments in different 
experimental models (chapter 1). The induc-
tion of tolerance in mouse embryos only re-
quires the tolerization of the  first compart-
ment and can be achieved without a ma-
nipulation of the peripheral immune system. 
In naïve  laboratory mice, young animals liv-
ing in a pathogen-free environment, induc-
tion and maintenance of tolerance  is possi-
ble if the first and second compartment are 
successfully tolerized. Finally, the tolerization 
of memory cells is crucial in large animals, 
non-human primates and in patients. Thus, 
a clinically applicable tolerance induction 
protocol consists of an induction phase 
targeting the  second and the third com-
partment and of a maintenance phase con-
trolling the first compartment.
Extensive  investigations about the processes 
involved in the tolerization of peripheral 
naïve T cells showed that regulatory 
mechanisms are  not sufficient to induce tol-
erance across MHC-mismatched barriers in 
non-immunocompromised animals (Lechler, 
Garden et al. 2003). Deletion is the funda-
mental mechanism of tolerance during the 
induction phase. The most radical way to 
eliminate  alloreactive T cells in mice is a 
complete T cell depletion by irradiation or 
depleting antibodies (Ildstad and Sachs 
1984). An important step in the develop-
ment of tolerance induction was the discov-
ery of costimulation blockers. These in-
duce a selective  deletion of alloreactive T 
cells primarily by activation of the  intrinsic 
apoptosis pathway (Wekerle, Kurtz et al. 
2002). The prerequisites to obtain a general-
ized deletion of allo-reactive  T cells by 
costimulation blockade are the activation of 
signal 1 (Li, Li et al. 1999) and a previous 
reduction of the clone size (Ford, Wagener 
et al. 2008). Bcl-2 inhibitors are ideal phar-
macological partners for costimulation 
blockers in this setting: ABT-737 induced 
clone size reduction and is likely to directly 
promote the process of peripheral deletion 
by activating the intrinsic apoptosis path-
way. As a result, CsA even promoted the 
tolerogenic effect of ABT-737 in our model.
Memory T cells have more recently been 
recognized as a fundamental barrier for the 
translation of tolerance induction protocol 
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to primates (Ford and Larsen 2011). Memory 
cells are  almost absent in the  immune sys-
tem of laboratory animals, but progressively 
replace naïve cells in humans in a process 
called immune senescence as a result of 
the daily exposure to pathogens and of the 
progressive functional decline of the  thymus 
(McElhaney and Effros 2009). Importantly, 
compared to naïve T cells, memory cells are 
much more resistant to costimulation block-
ade (Adams, Williams et al. 2003), deple-
tional therapy (Pearl, Parris et al. 2005) and 
regulation (Yang, Brook et al. 2007), and - 
despite  major efforts in this field (Weaver, 
Charafeddine et al. 2009) – efficacious op-
tions to inhibit memory cells are still not 
available. This limits the therapeutic options 
not only for sensitized patients, but – as a 
consequence of heterologous immunity – 
also the general efficacy of tolerance  induc-
tion protocols based on costimulation 
blockade (Adams, Williams et al. 2003). A 
recent study demonstrated that the success 
of tolerance induction in non-human pri-
mates was associated to the number of pre-
existing donor-reactive memory T cells, indi-
cating that quantitative and qualitative 
parameters may be relevant in this setting 
(Nadazdin, Boskovic et al. 2011). Therefore, 
a partial deletion of donor-reactive memory 
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Fig. 35. A three compartment model for tolerance induction
According to the  model described in the  text, the three  compartments, the theraputic 
options  to tolerize  them and their relevance in different animals  models (black: high 
relevance, white: no relevance) are described.
cells may be sufficient to restore sensitivity 
to costimulation blockade and allow the in-
duction of tolerance without completely im-
pairing the immune memory against patho-
gens. ABT-737 efficiently depleted memory 
cells and restored sensitivity to costimulation 
blockade in a skin graft model with DST. If 
the same effect will be confirmed in a  toler-
ance induction model and in large animals, 
Bcl-2 inhibitors may play a fundamental role 
for the translation of the mixed chimerism 
model to the clinic.
To maintain tolerance after a  successful in-
duction phase, it is necessary to control the 
generation and the activation of newly 
arising T cells that were not exposed to the 
tolerization process. As a  result, a complete 
peripheral deletion of alloreactive T cells was 
only sufficient to induce tolerance  after skin 
transplantion in thymectomized mice (Khan, 
Tomita et al. 1996). Regulatory or deletional 
mechanisms can be exploited to tolerize 
newly arising T cells: in mixed chimerism this 
is achieved by a central deletion of allo-
reactive thymocytes, whereas the generation 
of regulatory T cells – often induced by the 
graft itself – is pivotal in other models. The 
relevance of this compartment in the clinical 
setting remains a matter of debate: because 
of the  reduced activity of the  thymus in 
adults, it is not clear if strong immunological 
mechanisms are required to control the 
minimal number of newly arising lympho-
cytes or if weaker intra-graft regulation 
processes may be  sufficient to maintain tol-
erance after graft adaptation. This may ex-
plain the  controversial results of the  first pi-
lot studies using the mixed chimerism ap-
proach in patients (Kawai, Cosimi et al. 
2008). Although all these patients lost chi-
merism during the  first weeks after trans-
plantation, the kidney graft was not re-
jected. This phenomenon, called “split tol-
erance”, supports the hypothesis that in-
tragraft mechanisms may maintain toler-
ance, but the underlying immunological 
mechanisms are still not completely under-
stood. Similar mechanisms may explain how 
an induction therapy with ABT-737 as a sin-
gle agent induced long-term survival of 
minimally immunogenic pancreas islet 
transplanted under the kidney capsule (Car-
rington, Vikstrom et al. 2010). In our fully 
MHC mismatched model, ABT-737 in com-
bination with CsA and MR1 allowed the en-
graftment of bone marrow and induced a 
stable, low-level chimerism leading to sys-
temic tolerance. Further experiments are re-
quired to assess the effect of ABT-737 on 
Tregs and on central selection, particularly 
on the thymus engraftment of donor-
derived antigen presenting cells after bone 
marrow transplantation.
Clinical relevance and experimental out-
look
In a  clinical perspective, the most promising 
results obtained in this study are related to 
the tolerogenic effect of ABT-737 and to its 
efficacy on memory cells. The experience 
from clinical trials in oncology will show if 
the toxicity profile of navitoclax would al-
low a long-term therapy in patients with a 
non-malignant disease. In any case, available 
data  strongly suggest that a  short therapy 
with navitoclax should be associated with a 
favorable toxicity, so that the  further devel-
opment of our approach towards a  clinical 
application seems reasonable. Particularly 
because of the effect on memory cells ABT-
737 might represent an important factor for 
the development of the mixed chimerism 
approach towards a broad clinical applica-
tion. Therefore, tolerance should be con-
sidered as the final goal, but a multi-step 
procedure is necessary for a gradual intro-
duction of Bcl-2 inhibitors in transplantation 
without harm for the patients. Moreover, 
because of the excellent results achieved 
with conventional immunosuppressive drugs 
in current clinical use, for ethical reasons, 
the establishment of a tolerogenic therapy 
has to be developed in combination with a 
standard immunosuppression. In this con-
text, the opportunity to prevent the anti-
tolerogenic effect of CNIs using ABT-737 is 
of fundamental importance. Thus, the ap-
proach established in this project should be 
further developed on three parallel tracks in 
the clinic, in animal models and at the 
bench.
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A multi-step approach to introduce  ABT-737 
in clinical transplantation should be con-
sidered. First, the efficacy of ABT-737 and 
navitoclax as immunosuppressive drugs and 
particularly on memory cells has to be con-
firmed on human cells in vitro before pro-
ceeding to the first interventional studies in 
patients. Thereafter, the less dangerous way 
to initiate  a clinical application of navitoclax 
in transplant recipients is probably an induc-
tion therapy in highly sensitized patients. 
According to our data, the effect of navito-
clax in combination with DST and costimula-
tion blockade should lead to a depletion of 
donor-reactive memory cells and reduce the 
reactivity of the recipient towards donor 
cells. Thus, the efficacy of navitoclax in vivo 
may be first assessed comparing the  in vitro 
reactivity of recipient cells towards donor 
cells before and after treatment with DST 
and navitoclax, ideally in combination with 
costimulation blockade. Although this is a 
hard immunological challenge, if successful 
this procedure would allow the patient to 
proceed to transplantation, whereas a nega-
tive result would not worsen the clinical 
situation. Only if the in vitro results will be 
successful, we could then proceed to a pro-
tocol primarily finalized at organ transplan-
tation in sensitized and non-sensitized re-
cipients. This would represent the first step 
towards an induction therapy based on 
Bcl-2 inhibition. One major limitation for the 
clinical application of this approach is re-
lated to the fact that anti-CD154 antibodies 
were withdrawn from the market because 
of thromboembolic side effects (Kawai, An-
drews et al. 2000). CTLA4Ig has recently 
been introduced in the clinic, but was not 
sufficient to substitute MR1 in our model. 
The recent development of anti-CD40 block-
ing agents in our lab and by others may rep-
resent a good option in this setting (Page, 
Srinivasan et al. 2012).
In parallel, our tolerance induction protocol 
has to be further developed in animal mod-
els. Particularly, its application in large ani-
mals is absolutely required. Moreover, sev-
eral practical aspects should be  further in-
vestigated in the mouse. Additional experi-
ments are required to minimize the condi-
tioning phase, trying for example to reduce 
the exposure  to ABT-737 to the pre-
operative phase. Furthermore, a model to 
investigate  our tolerance induction protocol 
in sensitized mice would be very informa-
tive. The presence of pre-existing donor-
specific antibodies precluded the induction 
of tolerance  in our mouse model, but this 
problem is manageable in the  clinical set-
ting, where therapies targeting the B cells 
and plasmapheresis are available. Another 
pratical issue  is related to the  timing of tol-
erance induction. The group of David Sachs 
recently showed in primates that the toler-
ance induction protocol is also effective if 
performed months after transplantation in 
recipients previously treated with standard 
immunosuppression (Yamada, Boskovic et 
al. 2011). This would represent a  great ad-
vantage in the  clinic. The synergistic effect 
of ABT-737 and CsA may be beneficial in 
this setting.
Finally, further mechanistic studies are 
necessary to better understand the regula-
tion of apoptosis in the context of transplan-
tation and tolerance in order to completely 
exploit the potential of this approach. The 
exact mechanism leading to CD8 T cell 
apoptosis under the effect of anti-CD154 is 
still incompletely understood, but it is very 
unlikely that a  direct signal through CD154 
provides a survival stimulus to CD8 T cells. 
Further studies are  required to assess which 
signal is directly involved in the regulation of 
the intrinsic apoptosis pathway, and particu-
larly in the regulation of Bim, in alloreactive 
T cells under the effect of costimulation 
blockade. The relative resistance to ABT-737 
observed in Tregs and the effect of ABT-737 
on thymus engraftment and on central se-
lection is of critical interest for the further 
development of this approach.
The fascinating complexity of nature is an 
insurmountable obstacle for a  complete un-
derstanding of the “immune self”. How-
ever, a pragmatic application of our minimal 
knowledge may result in a substantial bene-
fit for the quality of life of our patients. 
Memory cells and the toxicity of condition-
ing regimens are currently considered the 
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most important barriers to tolerance induc-
tion as an ideal strategy to prevent solid al-
lograft rejection. The future will tell us, if a 
pharmacological modulation of the  apopto-
sis pathway in lymphocytes might represent 
a good solution to these problems.
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“Considerate la vostra semenza:
fatti non foste a viver come bruti,
ma per seguir virtute e canoscenza”.
(Dante Alighieri, Divina Commedia, 
Inferno, Canto XXVI)
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